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Chapter 1
General introduction
Let’s start at the very beginning – a very good place to start 
(The Sound of  Music)
Chapter 1
8
INTRODUCTION 
For individuals with an increased familial colorectal cancer (CRC) risk, preventive measures 
such as surveillance colonoscopies have been shown to be highly effective in decreasing 
their cancer risk with up to 80%.1,2 For effective use of these preventive measures, at-risk 
individuals need to be identified as such, followed by adequate referral, while those without 
such familial risk can be reassured that no such preventive measures are needed. These 
recommendations form the basis for the Dutch multidisciplinary guideline on hereditary 
CRC, which was developed in 2008.3 
However, previous studies have shown that implementation of similar guidelines proved to 
be difficult. As a result, only 12-30% of individuals with an increased familial CRC risk are 
referred for adequate preventive measures.4-11 For more effective cancer prevention, this 
percentage needs to be increased. Therefore, this thesis focuses on studying 1) current care 
regarding the identification and referral of individuals with an increased familial CRC risk and 
2) several strategies to improve guideline implementation, particularly regarding familial 
CRC risk assessment, interpretation (i.e. determination of appropriate preventive measures) 
and communication. 
In this introductory chapter, the identification and referral of individuals with an increased 
familial colorectal cancer (CRC) risk are addressed. First, more detailed information about 
the familial CRC risk and corresponding preventive measures is provided. Next, different 
ways to identify those with an increased familial CRC risk are addressed, as well as the 
current situation regarding referral for preventive measures. After that, the rationale for a 
strategy aimed at improvement of familial CRC risk identification and referral for preventive 
measures is described, followed by the main goal of the study described in this thesis, and 
by an overview of the thesis chapters.
FAMILIAL COLORECTAL CANCER RISK AND PREVENTIVE 
MEASURES 
Identification of  familial colorectal cancer risk 
The familial CRC risk depends on the number of affected relatives, age at diagnosis, the 
presence of synchronous or metachronous adenomas, CRCs and other related tumours, and 
molecular characteristics of the tumours such as microsatellite instability (MSI).12 Familial 
CRC risk is generally divided into three risk categories: high (cumulative familial CRC risk 
above 15%), moderate (10-15%), and low (below 10%).3,13-15 
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1In essence, familial CRC risk assessment is similar for CRC patients and unaffected relatives. 
However, the setting in which familial CRC risk assessment, leading to the identification of 
families with an increased risk of CRC, is different for affected and unaffected individuals. 
As shown in figure 1, familial CRC risk assessment generally takes place in any of these 
three settings: 1) through a CRC patient presenting to a hospital clinician or other healthcare 
provider; 2) through an individual participating in the population screening program, where 
family history is assessed after a positive FOBT has been found; and 3) through a healthy 
person with a positive family history of cancer presenting to a general practitioner or other 
healthcare provider with questions about his/her familial CRC risk and need for surveillance. 
For practical reasons, this thesis focuses on the first two settings. The third is only addressed 
in the general discussion. 
Since familial CRC risk identification can take place at various stages in the referral process 
(e.g. upon diagnosis by a gastroenterologist or surgeon, or after genetic counselling and 
testing), the final classification of familial CRC risk can change during this time. For example, a 
patient with CRC below the age of 50 and a negative family history is assumed to have a high 
familial CRC risk until MSI analysis has been performed, in which case the familial CRC risk is 
confirmed to be high (in case of an MSI-positive result) or changed to moderate (in case of 
an MSI-negative tumour).15 Also, a more detailed family history taken by a clinical geneticist 
can lead to a higher or lower familial CRC risk than previously thought, because relevant 
tumours may prove to be of a different type when confirmed from pathology records, or age 
at diagnosis may differ. It is therefore important that clinicians use all available and relevant 
methods to identify increased familial CRC risk (e.g. perform MSI analysis if indicated). 
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Figure 1. Pathway for familial colorectal cancer identification and referral
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In figure 1, the pathway for familial colorectal cancer identification and referral is shown for colorectal 
cancer patients and individuals unaffected with cancer. Recommendations for preventive measures are in 
accordance with national guidelines.3 Chapters of this thesis in which the items are addressed are shown.
CRC: colorectal cancer; FOBT: faecal occult blood test; MSI: microsatellite instability analysis
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1Preventive measures 
For each familial CRC risk category, different preventive measures are recommended to 
decrease CRC risk, such as colonoscopies in case of an increased familial CRC risk, and faecal 
occult blood tests in case of a low familial CRC risk.3,13-16 Individuals with a high familial CRC 
risk are recommended to attend genetic counselling, where tailored surveillance advice is 
given.3 Besides the type, the frequency and starting age of these measures vary per familial 
CRC risk category, as shown in figures 1 and 2. Details of these risk categories and preventive 
measures are described in the following paragraphs. 
Figure 2. Recommended preventive measures by familial colorectal cancer risk 
category 
Familial CRC risk Recommendations for 
patients and relatives
Genetic counselling with 
5-10% High tailored surveillance 
recommendations
10-25% Surveillance colonoscopies 
70-85% Moderate once every 6 years from age 45
Population screening with
Low FOBT once every 2 years
from age 55
In figure 2, the familial colorectal cancer risk levels (i.e. the cumulative lifetime risk of developing colorectal 
cancer for patients’ first-degree relatives) are shown with the corresponding recommendations for 
preventive measures in accordance with national guidelines.3 
CRC: colorectal cancer 
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High familial CRC risk 
Definition 
Approximately 5-10% of CRC patients have a high familial CRC risk, meaning that their 
relatives have a cumulative lifetime risk of developing CRC of more than 15%.17,18 Moreover, 
these patients have an increased risk of developing metachronous CRCs themselves, 
which may be as high as 29% within ten years.19-21 Genetic causes play a major role in the 
development of CRCs in these high-risk families. 
Genetic counselling and testing 
In international and national guidelines, genetic counselling is recommended for 
individuals with a high familial CRC risk.3,14,15 Based on a more detailed pedigree analysis 
and DNA analysis, a clinical geneticist can then diagnose the presence of a hereditary CRC 
syndrome such as Lynch syndrome. Among other things, cancer risks, tailored surveillance 
recommendations and consequences for the patient and their relatives are communicated 
at the familial cancer clinic. Relatives who test negative for a mutation that runs in the family 
can be reassured that their cancer risk is not increased.22 In table 1, the Dutch guideline 
referral criteria for genetic counselling are shown, which are based on age at diagnosis, 
personal and family history of adenomas, CRC and/or other Lynch syndrome associated 
tumours, and molecular characteristics such as microsatellite instability (MSI). 
Lynch syndrome 
The most common hereditary CRC syndrome is Lynch syndrome, previously known as 
Hereditary Nonpolyposis Colorectal Cancer (HNPCC). This autosomal dominant syndrome 
is caused by mutations in the mismatch repair genes MLH1, MSH2, MSH6, PMS2 and the 
more recently discovered EPCAM gene.23 Other hereditary CRC syndromes, such as Familial 
Adenomatous Polyposis syndrome (FAP), are even more rare than Lynch syndrome and have 
a distinct clinical phenotype with many adenomas; therefore, these syndromes fall outside 
the scope of this thesis. 
Cancer risk 
Lynch syndrome mutation carriers have high risks of CRC (12-83%), endometrial cancer (15-
80%), and increased risks of other Lynch syndrome associated tumours, including ovarian, 
gastric and urothelial cancer.24-36 Mean age at diagnosis of these cancers in Lynch syndrome 
is significantly lower than in the general population: 41-54 years for CRC (versus 70 years 
in the general population) and 54-59 years for endometrial cancer (versus 68 years in the 
general population).32-35 
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1Preventive measures 
To decrease the risk of developing (metachronous) cancers, surveillance recommendations 
for Lynch syndrome mutation carriers include surveillance colonoscopies every 1-2 years 
from age 25, annual gynaecological surveillance from age 30-35, and in selected families, 
surveillance for urothelial and gastric cancer as well.3,21,37-39 Performing surveillance 
colonoscopies in Lynch syndrome mutation carriers has been proven to decrease CRC-
related morbidity and mortality with up to 65%.1 
Treatment 
Besides affecting cancer prevention in patients and relatives, familial risk identification 
and genetic testing also influence treatment decisions. For example, patients with Lynch 
syndrome may benefit from subtotal colectomy instead of limited resection to decrease 
their risk of metachronous CRCs.19-21 Furthermore, patients with Lynch syndrome associated 
CRCs seem not to benefit from 5-FU-based chemotherapy.40
Chapter 1
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Table 1. Referral criteria for genetic counselling 
 
In table 1, referral criteria for genetic counselling for hereditary colorectal cancer are shown.3 Individuals 
who meet one or more of these criteria have a high familial colorectal cancer risk and are recommended to 
attend genetic counselling to receive tailored surveillance recommendations. 
* As the likelihood of a genetic abnormality increases if the person is younger and/or the number of 
adenomas is greater, referral for genetic counselling should also be considered for young patients with less 
than 10 colorectal adenomas and for patients ≥ 60 years old with many adenomas. 
APC: adenomatous polyposis coli; First-degree relatives: parents, siblings and children; Lynch syndrome 
associated tumours: malignancies of the endometrium, stomach, small intestine, bile ducts, ovaries, upper 
urinary tract and adenoma or carcinoma of the sebaceous glands; MSI: microsatellite instability; MUTYH: 
mutY homolog; Second-degree relatives: grandparents, aunts, uncles, nieces, nephews, grandchildren. 
Moderate familial CRC risk 
Definition 
In 10-25% of CRC patients, familial clustering of CRC and/or a young age at diagnosis is seen, 
but without molecular evidence of genetic syndromes such as Lynch syndrome.17,18,41,42 In 
these families, the familial CRC risk is moderately increased (cumulative lifetime risk of 10-
15%).37,43,44 
Dutch guideline referral criteria for genetic counselling for hereditary colorectal cancer
Healthy individual, or patient with MSI-negative colorectal cancer, and:
•	 First-degree relative with colorectal or endometrial cancer before age 50
•	 Three or more (first- or second-degree) relatives with colorectal cancer or a Lynch 
syndrome associated tumour before age 70
•	 Mismatch repair gene mutation in the family
Patient with colorectal cancer and:
•	 Age at diagnosis before age 50
•	 First-degree relative with colorectal cancer or a Lynch syndrome associated tumour 
before age 50
•	 Second colorectal cancer before age 70
•	 Colorectal cancer and a Lynch syndrome associated tumour before age 70
•	 Two or more (first- or second-degree) relatives with colorectal cancer or a Lynch 
syndrome associated tumour before age 70
•	 MSI-positive colorectal cancer
Patient with colorectal adenoma with high-grade dysplasia before age 40
Patient with a Lynch syndrome associated tumour before age 50
Individual with a personal history or first-degree relatives with:
•	 Adenomatous polyposis 
•	 Pathogenic mutation in the APC gene
•	 Biallelic pathogenic mutations in the MUTYH gene
•	 More than ten synchronous or metachronous colorectal adenomas before age 60 *
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1Preventive measures 
It is important to distinguish individuals with a high familial CRC risk from moderate-risk 
individuals, as in the latter group, less stringent preventive measures are recommended 
than in the high-risk group. Performing surveillance colonoscopies every 6 years from 
age 45 has been shown to be cost-effective in these moderate-risk families.45 In table 2, 
the referral criteria for surveillance colonoscopies for a moderate familial CRC risk from 
the Dutch guideline are shown.3 Dove-Edwin et al compared moderate-risk individuals 
undergoing regular surveillance colonoscopies with a slightly higher frequency than in the 
Dutch guideline (mean time between colonoscopies: 4.6-5.1 years) to those who did not 
undergo surveillance, and showed that the incidence of CRC was 80% lower in the group 
undergoing colonoscopies.2 
Table 2. Referral criteria for surveillance colonoscopies 
In table 2, referral criteria for surveillance colonoscopies are shown.3 Individuals who meet one or more of 
these criteria have a moderate familial colorectal cancer risk and are recommended to undergo surveillance 
colonoscopies once every 6 years starting at age 45. 
First-degree relatives: parents, siblings and children; MSI: microsatellite instability; Second-degree relatives: 
grandparents, aunts, uncles, nieces, nephews, grandchildren.
Low familial CRC risk 
Definition 
Approximately 70-85% of all CRC cases are sporadic, meaning that these cases do not meet 
criteria for an increased familial CRC risk, and that environmental factors play an important 
role in their aetiology.17,18 Cumulative lifetime risks of CRC for these individuals are equal to 
the population risk or slightly increased, but do not exceed 10%.17 
Dutch guideline referral criteria for surveillance colonoscopies every 6 years from age 45
•	 Exclusion of hereditary colorectal cancer and diagnosis of familial colorectal cancer by a 
clinical geneticist 
•	 Two first-degree relatives with colorectal cancer between age 50-70
•	 A first-degree relative with colorectal cancer between age 50-70 and a second-degree 
relative with colorectal cancer before age 70
•	 A first-degree relative with an MSI-negative colorectal cancer before age 50
Chapter 1
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Preventive measures 
For individuals with a low familial CRC risk, participation in population screening programs is 
recommended.16 In the Netherlands, this screening program will start in 2013 for individuals 
aged 55-75. The screening program includes biennial immunochemical faecal occult 
blood testing (FOBT), followed by colonoscopy in case of a positive FOBT result. Based on 
calculations from pilot studies, this program will prevent approximately 1400 deaths due to 
CRC annually.16 For effective cancer prevention, it is important to distinguish individuals with 
a low familial CRC risk eligible for population screening from those with an increased familial 
CRC risk, since earlier and more intensive surveillance with colonoscopies is indicated for 
the latter group.3,16 The population screening program may serve as a good complementary 
method to identify individuals with an increased familial CRC risk and is therefore studied 
in this thesis. 
IDENTIFICATION OF FAMILIAL COLORECTAL CANCER RISK 
Multiple complementary data can be used to determine whether familial CRC risk is increased 
and preventive measures are indicated (figure 1): age at diagnosis, presence of synchronous 
or metachronous tumours, family history, and analysis of microsatellite instability (MSI) in 
tumour tissue.12,46,47 Age at diagnosis is substantially lower in individuals with hereditary CRC 
syndromes (41-54 years versus 70 years in the general population) and thus can provide an 
important clue to the presence of such syndromes, as can the presence of multiple CRCs 
and other Lynch syndrome associated tumours in one patient or in a family.32-35 Current 
Dutch guidelines recommend that clinicians take a family history for first- and second-
degree relatives, including type of cancer and age of diagnosis.3 Next, it is necessary to 
determine whether the patient is eligible for genetic counselling for a high familial CRC risk, 
surveillance colonoscopies without genetic counselling for a moderate familial CRC risk, or 
population screening with FOBT in case of a low familial CRC risk.3,16 However, difficulties can 
be expected in each of these steps, thus limiting guideline implementation. 
An important problem is that clinical criteria such as family history have been shown to miss 
up to 88% of Lynch syndrome mutation carriers, either because family history assessment 
was incomplete or because families do not meet the criteria but still carry a mismatch repair 
mutation.12,47-50 Therefore, additional strategies are needed to identify individuals with an 
increased familial CRC risk. More than 95% of CRCs due to Lynch syndrome show MSI, in 
comparison to 15% of sporadic CRCs.15 Current Dutch guidelines recommend performance 
of MSI analysis in all patients meeting the MIPA (MSI-testing-by-a-pathologist) criteria, 
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1which include CRC before age 50 and a second CRC before age 70 (table 3).3,45 However, MSI 
analysis is not always performed in patients meeting criteria for MSI analysis (e.g. age at 
diagnosis of CRC < 50 years), as shown by MSI analysis rates of 9-59% in previous studies.5,51,52
Table 3. Criteria for microsatellite instability analysis 
In table 3, the MIPA criteria (microsatellite instability analysis initiated by a pathologist) for newly diagnosed 
patients with colorectal cancer and other Lynch syndrome associated tumours are shown.45 The Dutch 
guideline recommends that microsatellite instability analysis is performed by a pathologist in individuals 
who meet one or more of these criteria.3 
Lynch syndrome associated tumours: malignancies of the endometrium, stomach, small intestine, bile ducts, 
ovaries, upper urinary tract and adenoma or carcinoma of the sebaceous glands 
REFERRAL OF INDIVIDUALS WITH AN INCREASED FAMILIAL 
COLORECTAL CANCER RISK 
After familial CRC risk identification, patients have to be referred adequately for preventive 
measures. Therefore, clinicians need to discuss the familial CRC risk and indicated preventive 
measures with their CRC patients, who in turn are asked to share this information with the 
relatives for whom it is relevant (figure 1).3 Proper risk communication has been shown to 
improve adherence to surveillance recommendations and acceptance of genetic counselling 
by patients with an increased familial CRC risk, and to limit the use of these preventive 
measures by individuals without such risk.53 However, familial CRC risk is only discussed 
by the clinician with a minority of patients (23% in a previous study).4 This lack of risk 
communication is probably a major problem in the referral process of individuals with an 
increased familial CRC risk and provides an important target for improvement strategies. 
The referral for patients after MSI analysis is a point of concern as well. Patients with an 
MSI-positive tumour need to be referred for genetic counselling, because such a test result 
is highly suggestive of a genetic predisposition for Lynch syndrome.12,15 A study by Overbeek 
Criteria for microsatellite instability analysis initiated by a pathologist (MIPA)
•	 Colorectal cancer before age 50
•	 Endometrial cancer before age 50
•	 Second colorectal cancer before age 70
•	 Colorectal cancer and other Lynch syndrome associated tumour before age 70
Chapter 1
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et al has shown that only 59-77% of patients with MSI-positive tumours initiated by a 
pathologist are subsequently referred for genetic counselling.51 In case of an MSI-negative 
tumour in patients meeting MIPA criteria in the absence of other high-risk criteria (such 
as other relatives meeting MIPA criteria or a clinical phenotype of polyposis), a moderate 
familial CRC risk is present.15 In these moderate-risk families, patients and their first-degree 
relatives are recommended to undergo surveillance colonoscopies once every 6 years from 
age 45.3 However, the percentage of patients and relatives who actually undergo surveillance 
colonoscopies is still unknown.
TARGETS FOR IMPROVEMENT 
In spite of recommendations in international and national guidelines, the vast majority of 
CRC patients with an increased familial risk are not referred for preventive measures.3-11 
Recent Dutch studies have shown that only 15-30% of high-risk CRC patients visited a cancer 
genetics clinic.4,5,8 In these studies, patients who were more likely to be referred included 
those in whom a complete family history was recorded, patients with whom referral was 
discussed, and patients who were treated in a teaching hospital. Studies from the UK, USA 
and Australia have shown comparable results.6,7,9-11 
Several factors may contribute to these low referral rates. Previous studies have shown a 
general lack of awareness and knowledge of familial and hereditary CRC among clinicians 
as well as patients.54-57 Family history is recorded in only 16-62% of CRC patients, while 
information necessary for familial risk assessment is often incomplete.5,6,58 A large variation of 
9-59% in MSI analysis rates exists in patients meeting criteria for MSI analysis.5,51,52 Moreover, 
clinicians regularly interpret the results of family history and MSI analysis incorrectly, 
leading to under-referral of individuals with an increased familial CRC risk, and over-referral 
of individuals with a low or moderate familial risk.7,51,59,60 Also, communication of the familial 
CRC risk between at-risk relatives is often incomplete.61-64 Finally, not everyone wants to 
be referred for genetic counselling or surveillance colonoscopies if recommended. Uptake 
of surveillance colonoscopies in individuals with a moderate familial CRC risk ranged from 
48-83% in previous studies, while uptake of genetic counselling among high-risk individuals 
ranged between 26-70%.4,65-68 
It is not effective to focus on improving just one of these factors, if the rest of the referral 
process (figure 1) does not improve. In this thesis we examine each of these factors 
separately and evaluate the process as a whole, looking at familial CRC risk assessment, 
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1interpretation and communication. We discuss several strategies and tools aimed at 
improving familial CRC risk identification, as well as referral of individuals with an increased 
familial CRC risk. The focus is on CRC patients, whereas less attention will be paid to relatives 
who may be at increased risk of developing CRC themselves. While these relatives often 
present themselves to general practitioners and other healthcare providers with questions 
about their familial CRC risk and eligibility for preventive measures, patients with CRC are 
the first one in the family to provide a clue to the possible presence of an increased familial 
CRC risk. These patients have therefore been selected as a starting point for the studies in 
this thesis. Additionally, the population CRC screening program is explored as a resource for 
further improving the identification of individuals with an increased familial CRC risk.
GUIDELINE DEVELOPMENT, IMPLEMENTATION AND 
EVALUATION 
Guideline development 
In general, guidelines are developed to support clinicians in their clinical decision making, 
improve outcomes for patients and ensure efficient use of healthcare resources, by 
providing recommendations which are based on the best available evidence.69-71 In 2008, the 
multidisciplinary evidence-based guideline “Hereditary colorectal cancer” was developed in 
the Netherlands.3 The guideline contains recommendations for referral of CRC patients and 
their relatives with an increased familial CRC risk for surveillance colonoscopies and genetic 
counselling. Referral criteria for preventive measures for the high and moderate familial 
CRC risk categories and for MSI analysis (tables 1-3) are clearly described in the guideline.3,45 
Guideline implementation and evaluation 
The Dutch hereditary CRC guideline was distributed among clinicians from relevant 
medical specialties by mail and made available online on http://www.oncoline.nl. 
However, implementation of guidelines by simple dissemination is known to be largely 
ineffective.72-74 No single implementation strategy has been found to be effective by itself, 
and implementation strategies that are effective in one setting may prove futile in others.72,75 
Therefore, Grol et al proposed a framework for changing clinical practice, which includes the 
development of a concrete proposal for change; analysis of the target setting by measuring 
current care and to identify obstacles to change; linking interventions to needs, facilitators, 
and obstacles to change; development of an implementation plan; and monitoring progress 
with implementation.72,76 
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During the development of the hereditary CRC guideline, experts agreed that spontaneous 
guideline implementation would be unlikely, as familial CRC risk assessment, interpretation 
and communication, which are necessary for adequate risk identification and referral, are 
relatively new tasks to many clinicians outside the field of medical genetics. It also means 
that clinicians need to consider not only the patient in front of them, but have a responsibility 
towards their relatives as well. Clinicians and patients from the guideline development 
committee expected that the main implementation barriers would be clinicians’ lack of 
knowledge and skills in familial CRC risk assessment, interpretation and communication, as 
well as a lack of awareness of the subject among CRC patients. 
To increase implementation of the hereditary CRC guideline, a multi-faceted strategy 
called RISCO (risk of colorectal cancer) was developed, aimed at both CRC patients and 
clinicians. To improve clinicians’ knowledge and skills of familial CRC risk assessment, 
referral for preventive measures and communication of the familial risk, the strategy for 
clinicians consisted of education, the RISCO website with information on familial CRC risk 
and preventive measures as well as risk calculators, and pocket cards with the guideline 
referral criteria.3 To enhance patients’ knowledge, familial CRC risk perception, and uptake 
of preventive measures, a brochure with information on familial CRC risk and preventive 
measures was developed, as well as a part of the RISCO website with similar information, 
risk calculators and a decision support intervention. After pilot tests among CRC patients 
and clinicians, the multi-faceted implementation strategy was evaluated in a clustered 
randomised controlled trial, both regarding effectiveness and feasibility (i.e. use of and 
experiences with the strategy). This evaluation forms the basis for this thesis. Additional 
studies were performed to evaluate possible manners in which to improve the identification 
of and care for individuals with an increased familial CRC risk. These include a study on 
the prevalence of an increased familial CRC risk among participants in the population CRC 
screening program; a new online referral test for familial CRC risk identification and referral 
advice; and a study on how to improve the genetic counselling process for individuals with 
a high familial CRC risk.
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1THESIS OUTLINE
This thesis contains the results of the RISCO study (risk of colorectal cancer), which was 
performed to improve the identification and referral of CRC patients and their relatives with 
an increased familial risk by clinicians in the Netherlands, and enhance informed choice 
of preventive measures by patients. In this chapter (chapter 1), a general introduction on 
familial CRC risk identification and preventive measures is provided, as well as the rationale 
for this thesis. 
The first step in any improvement process is to evaluate the current situation. This is done to 
find clues for improvement strategies, and to provide baseline measurements against which 
the effectiveness of such improvement strategies can be compared. In the first section of 
this thesis, the current situation regarding the identification and referral of individuals with 
an increased familial CRC risk was explored in two different settings (figure 1): CRC patients 
seen by a hospital clinician (gastroenterologist and/or surgeon) and healthy individuals 
participating in the pilot population screening program.
Chapter 2 contains a study which was performed in eighteen community hospitals to 
measure familial CRC risk identification and referral for preventive measures of CRC patients 
in clinical practice. Additionally, it contains a national cohort study which was performed to 
assess doctors’ knowledge, which is known to play an important role in the identification 
and referral of individuals with an increased familial CRC risk.
Chapter 3 addresses another option for identifying individuals with an increased familial CRC 
risk, namely the population screening program. In the Netherlands, this program will start 
in 2013. It is not yet known how many participants with a positive FOBT have an increased 
familial CRC risk, i.e. whether using this program to identify families with an increased CRC 
might be effective. Therefore, the prevalence of a positive family history of cancer and 
familial CRC risk in participants of a pilot screening program was assessed.
To improve identification and referral of individuals with an increased familial CRC risk, 
adequate risk assessment, interpretation and communication are very important. These 
items were chosen as the starting point for the second section of this thesis, in which 
different guideline implementation strategies were studied. 
Chapter 1
22
Chapter 4 contains the study protocol for the RISCO study, a clustered randomised controlled 
trial in which two implementation strategies of the hereditary CRC guideline are compared. 
These strategies focus on clinicians’ familial CRC risk identification, interpretation, and 
communication, as well as patients’ uptake of preventive measures. 
In chapter 5, the development and pilot testing of one of the implementation tools is 
described, namely the RISCO website. This website contains information about familial 
CRC risk, risk calculation tools and a decision support intervention for patients with a high 
familial CRC risk. 
The effect of the two implementation strategies on referral rates and uptake of preventive 
measures were evaluated in a clustered randomised controlled trial (RISCO study) described 
in chapter 6. To determine which elements of the implementation strategies were especially 
useful in improving guideline implementation, patients’ and clinicians’ experience with 
these elements were studied in a process evaluation. 
Besides the implementation strategies described in chapters 4-6, an alternative approach to 
improve implementation of the hereditary CRC guideline was developed and evaluated. This 
alternative consists of a new online referral test, aimed at improving the identification and 
referral of individuals with a high familial CRC risk for genetic counselling. In chapter 7, the 
sensitivity and usability of this online referral test were assessed. 
Once it has been established that the familial CRC risk is high (lifetime risk >15%), referral 
for genetic counselling is recommended. It is vital that the counselling is optimal, because 
satisfaction with genetic counselling has been shown to improve adherence to surveillance 
recommendations. Therefore, counselees’ information needs and preferences regarding the 
content, process and communication at the familial cancer clinic were studied to determine 
how the genetic counselling process may be further improved. This study is reported in 
chapter 8.
Finally, a general discussion on familial CRC prevention and future perspectives is presented 
in chapter 9.
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CURRENT SITUATION
I’m preaching this sermon to show it ain’t necessarily so 
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ABSTRACT 
Aims: Previous data indicate that 12-30% of colorectal cancer (CRC) patients and relatives 
with an increased familial risk are referred for preventive surveillance. New guidelines 
recommend genetic counselling for high-risk families, and surveillance colonoscopies for 
moderate-risk families. In the present study, familial risk of CRC and referral rates for these 
preventive measures were determined one year after introduction of the new guidelines. 
Methods: Assessment of familial risk of CRC and referral for preventive measures were 
studied among CRC patients (n=358) attending eighteen hospitals using medical records 
and questionnaires. Additionally, a knowledge survey was performed among clinicians.
Results: Sixty five (67%) of 97 patients with increased familial risk and 61 (23%) of 261 with 
low risk were referred for preventive measures. Uptake of genetic counselling in high-risk 
families was 33% (n=12/36). Uptake of surveillance colonoscopy in moderate-risk families 
was 34% (n=21/61). In the knowledge survey, clinicians correctly determined familial risk in 
55% of ten cases and preventive measures in 65%.
Conclusion: Currently, 67% of individuals with an increased familial risk of CRC is referred 
for preventive measures. Only one-third of increased-risk families is referred in accordance 
with guidelines. To further enhance efficacy of cancer prevention, clinician education may 
be useful. 
* RISCO study group: G. Elwyn, H. De Wilt, N. van Sluisveld, E. Adang,  T. van der Weijden, R. Sijmons, 
J. Kleibeuker, R. Tollenaar, E. Dekker, F. Menko, M. van Leerdam, P. van Duijvendijk, A. Tan, G. 
Nieuwenhuijzen, M. Liem, B. Lemaire, J. Tjhie-Wensing, K. Bosscha, D. Schipper, L. Engels, E. Keulen, 
M. Verhulst, G. Slooter, C. Hoff, H. Jebbink, F. Wolters, E. van Duijn, N. van Bentem, F. Berends, P. 
van de Meeberg, K. van Engelenburg, M. Grubben, J. Heisterkamp, I. Ahmad, A. Brink, A. Claassen, P. 
Swartbol, R. Van Roermund, J. Baumann, K. Bruin, M. Ibelings, R. Tobon Morales, J. Groen.
Familial colorectal cancer risk assessment needs improvement for more cancer prevention 
31
2
INTRODUCTION
Familial or hereditary factors cause approximately 15-30% of all colorectal cancers (CRC).1 
This includes families with multiple affected relatives and/or relatives with early-onset 
CRC, in which healthy relatives have an increased familial risk of CRC, and affected relatives 
have an increased risk of metachronous cancers.2,3 International guidelines recommend 
surveillance colonoscopies for these at-risk individuals, which reduce CRC-related morbidity 
and mortality by 43-80% and 65-81%, respectively.4-9 However, 70-88% of individuals with 
an increased familial risk of CRC are not referred for these highly effective preventive 
measures.10-13
  
The familial risk level is important to determine which preventive measures are indicated. 
As shown in table 1 and figure 1, familial risk is generally divided into three categories: 
low (cumulative lifetime risk of CRC below 10%); moderate (10-15%); and high (exceeding 
15%).7-9,14 For low-risk individuals, population screening with faecal occult blood testing is 
recommended.9 For moderate-risk families, surveillance colonoscopies every 3-6 years from 
age 40-50 are recommended.6-9,14 Genetic counselling is recommended for CRC patients 
and their relatives with a high familial risk of CRC.6-9,14 A clinical geneticist then determines 
whether a hereditary CRC syndrome is present. Lynch syndrome, previously referred to 
as Hereditary Non-Polyposis Colorectal Cancer or HNPCC, is the most common form of 
hereditary CRC. Lynch syndrome mutation carriers have high cumulative lifetime risks of CRC 
and endometrial cancer of up to 80%, and increased risks of other Lynch syndrome associated 
tumours (LSAT), such as ovarian and gastric cancer.6-9,14-15 Surveillance recommendations 
include colonoscopies every 1-2 years from age 25, and gynaecological surveillance from 
age 30-35. Other hereditary CRC syndromes, such as familial adenomatous polyposis, are 
rarer and are disregarded in this paper.
For effective cancer prevention, it is vital to identify families with an increased risk of CRC 
and refer them for surveillance colonoscopies or genetic counselling, and not refer families 
at low risk. After assessment of familial risk and preventive measures, clinicians must discuss 
these with their patients, who are asked to share this information with their relatives. 
Previous studies have shown acceptance rates of genetic counselling between 26-93%, 
while uptake of surveillance colonoscopies was 48-83%.16-21 Although insurance coverage 
plays an important role in some countries, these costs are fully reimbursed by compulsory 
healthcare insurance in the Netherlands.22 
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Prior research has shown that many clinicians lack knowledge regarding familial risk of 
CRC and preventive measures, resulting in low referral rates of 12-30%.6-9,23-24 An evidence-
based guideline on hereditary CRC was therefore developed in the Netherlands in 2008.6-9,14 
Because familial CRC risk assessment and communication are new concepts for many 
clinicians, we hypothesized that lack of knowledge may be an important barrier to 
guideline implementation. The current study was performed 1) to measure assessment and 
communication of familial risk of CRC and referral for preventive measures in clinical practice 
and 2) to assess clinicians’ knowledge of familial risk of CRC and preventive measures, one 
year after publication of the new guideline.
 
Figure 1. Recommended preventive measures by familial risk of  colorectal 
cancer category
Familial CRC risk Recommendations for 
patients and relatives
Genetic counselling with 
10%
High tailored surveillance 
recommendations
17% Surveillance colonoscopies 
73% Moderate once every 6 years from age 45
Population screening with
Low FOBT once every 2 years
from age 55
In figure 1, the familial risk of colorectal cancer is shown in combination with the corresponding 
recommendations for colorectal cancer patients and their relatives. In our study, 10% of colorectal cancer 
patients had a high familial risk of colorectal cancer, 17% a moderate familial risk of colorectal cancer, and 
73% a low familial risk of colorectal cancer. 
CRC = colorectal cancer; FOBT = faecal occult blood test
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Table 1. Categorization of  familial risk of  colorectal cancer
Familial risk of colorectal cancer (CRC) based on the Dutch guidelines on hereditary colorectal cancer.14 
Individuals not meeting any of these criteria have a low familial risk of colorectal cancer (<10% 
cumulative lifetime risk).
High familial risk of CRC (>15%), indication for genetic counselling
Healthy individual or patient with MSI negative CRC and:
•	 First-degree relative with CRC or endometrial cancer before age 50
•	 Three or more (first- or second degree) relatives with CRC or LSAT before age 70
•	 Mismatch repair gene mutation in the family
•	 MSI positive tumour
Patient with CRC and:
•	 Age at diagnosis below age 50
•	 First-degree relative with CRC or LSAT before age 50
•	 Second CRC before age 70
•	 CRC and LSAT before age 70
•	 Two or more (first- or second degree) relatives with CRC or LSAT before age 70
Patient with colorectal adenoma with high-grade dysplasia before age 40
Patient with endometrial carcinoma before age 50
Moderate familial risk of CRC (10-15%), indication for surveillance colonoscopy every 3-6 years 
from age 45-50 but no genetic counselling
•	 Exclusion of hereditary CRC and diagnosis of familial CRC by a clinical geneticist 
•	 Two first-degree relatives with CRC between age 50-70
•	 A first-degree relative with CRC between age 50-70 and a second-degree relative with 
CRC before age 70
•	 A first-degree relative with an MSI negative CRC before age 50
First-degree relatives = parents, siblings and children; LSAT = Lynch syndrome associated tumours (i.e. 
malignancies of the endometrium, ovaries, stomach, small bowel, bile ducts, upper urinary tract and 
sebaceous glands); MSI = microsatellite instability; Second degree relatives = grandparents, aunts, uncles, 
nieces, nephews, grandchildren
METHODS
Study design and setting
Practice measurements were performed retrospectively among CRC patients and clinicians 
to measure assessment and communication of familial risk of CRC and preventive measures 
(surveillance colonoscopy and genetic counselling), and the uptake of these measures in 
clinical practice. Secondly, theoretical knowledge of familial risk of CRC and preventive 
measures was assessed in a national cohort study among clinicians. 
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Practice measurements
Patients and clinicians
CRC patients and their clinicians (surgeons and gastroenterologists) from eighteen Dutch 
community hospitals participated in the practice measurements. All patients newly 
diagnosed with colorectal adenocarcinoma before age 70 years between January 1st and 
July 31st 2009 were selected by the hospitals. Patients with previously known hereditary CRC 
were excluded. All patients received an information letter with an informed consent form 
and a questionnaire, signed by their clinician or the local study coordinator. Non-responders 
were mailed one reminder.
Patient baseline data including age, gender, and personal cancer history were collected 
retrospectively from medical records. Ethnicity, educational level and previous medical 
training were collected from questionnaires. Clinicians completed a questionnaire shortly 
before the start of the study providing baseline data on specialization and experience. 
Assessment of  familial risk of  CRC
Questionnaires and medical records were used to determine whether a family history of 
cancer was taken. If positive, the number of affected relatives, type of cancer (CRC, LSAT, or 
other), age at diagnosis and level of kinship were recorded. From patient questionnaires, 
family history was assessed for first-degree relatives (parents, siblings, and children) only. 
Formal familial risk of CRC and corresponding preventive measures were determined by 
one of the researchers (ND), using family history and microsatellite instability (MSI) test 
results on tumour tissue where available. A positive MSI test indicated a high risk for Lynch 
syndrome, the most common form of hereditary CRC. MSI testing was indicated in patients 
with CRC before age 50 years or a second CRC before age 70.14 
These formal familial risks of CRC (table 1) were based on criteria for MSI testing and the 
guideline criteria for referral for surveillance colonoscopy (for moderate risk of familial 
CRC) and genetic counselling (for high risk).14 Patients meeting the criteria for MSI testing 
in whom this was not performed, were scored as having a high formal familial risk of CRC. 
Endpoints
The endpoints were defined as follows:
•	 Familial risk of CRC assessed: Familial risk of CRC mentioned in medical records, or 
communication of the familial risk according to the patient questionnaire.
•	 Familial risk of CRC correct: Familial risk of CRC from medical records or patient 
questionnaires equal to the formal risk. 
•	 Preventive measures determined: Preventive measures (genetic counselling or 
surveillance colonoscopies, or explicitly no measures) mentioned in medical records 
and/or patient questionnaires. Recommendations for surveillance colonoscopy 
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for CRC patients themselves were not included, since they will be in follow-up for 
several years after diagnosis, and are not yet eligible for surveillance colonoscopy 
for their increased familial risk. 
•	 Prevention recommendations correct: Recommendations for preventive measures 
equal to formal measures: genetic counselling for a high familial risk of CRC; 
surveillance colonoscopy for a moderate familial risk of CRC; and no measures for 
a low familial risk of CRC.
•	 Uptake of prevention: For high familial risk of CRC patients: confirmation from a 
familial cancer clinic or the patient questionnaire that the patient had attended 
genetic counselling for CRC. For moderate familial risk of CRC patients: report in the 
patient questionnaire that their first-degree relatives had undergone one or more 
colonoscopy. For low familial risk of CRC patients: not having undergone these 
preventive measures. 
•	 Willingness to undergo preventive measures: This was determined from patient 
questionnaires by asking whether patients would want to attend genetic counselling, 
or whether their relatives would want to undergo surveillance colonoscopy upon 
clinicians’ recommendations. 
Statistical analysis
Descriptive statistics were used to present baseline data. Baseline data and endpoints 
were compared between different formal familial risk in CRC categories (high/moderate/
low and increased/low) using univariate analysis of variance (ANOVA), logistic regression 
and Pearson’s Chi-square test. Significance was set at p<0.05. All statistical analyses were 
performed using SPSS v16.0.
Knowledge survey 
Clinicians
All surgeons and gastroenterologists (including those in training), clinical oncogeneticists, 
and clinical geneticists in training from the Netherlands, and general practitioners (GPs) 
from the Nijmegen University Network of General Practitioners were invited to participate 
in a theoretical knowledge survey. The survey test version consisted of seven clinical cases 
(four high, one moderate, and two low familial risk of CRC), based on referral criteria for 
preventive measures.14 All cases described a fictitious patient and included information on 
the number of times they had had CRC (1-2), the number of CRC-affected relatives (0-3) and 
age at diagnosis. Twenty-three oncogeneticists and genetic counsellors reviewed the survey. 
Based on their suggestions, MSI test results were added to the cases, where applicable. The 
final survey was web-based and consisted of ten cases (four high-, four moderate- and two 
low familial risk of CRC). Clinicians assessed familial risk of CRC and preventive measures for 
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each case. Baseline variables were collected in the survey and included specialisation, age, 
gender, experience and whether in training or not. 
Statistical analysis
Data from clinicians who completed at least one case were included. Baseline variables 
are presented using descriptive statistics and compared between different familial risk of 
CRC categories (high/moderate/low and increased/low) using univariate ANOVA. Scores 
for familial risk of CRC and preventive measures were compared between clinicians using 
multivariate ANOVA. The influence of baseline variables on the scores were analyzed using 
univariate logistic regression. Significance was set at p ≤0.05. All statistical analyses were 
performed using SPSS v16.0.
RESULTS
Practice measurements
Patients and clinicians
Seventy three surgeons and 64 gastroenterologists participated. Of these, 50 (36%) 
completed a questionnaire. Their median age was 44 years (31-61) years; 36 clinicians (72%) 
were men. Their median experience was 9 (0-30) years. 
537 (65%) of 820 CRC patients completed a questionnaire. Another 100 patients (12%) met 
exclusion criteria during medical record analysis, mainly because their date of diagnosis 
did not fall within the study period (figure 2). Data on family history and MSI results were 
not reported in the medical records of another 79 (10%) patients, making it impossible to 
determine their formal familial risk of CRC. Baseline data of the 358 (44%) participating CRC 
patients are shown in table 2. Overall 60% (n=216) were male. Their median age was 61 
(25-69) years. Patients with an increased familial risk of CRC were significantly younger than 
low-risk patients (54 vs. 61 years, p<0.001). Nearly all (99%) patients were Dutch. 
Familial risk of  CRC
A family history was obtained in 348 (80%) patients. MSI testing was performed in 44 (67%) 
of 66 patients meeting the criteria for MSI testing.14 Combining family history and MSI 
results, the risk of CRC was high in 36 (10%) patients, moderate in 61 (17%), and low in 261 
(73%). The level of familial risk of CRC determined from the questionnaire equalled 47 (56%) 
of 84 patients who reported their risk level in the questionnaire. 
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Figure 2. Flowchart of  patient inclusion and familial risk stratification
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No participation: n=77 
No response: n=156 
Met exclusion criteria upon 
medical record analysis: 
Incorrect date of diagnosis: n=69 
No CRC: n=12 
Age above 69: n=10 
Hereditary CRC: n=9 
Total eligible 
n=437 
Total invited 
n=820 
Familial risk unclassifiable 
n=79 
Total included 
n=358 
Moderate risk 
n=61 
Low risk 
n=261 
High risk 
n=36 
Increased risk 
n=97 
 
In figure 2, the inclusion pathway and familial risk stratification of colorectal cancer patients in the clinical 
practice measures are shown.
CRC = colorectal cancer
Chapter 2
38
Table 2. Baseline characteristics of  358 colorectal cancer patients by familial 
risk of  colorectal cancer category
Baseline characteristics of 358 colorectal cancer patients whose data were available for familial risk 
stratification. Totals do not always add up to 100% due to missing data and/or rounding off.
Familial risk of CRC category High
n=36
Moderate
n=61
Low
n=261
Determinant n % / SD n % / SD n % / SD
Gender Male 23 64% 34 56% 159 61%
Age at diagnosis (years) Mean 55.1 11.7 53.9 10.7 61.0 5.3
Educational level
 Low
 Medium
 High  
13
15
7
36%
42%
19%
17
25
17
28%
41%
28%
88
110
62
34%
42%
24%
Previous medical training 1 3% 6 10% 12 5%
Personal history of previous cancer
 Any cancer
 Second CRC 
 LSAT
 Other cancer
17
12
4
1
47%
33%
11%
3%
13
8
0
6
21%
13%
0%
10%
28
0
0
28
11%
0%
0%
11%
TNM stage
 I
 II
 III
 IV
 Unknown
7
11
13
4
1
19%
31%
36%
11%
3%
11
19
21
8
2
18%
31%
34%
13%
3%
40
83
95
37
6
15%
32%
36%
14%
2%
Tumour location (proximal) 11 31% 11 18% 61 23%
Family history of cancer
 Any cancer 
 CRC 
 LSAT  
 Other cancer
20
12
3
10
56%
33%
8%
28%
43
39
2
16
70%
64%
3%
26%
112
52
14
64
43%
20%
5%
25%
CRC = colorectal cancer; LSAT = Lynch syndrome associated tumours (i.e. malignancy of the endometrium, 
ovaries, stomach, small bowel, bile ducts, upper urinary tract and sebaceous glands); SD = standard 
deviation; TNM = pathological staging of tumour size and invasion, lymph nodes and metastasis 
Preventive measures
Preventive measures were taken by 67% of CRC patients with an increased familial risk of 
CRC (n=65/97) (figure 3, table 3). Genetic counselling was recommended to one-third of 
patients with a high familial risk of CRC (n=12/36). Eight of these and another four patients 
in addition (33%) had attended genetic counselling. Twenty-nine (81%) high-risk patients 
wanted to be referred for genetic counselling if recommended by their clinician. 
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Surveillance colonoscopy for relatives were recommended to 31 (51%) of 61 patients with 
a moderate familial risk of CRC. Uptake of surveillance colonoscopy was 34% (n=21/61) in 
relatives of patients with a moderate familial risk of CRC. Forty-three (70%) patients with 
a moderate familial risk reported that their relatives would want to undergo surveillance 
colonoscopy if recommended by their clinician. 
Overall, measures were in accordance with guidelines in 233 (66%) of 358 CRC patients.14 
For genetic counselling, this was 12 (23%) of 53 and for surveillance colonoscopy, 21 
(29%) of 73. Seventy-seven percent (200/261) of low familial risk of CRC patients were not 
referred. The guideline recommendations were therefore followed significantly more often 
in patients with a low familial risk of CRC compared with those with an increased familial risk 
(33 of 97, 34%) (p<0.001).14
Table 3. Endpoint in 358 colorectal cancer patients by familial risk of  colorectal 
cancer category
Outcome of familial risk assessment, communication and referral for preventive measures for 
358 colorectal cancer patients whose data were available for familial risk stratification. Preventive 
measures in accordance with guidelines are shown in bold and underlined.
High
n=36
Moderate
n=61
Low
n=261
n % n % n % 
Clinicians
Familial risk of CRC assessed
                          Family history taken
                          MSI-test performed
33
11
92%
31%
59
39
97%
64%
261
12
100%
5%
Familial risk of CRC communicated  18 50% 37 61% 48 18%
Advice given for 
                          Genetic counselling
                          Surveillance colonoscopies
12
16
33%
44%
27
31
44%
51%
19
41
7%
16%
Patients
Uptake of 
                          Genetic counselling
                          Surveillance colonoscopies
12
9
33%
25%
23
21
38%
34%
18
43
7%
16%
CRC = colorectal cancer; MSI = microsatellite instability
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Figure 3. Results from the national knowledge survey versus actual uptake of  
preventive measures in clinical practice
   A. High familial risk of colorectal cancer
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20% Genetic 
10% counselling66%66 33%
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   B. Moderate familial risk of colorectal cancer      C. Low familial risk of colorectal cancer
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50% 64% 34%
Surveillance 40%
colonoscopies30%
20% Genetic 
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4 cases 61 patients                          
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80%
70%
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10% Genetic 
counselling0%
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In figure 3, referral for preventive measures is shown for colorectal cancer patients with A) high familial 
risk of colorectal cancer, B) moderate familial risk of colorectal cancer, and C) low familial risk of colorectal 
cancer. The left columns depict referral advice in accordance with guidelines: genetic counselling for a high 
risk, surveillance colonoscopies for a moderate risk, and no measures for a low familial risk of colorectal 
cancer. The middle columns depict clinicians’ advice in a national theoretical knowledge survey. The columns 
on the right depict actual uptake of these preventive measures by 358 colorectal cancer patients in clinical 
practice. 
Knowledge survey
Clinicians
2,169 clinicians were invited to participate in the knowledge survey, of whom 312 (14%) 
completed at least one case. They included 144 surgeons, 89 gastroenterologists, 37 clinical 
geneticists and 39 general practitioners. Three clinicians did not state their speciality. Two 
hundred (64%) were male and the median age was 42 (25-64) years; 91 (29%) were in 
training. The median duration of clinical experience was 6 (0-37) years. 
100%
90%
80%
70%
No measures60%
50%
Surveillance 40%
colonoscopies30%
20% Genetic 
10% counselling66%66 33%
0%
Guideline Theory - 4 Practice -
4 36 patientscases
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Assessment of  familial risk of  CRC 
Familial risk of CRC was correctly assessed in 55% of cases (table 4). Risk assessment was 
better for low (77% correct answers) than moderate (44% correct answers, p=0.005) and 
high familial risk (54% correct answers, p<0.001). Familial risk of CRC was underestimated in 
43% of individuals at increased familial risk. Clinicians’ characteristics such as speciality, age, 
gender, experience and being in training did not significantly influence these scores. 
Preventive measures
Preventive measures determined by clinicians were in line with guidelines in 65% of all cases 
and 66% of increased familial risk of CRC cases (table 4 and figure 3). Clinical geneticists 
correctly determined preventive measures in 82% of cases, compared with 58% of surgeons 
(p=0.012). This did not differ significantly from gastroenterologists (69%) or GPs (62%). Age, 
gender, experience and being in training did not significantly influence these scores. 
Table 4. Assessment of  the theoretical knowledge survey among 312 clinicians
Clinicians’ referral advice in ten fictional cases in a theoretical knowledge survey. Familial risk of 
colorectal cancer levels was high, moderate, or low. Preventive measures in accordance with guidelines 
are shown in bold and underlined.
Case Familial risk of CRC % Clinicians’ advice %
High risk 
(4 cases)
Underestimated
Correct
Overestimated
46%
54%
NA
No measures
Surveillance colonoscopies
Genetic counselling
3%
31%
66%
Moderate risk 
(4 cases)
Underestimated
Correct
Overestimated
39%
44%
17%
No measures
Surveillance colonoscopies
Genetic counselling
18%
64%
18%
Low risk
(2 cases)
Underestimated
Correct
Overestimated
NA
77%
23%
No measures
Surveillance colonoscopies
Genetic counselling
65%
32%
3%
Total Correct 55% In accordance with guidelines 65%
CRC=colorectal cancer; NA=not applicable
Chapter 2
42
DISCUSSION
One year after publication of a guideline on hereditary colorectal cancer, two-thirds of 
families with an increased familial risk of CRC underwent preventive measures.14 Referral 
was in accordance with guidelines in one-third of increased familial risk of CRC patients, 
while 23% of patients with a low familial risk of CRC were referred for preventive measures 
without indication. 
While a family history was taken in 80% of patients, familial risk of CRC was discussed by the 
clinician with only 57% of members of families at increased risk of CRC. This shows that the 
assessment, interpretation and communication of the familial risk need to be embedded in 
clinical practice. This may be achieved by appointing a well-trained healthcare professional 
to be responsible for familial risk assessment for all CRC patients and who would discuss the 
familial risk and any preventive measures required. Incorporating this into local protocols 
could improve the assessment of familial risk and serve as a reminder for clinicians to discuss 
familial risk and preventive measures with their patients.
Relatives in one-third of moderate familial risk of CRC families underwent surveillance 
colonoscopy, while willingness to undergo this investigation was twice as high. This may 
be for several reasons. Actual willingness and uptake may be lower than the reported data, 
since CRC patients reported this for their relatives, and it is known that relatives do not 
always inform each other that they had a colonoscopy.26 Unfortunately, directly approaching 
such relatives was not possible in our study for ethical reasons. Furthermore, both clinicians 
and patients may not realise that siblings have an increased familial risk of CRC. They think 
that only the children of the patient are at risk, and surveillance colonoscopy may not be 
discussed since the children are often too young. Also, not everyone follows surveillance 
recommendations, as colonoscopy uptake in relatives ranged from 48-83% in previous 
studies.16-18 
Only one third of all referrals for preventive measures in CRC patients with an increased 
familial risk was in accordance with the guidelines. The absolute number of patients at 
increased familial risk referred for preventive measures is roughly equal to the number 
referred with a low familial risk, for whom these measures are not indicated. Both underuse 
and overuse of preventive measures has a significant impact on patients and their relatives 
and may lead to the inefficient use of resources and unnecessary costs.
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Since the response rate of the clinicians was low, conclusions regarding their knowledge 
should be drawn with caution. They seemed to be more aware of preventive measures 
than the criteria for referral. Previous studies have shown comparable results. Thus, 26-
75% of clinicians recommended genetic counselling in individuals at high familial risk of 
CRC.24,25,27,28 Selection bias cannot be excluded, as clinicians interested in genetics may have 
been more willing to participate in the survey. Tailored paper and digital materials to further 
improve clinicians’ knowledge of familial risk of CRC assessment and preventive measures 
are currently being tested in a randomised controlled trial.28 
A main strength of this study is the use of mixed methods, as this gives a better view of actual 
practice. Generally, more information is communicated to the individual than is reported in 
the medical record. Another strength is the fact that a national sample of clinicians from 
multiple specialties involved in the care for CRC patients assessed the familial risk of CRC 
and preventive measures of realistic clinical cases. Unfortunately however, the participation 
was low in both the knowledge survey and the practice measurements. Clinicians may be 
reluctant to complete questionnaires for research purposes owing to their workload.29 
Furthermore, the survey could not be sent to gastrointestinal and oncologic surgeons 
specifically but it was sent to all surgeons, who do not all treat CRC patients. Thus, the actual 
participation rate was higher among surgeons. 
Another limitation of the study is that 19% of CRC patients were invited to participate 
despite meeting the exclusion criteria, generally due to registration errors. Participation 
was, however, high (65%) in the 670 patients who fulfilled the inclusion criteria. In some 
instances the familial risk may not have been assessed until one to two years after diagnosis, 
despite the recommendation in the guidelines that this should be done immediately after 
diagnosis.14 
In conclusion, the study showed that two-thirds of CRC patients and their relatives with an 
increased familial risk of CRC were referred for preventive measures. Half of these referrals 
were in accordance with the guidelines, while one quarter of patients with a low familial 
risk of CRC underwent preventive measures not indicated by the guidelines. Improving 
assessment of familial risk of CRC and referral for genetic counselling and surveillance 
colonoscopy can be accomplished by referring fewer CRC patients and relatives with a low 
familial risk and by improving the distinction between moderate and high risk. This will 
increase the efficacy of the process as fewer patients will be referred unnecessarily and lead 
to better cancer prevention of patients and their relatives with an increased familial risk of 
CRC in accordance with international guidelines. 
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ABSTRACT
Background: The Dutch Health Council recently recommended the introduction of a 
colorectal cancer (CRC) screening program by faecal occult blood testing (FOBT) for 
individuals aged 55-75 at population risk of CRC. Individuals at an increased familial CRC risk 
(≥ 2 times population risk) should be identified at a younger age, so they and their relatives 
can receive earlier, more intensive surveillance instead of FOBT.
Aims: To determine the percentage of participants with a positive FOBT in a CRC screening 
program with an increased familial CRC risk.
Methods: In a population-based study, 10,569 individuals aged 50-75 received an FOBT. 
Individuals with a positive FOBT were invited for colonoscopy and familial risk assessment. 
Participants with an average familial CRC risk were compared to those with an increased 
risk. Increased familial CRC risk was defined as a cumulative lifetime risk of CRC of at least 
10%.
Results: Of 6,001 participants, 430 had a positive FOBT, of whom 324 (63% males; mean 
age 63 years) completed colonoscopy and familial risk assessment. CRC (n=22) and/or 
advanced adenomas (n=122) were found in 133 participants. Familial CRC risk was increased 
in 6% of participants with a positive FOBT. No significant differences were found between 
participants with an average versus an increased familial CRC risk.
Conclusion: Six percent of participants with a positive FOBT had an increased familial CRC 
risk. Identifying at-risk participants enables them and their relatives to undergo regular 
colonoscopies. Adding familial risk assessment to FOBT screening may thus prevent a 
substantial number of CRCs. 
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INTRODUCTION
 
In Western society, the lifetime risk of developing colorectal cancer (CRC) is 5-6%.1-3 In 
concordance with advice by the European Union, the Health Council of the Netherlands 
recommended the introduction of a CRC screening programme for individuals aged 55-75, 
consisting of a biennial faecal occult blood test (FOBT), followed by colonoscopy in case of 
a positive FOBT.4,5
Familial and hereditary CRCs account for 15-20% of all CRCs.6-8 De Jong et al found that 
2.3% of the Dutch population had multiple relatives with CRC and/or a relative with CRC 
before the age of 50.7 Members of these families have an increased familial CRC risk, i.e., 
a cumulative lifetime risk of developing CRC of at least 10%. According to international 
guidelines, these individuals should be identified at a younger age than the advised 
screening age of 55-75 years, to receive increased surveillance by regular colonoscopy.9,10 
Surveillance of moderate to high risk groups by regular colonoscopy significantly reduces the 
incidence of CRC and CRC-related mortality.11,12 It is considered cost-effective to recommend 
a colonoscopy every 6 years from the age of 45 years to individuals with a moderate familial 
CRC risk of 10-15%.9,10,13,14 For individuals with a high familial CRC risk above 15%, referral to 
a clinical geneticist is recommended for more precise risk assessment and determination of 
individualised preventive measures.9,10,15
However, many individuals with an increased familial CRC risk are still unidentified. If they 
are invited for population CRC screening, three scenarios can occur: 1) they decline to 
participate; 2) they have a negative FOBT; or 3) they have a positive FOBT. With the current 
design of the screening program, only participants with a positive FOBT are invited for 
colonoscopy and familial risk assessment. Thus, individuals with an increased familial CRC 
risk in the first two groups will remain unidentified as being high-risk. As a consequence, 
they cannot benefit from surveillance by regular colonoscopies; nor can their close relatives, 
who may also have an increased risk of developing CRC. 
Two previous studies have assessed familial risk among participants in an FOBT screening 
program.16,17 In both studies, familial CRC risk was assessed using questionnaires, which 
were sent along with the invitation for participation in the screening program. However, 
Navarro et al excluded individuals meeting criteria for Lynch syndrome, and only determined 
whether participants had a positive family history, defined as having a family member with 
CRC, endometrial or kidney cancer.17 Worthley et al found that 4.2% of Australian participants 
had a familial CRC risk above 10%, warranting increased surveillance.16 In the present 
study, familial risk assessment was performed among participants with a positive FOBT by 
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an experienced nurse or gastroenterologist to determine the percentage of – previously 
unidentified- participants in a Dutch CRC screening program who have an increased familial 
CRC risk. 
METHODS 
Study design and setting
From June 2006 to February 2007, a random sample of 10,569 individuals aged 50-75 in 
Nijmegen and surrounding areas were invited to a pilot CRC screening program. Individuals 
were randomised to receive either a guaiac-based FOBT (gFOBT) (Hemoccult II®) or an 
immunochemical FOBT (iFOBT) (OC-sensor®). This population-based study is described in 
detail elsewhere.18
Individuals with a positive FOBT were invited for colonoscopy. Everyone who accepted the 
invitation was seen by a specialised nurse or gastroenterologist who took a medical and 
family history, with the aid of a checklist. If the family history was positive for cancer, a more 
detailed pedigree was drawn.
Colonoscopy was performed by an experienced gastroenterologist. If possible, all observed 
neoplasms were removed, and other lesions were biopsied, if necessary. Histology was 
evaluated by an experienced pathologist. All colonoscopies were completed in May 2007.
The study was reviewed and approved by the Dutch Health Council. All participants gave 
written informed consent for the FOBT and, if applicable, for colonoscopy.
Data collection 
From the checklists filled in during the visit and medical records, the following items were 
collected: demographic data (such as age and gender), FOBT results, pathology results, 
personal and family history of cancer, and possible confounders. Details and definitions are 
shown in table 1. Familial CRC risks were calculated from these data. Increased familial CRC 
risk was defined as a cumulative lifetime risk of CRC of at least 10%, i.e., a moderate or high 
familial CRC risk.9
Data analysis
Descriptive statistics were used to characterize the study population, family history and 
familial CRC risk. Age comparisons between the groups with true and false positive FOBTs 
were performed using independent samples T-tests (2-tailed). Gender (male/female), test 
type (iFOBT/gFOBT), personal and family history of any cancer/CRC/LSAT (yes/no) and 
possible signs of CRC, smoking and alcohol use (yes/no) were analysed as dichotomous 
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variables. These variables, as well as medication use (none/NSAIDs/anticoagulants/
combined use of NSAIDs and anticoagulants) and familial CRC risk categories (not increased 
[average] and increased [moderate or high]), were compared between participants with 
true and false positive FOBTs, and between participants with an average versus an increased 
familial CRC risk, using Pearson Chi-Square tests. 
Significance was defined at the p≤0.05 level. All statistical analyses were performed using 
SPSS version 16.0.
RESULTS 
Study population
Of the 10,569 participants, 57% (n=6,001) completed FOBT (Hemoccult® 51%, OC-Sensor® 
62%) (figure 1). A positive FOBT was found in 430 participants (7%). The study population of 
the present study consists of the 324 participants with a positive FOBT (75%) who completed 
colonoscopy and familial risk assessment. The study population was predominantly male 
(63%) with a mean age of 63 years (SD 6.9) (table 2). 
CRC (n=22) and/or advanced adenomas (n=122) were found in 133 participants. Thus, 
41% of participants had a true positive FOBT. The remaining 191 individuals had a false 
positive FOBT, with minor adenomas (n= 77) and/or other pathology (n=81), or no pathology 
detected (n=55). 
No significant relevant differences were found between participants with true versus false 
positive FOBTs. 
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Table 1. Variables measured in the study
Variable Definition
FOBT results:
True positive
False positive
CRC and/or advanced adenoma(s) upon colonoscopy
All other or no pathology upon colonoscopy
Pathology results:
Colorectal carcinoma
Advanced adenoma
Other lesions
Adenocarcinoma of the colorectum
Adenomas ≥ 10 mm, with high-grade dysplasia or a villous component ≥ 20% 19
Any lesions except for colorectal carcinoma or advanced adenoma (e.g., benign 
polyps, inflammations)
Personal history of:
- Any cancer
- CRC
- Definite LSAT
- Possible LSAT
Any malignant tumour
Adenocarcinoma of the colorectum
Epithelial ovarian carcinoma (including fallopian tube and primary peritoneal 
cancer), and malignancies of the endometrium, stomach, biliary tract, small 
intestine, upper urinary tract and benign and malignant tumours of the 
sebaceous glands 9
Abdominal tumours NOS, kidney tumours NOS, pancreatic cancer, and 
carcinomas of the brain and urinary bladder
Family history:
Family size
Family history of CRC
Family history of LSAT
Family history of other cancers
The number of first-, second-, and third-degree relatives
CRC in first-, second-, and/or third-degree relatives
LSAT in first-, second-, and/or third-degree relatives
Other cancers than CRC or LSAT in first-, second-, and/or third-degree relatives
Familial CRC riska:
Average (CRC risk <10%)
Moderate (CRC risk 10-15%)
High (CRC risk >15%)
Negative family history for CRC and LSAT; or one relative with CRC > 50 years
One relative with CRC < 50 years, or two first- or second-degree relatives with 
CRC between 50-70 years
Meeting Amsterdam I/II or Bethesda criteria 9,15,20,21
Confounders:
Possible signs of CRC
        
Medication use
Smoking
Alcohol use
Changed bowel habits, rectal blood lossb, melena, abdominal pain, feeling of 
incomplete bowel movement, unintentional weight loss
Use of NSAIDS and/or anticoagulants
Smoking of any amount of tobacco-containing products
Drinking of any amount of alcohol-containing beverages
CRC = colorectal cancer; FOBT = faecal occult blood test; LSAT = Lynch syndrome associated tumours; NOS = not 
otherwise specified; NSAIDs = Non-Steroidal Anti-Inflammatory Drugs
a Familial CRC risk = cumulative lifetime risk of developing CRC 
b Excluding bleeding from known haemorrhoids
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Table 2. Baseline characteristics of  324 individuals with a positive FOBT in a 
CRC screening program
False positive FOBT True positive FOBT Total
n % n % n %
N of individuals (% of total) 191 59.0 133 41.0 324 100
Male gender 115 60.2 90 77.7 205 63.3
Mean age (SD) 62.1 (7.0) 63.4 (6.7) 62.6 (6.9)
Number of iFOBTs (vs gFOBTs)* 173 90.6 108 81.2 281 86.7
Colonoscopy results†
- CRC
- Advanced adenoma
- Minor adenoma
- Other pathology
- No pathology
0
0
67
59
55
0
0
20.7 
30.9
28.8 
22
122
10
22
0
16.5
91.7
30.9
16.5
0
22
122
77
81
55 
6.8
37.7
23.8
25.0
17.0
Possible signs of CRC
- Changed bowel habits
- Rectal blood loss#
- Melena
- Abdominal pain
- Feeling of incomplete bowel movement 
- Unintentional weight loss
9
19
1
14
9
8
4.7
10.0
0.5
7.3
4.7
4.2
7
24
1
8
7
4
5.3
18.0
0.8
6.0
5.3
3.0
16
43
2
22
16
12
4.9
13.3
0.6
6.8
4.9
3.7
Medication use
- NSAIDs
- Anticoagulants
37
7
19.4
3.7
28
2
21.1
1.5
65
9
20.1
2.8
Smoking 44 23.0 43 32.3 87 26.9
Alcohol use 153 80.1 102 76.7 255 78.7
* p=0.021
† Results exceed 100%, since participants may have had more than one type of pathology
#Excluding bleeding from known haemorrhoids
CRC = colorectal cancer; FOBT = faecal occult blood test; gFOBT = guaiac-based FOBT; iFOBT = immunochemical 
FOBT; NA = not applicable; NSAIDs = Non-Steroidal Anti-Inflammatory Drugs; SD = standard deviation
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Figure 1. Flow chart from invitation to familial risk assessment
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Average familial CRC risk = cumulative lifetime risk of developing colorectal cancer below 10%; CRC = colorectal cancer; 
FOBT = faecal occult blood test; Increased familial CRC risk: cumulative lifetime risk of developing colorectal cancer of at 
least 10%
Invited for the study 
n=10,569 
Completed FOBT  
n=6,001 (57%) 
FOBT positive 
n=430 (7%) 
Completed colonoscopy and 
familial risk assessment 
n=324 (75%) 
Family history positive for CRC 
n=55 (17%) 
Average familial CRC risk: n=38 (12%) 
Increased familial CRC risk: n=17 (6%) 
 Moderate (10-15%): n=3 (0.9%) 
 High (> 15%): n=14 (4%) 
Declined FOBT 
n=4,568 
FOBT negative 
n=5,571 
Declined colonoscopy and/or 
familial risk assessment 
n=106 
Family history negative for CRC 
n=269 
Average familial CRC risk = cumulative lifetime risk of developing colorectal cancer below 10%; 
CRC = colorectal cancer; FOBT = faecal occult blood test; Increased familial CRC risk: cumulative lifetime risk 
of developing colorectal cancer of at least 10%
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Personal history of  cancer
Details of personal and family history are shown in table 3. Approximately 10% of all 
participants reported a personal history of cancer (other than CRC and Lynch syndrome 
associated tumours). Three participants had a positive history of CRC or LSAT. 
Family history of  colorectal cancer
Information on family size was reported in pedigrees of 38 participants (12%) and in most 
cases, only included the number of brothers, sisters and/or children. One participant was 
adopted; no information on her biological relatives was known. Fifty-five participants (17%) 
had a positive family history of CRC; 36 with a false positive FOBT and 19 with a true positive 
FOBT.  
Increased familial colorectal cancer risk
Six percent of participants had an increased familial CRC risk, i.e., a familial CRC risk above 
10% (n=6 and n=11 among participants with true and false positive FOBTs, respectively). 
Familial CRC risk was above 15% in fourteen participants. In the other 38 participants with 
a positive family history of CRC, familial CRC risk was below 10%. No significant differences 
were found between participants with an average versus an increased familial CRC risk (data 
not shown).
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Table 3. Personal and family history in 324 individuals with a positive FOBT in 
a CRC screening program
False positive FOBT
(n=191)
True positive FOBT
(n=133)a
Total
(n=324)
n % n % n %
N of patients with personal history of:
- Any cancer
- CRC/LSAT
14 
1 
7.3
0.5
18
2
13.5
1.5
32
3
9.9
0.9
N of patients with FH of CRC:
- Positive FH of CRC
- ≥ 1 FDR with CRC
- ≥ 1 SDR with CRC
- Unknowna
36 
36 
11 
0
18.8
18.8
5.8
0
19
19
0
1
14.3
14.3
0
0.8
55
55
11
1
17.0
17.0
3.4
0.3
N of patients with FH of definite/possible LSATb:
- Positive FH of LSAT
- ≥ 1 FDR with LSAT
- ≥ 1 SDR with LSAT
- Unknowna
5
5
0
0
2.6
2.6
0
0
0
0
0
1
0
0
0
0.8
5
5
0
1
1.5
1.5
0
0.3
N of patients with FH of other cancers:
- Positive FH of cancer 
- ≥ 1 FDR with cancer
- ≥ 1 SDR with cancer
- Unknowna
15 
15 
1 
0
7.9
7.9
0.5
0
5
5
0
1
3.8
3.8
0
0.8
20
20
1
1
6.2
6.2
0.3
0.3
Familial CRC risk:
- Average
- Moderate
- High
- Unknowna
180 
2 
9
0 
94.2
1.0
4.7
0
126
1
5
1
94.7
0.8
3.8
0.8
306
3
14
1
94.4
0.9
4.3
0.3
a 1 missing: family history unknown because of adoption
b 3 definite, 2 possible
CRC = colorectal cancer; FDR = first degree relative; FH = family history; FOBT = faecal occult blood test; 
LSAT = Lynch syndrome associated tumours; Definite LSAT = epithelial ovarian carcinoma (including fallopian 
tube and primary peritoneal cancer), and malignancies of the endometrium, stomach, biliary tract, small 
intestine, upper urinary tract and benign and malignant tumours of the sebaceous glands; Possible LSAT = 
abdominal tumours not otherwise specified (NOS), kidney tumours NOS, pancreatic cancer, and carcinomas 
of the brain and urinary bladder; SDR = second degree relative
DISCUSSION
In this study, 17% of participants with a positive FOBT in a CRC screening program had a 
positive family history of CRC. Six percent of participants had a familial CRC risk of at least 
10%. These prevalences are higher than previously reported in the general Dutch population 
by De Jong et al.7 They performed a study among 5,072 Dutch individuals aged 45-70, who 
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filled in a questionnaire about the occurrence of CRC in their first-degree relatives (FDRs). 
Eleven percent of the 3,973 responders reported at least one FDR with CRC, while 2.3% of 
unaffected responders reported a FDR with CRC diagnosed before the age of 50, or two or 
more FDRs with CRC (i.e., a familial CRC risk above 10%). We cannot exclude that a positive 
family history of CRC is one of the reasons to participate in a screening program.22 Also, 
advanced adenomas and CRCs might occur more often in participants with an increased 
familial CRC risk compared to those with a negative family history.23,24 Since family history was 
not assessed in participants with a negative FOBT and decliners, the number of individuals 
with an increased familial CRC risk may therefore be higher in our study.
However, our results are in line with two other studies. First, an Australian study, where 
19.6% of 2538 participants in an FOBT screening program reported a positive family history 
of CRC in a questionnaire.16 Of these participants, 106 (4.2%) had a familial CRC risk high 
enough to warrant increased surveillance by colonoscopy rather than participation in a 
screening program. However, of the 377 participants with an increased familial CRC risk, 
only 28 (7.4%) had a positive gFOBT or iFOBT. In a Spanish study, 731 of 18,405 participants 
(4.9%) in a gFOBT screening program reported a positive family history, defined as having 
a family member with CRC, endometrial or kidney cancer.17 Among those with a positive 
gFOBT, this percentage was 11.0%; 7.3% of participants with a negative gFOBT had a positive 
family history (p<0.005). 
Strengths of our study include the assessment of family history by a small number of nurses 
and gastroenterologists who are very experienced in familial and hereditary CRC and all 
determined familial CRC risk as defined by the most recent guidelines.9 Moreover, the large 
number of participants make for a good representation of the general population eligible 
for FOBT screening. A limitation of our study is that cancer diagnoses of relatives were not 
verified in medical records. The accuracy of a family history for CRC in first-degree relatives 
is very high, approximately 90%.25,26 However, such accuracy is lower for second- and third-
degree relatives, and for other cancer types, which can influence familial CRC risk. Since 
family history of colorectal cancer is correlated with family size, another limitation of our 
study could be that information about family size was mainly limited to first-degree relatives.7 
In addition, a quarter of all individuals with a positive FOBT did not complete colonoscopy 
and familial risk assessment, leading to a possible selection bias. We cannot be sure that no 
significant differences were present between individuals who underwent a colonoscopy and 
those who did not. Participants with a negative family history might feel that their risk of 
developing CRC is lower than in those with a positive family history and might therefore be 
less inclined to undergo colonoscopy and familial risk assessment.22 
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We estimated the number of CRCs that may be prevented by adding familial risk assessment 
to FOBT screening, based on the following assumptions. The first assumption is that the 
effectiveness of surveillance by regular colonoscopies in individuals with an increased familial 
CRC risk is identical to the effectiveness as described by Järvinen et al and Dove-Edwin et 
al.11,12 In the study by Järvinen et al, 6% of high-risk participants undergoing surveillance 
developed CRC during the 15-year follow-up of the trial, compared to 16% of participants 
who did not undergo surveillance.12 Dove-Edwin et al showed that the incidence of CRC was 
43% lower in high-risk individuals, and 80% lower in participants with a moderate familial CRC 
risk, than the expected incidence in the absence of surveillance.11 The second assumption is 
that participants have a mean number of three first-degree relatives (i.e., brothers, sisters 
and children) whose CRC risk is as high as that of the participant, and that these relatives do 
not yet participate in the screening program.13 Based on these assumptions, an additional 
172-184 CRCs may be prevented annually among participants with a positive FOBT and 
their relatives in the eligible Dutch screening population of 3.5 million individuals (with an 
expected uptake of 60%). This is just a tip of the iceberg, since many participants with a 
negative FOBT, as well as non-participants, also have an increased familial CRC risk.16,17 
In conclusion, six percent of participants with a positive FOBT in a CRC screening program 
had a familial CRC risk above 10%. Although the FOBT screening program may serve as a way 
to identify these individuals, they should be referred for intensive surveillance by regular 
colonoscopies instead of participating in the FOBT screening program. Adding familial risk 
assessment to population screening with FOBT may therefore lead to the prevention of a 
substantial number of CRCs. Other methods are needed to assess familial CRC risk among 
non-participants.
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ABSTRACT 
Background: Individuals with multiple relatives with colorectal cancer (CRC) and/or a 
relative with early-onset CRC have an increased risk of developing CRC. They are eligible 
for preventive measures, such as surveillance by regular colonoscopy and/or genetic 
counselling. Currently, most at-risk individuals do not follow the indicated follow-up policy. 
In a new guideline on familial and hereditary CRC, clinicians have new tasks in calculating, 
interpreting, and communicating familial CRC risk. This will lead to better recognition of 
individuals at an increased familial CRC risk, enabling them to take effective preventive 
measures. This trial compares two implementation strategies (a common versus an 
intensive implementation strategy), focussing on clinicians’ risk calculation, interpretation, 
and communication, as well as patients’ uptake of the indicated follow-up policy. 
Methods: A clustered randomized controlled trial including an effect, process, and cost 
evaluation will be conducted in eighteen hospitals. Nine hospitals in the control group will 
receive the common implementation strategy (i.e., dissemination of the guideline). In the 
intervention group, an intensive implementation strategy will be introduced. Clinicians will 
receive education and tools for risk calculation, interpretation, and communication. Patients 
will also receive these tools, in addition to patient decision aids. The effect evaluation 
includes assessment of the number of patients for whom risk calculation, interpretation, 
and communication is performed correctly, and the number of patients following the 
indicated follow-up policy. The actual exposure to the implementation strategies and users’ 
experiences will be assessed in the process evaluation. In a cost evaluation, the costs of the 
implementation strategies will be determined. 
Discussion: The results of this study will help determine the most effective method as well 
as the costs of improving the recognition of individuals at an increased familial CRC risk. It 
will provide insight into the experiences of both patients and clinicians with these strategies. 
The knowledge gathered in this study can be used to improve the recognition of familial and 
hereditary CRC at both the national and international level, and will serve as an example to 
improve care for patients and their relatives worldwide. Our results may also be useful in 
improving healthcare in other diseases.
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BACKGROUND
The lifetime risk of developing colorectal cancer (CRC) in Western society is 5 to 6%.1,2 
Familial and hereditary cancers account for approximately 15 to 20% of all CRCs.3-5 In these 
families, healthy relatives of CRC patients may have an increased risk of developing CRC 
themselves. This so-called familial CRC risk can be divided into three groups, based on 
cumulative lifetime risks of developing CRC:
1. Average: familial CRC risk below 10%.
2. Moderate: familial CRC risk of 10-15%. 
3. High: familial CRC risk above 15%.
For each group, a different follow-up policy applies. For individuals with an average familial 
CRC risk, neither surveillance nor genetic counselling is indicated. For individuals with a 
moderate familial CRC risk, surveillance by regular colonoscopy is indicated. For individuals 
with a high familial CRC risk, referral for genetic counselling is recommended. Identification 
of individuals with an increased familial CRC risk is crucial because surveillance significantly 
reduces CRC-related morbidity and mortality, by 43 to 80% and 65 to 81%, respectively.6,7 
Both underuse and overuse of surveillance and genetic counselling have a significant impact 
on patients and their relatives, and may lead to unnecessary costs. 
Familial CRC risk is assessed by family history and, in a subset of patients, microsatellite 
instability (MSI) analysis performed by pathologists. Unfortunately, both procedures 
are difficult. Previous research has shown that patient family history often is missing or 
incomplete, and information provided by patients is not always accurate.4,8-11 Furthermore, 
interpretation of the family history (determining the indicated follow-up policy) is not always 
correct.12 Pathologists’ selection of patients for MSI is often incomplete, while clinicians 
regularly interpret the results incorrectly.13 Consequently, only 12 to 30% of CRC patients 
with a high familial CRC risk are referred for genetic counselling.4,10,14-16 Other studies have 
shown that many CRC patients referred to a familial cancer clinic belong to an average or 
moderate risk population for whom genetic counselling is not indicated.17,18 
Clinicians involved in the care for CRC patients recognize the need for improvement in this 
area. Therefore, a multidisciplinary evidence-based guideline on familial and hereditary 
colorectal cancer (FHCC) was launched in the Netherlands in 2008.19 An important 
addition compared to previous national and international guidelines is that surgeons and 
gastroenterologists (referred to as ‘clinicians’ in this protocol) have new tasks in calculating, 
interpreting, and communicating familial CRC risk. Because clinicians are often unfamiliar 
with these tasks, implementation strategies are needed to ensure that patients and their 
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relatives receive proper counselling and follow-up.15 In a previous trial, an electronic 
reminder system specifically aimed at pathologists improved completeness of patient 
selection for MSI testing.13 In this trial, we will provide support at both clinician and patient 
level to further implement the guideline.
This trial compares two implementation strategies: a common strategy (i.e., dissemination 
of the guideline) versus an intensive implementation strategy, focussing on clinicians’ risk 
calculation, interpretation, and communication, as well as patients’ uptake of the indicated 
follow-up policy. An effect, process, and cost evaluation will be performed. The improvement 
of the identification and referral of patients at an increased familial CRC risk will lead to 
a higher number of individuals following an appropriate surveillance program, thereby 
reducing CRC-related morbidity and mortality. 
METHODS
Study design and setting 
A clustered randomized controlled trial including an effect, process, and cost evaluation 
will be conducted in eighteen community hospitals. All patients with CRC diagnosed 
under the age of 70 years and their clinicians will be invited to participate. To prevent 
contamination bias, randomization will take place at hospital level. Stratification will take 
place according to hospital size (<500, 500 to 700, and >700 beds), and be performed by 
means of a computerized randomization system. This study was approved by the Committee 
on Research Involving Human Subjects of the region Arnhem-Nijmegen. 
Primary objectives 
This trial compares two implementation strategies: a common strategy versus an intensive 
implementation strategy, focussing on clinicians’ risk calculation, interpretation, and 
communication, as well as patients’ uptake of the indicated follow-up policy. 
Hypothesis
Providing patients and clinicians with information on CRC, a risk assessment tool, risk 
communication aids, and decision aids will improve calculation, interpretation, and 
communication of the familial CRC risk by clinicians, as well as patients’ uptake of the 
indicated follow-up policy more than dissemination of the guideline only.
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Outcome measures 
Effect evaluation
1. The percentage of CRC patients for whom a correct familial CRC risk is calculated by 
clinicians.
2. The percentage of CRC patients for whom a calculated familial CRC risk is correctly 
interpreted by clinicians.
3. The percentage of CRC patients with whom a calculated familial CRC risk and/or follow-
up policy is communicated by clinicians.
4. Patients’ uptake of the indicated follow-up policy.
Process evaluation
1. Actual exposure to the different elements of the implementation strategies.
2. The experiences of patients and clinicians with these elements.
Cost evaluation
Costs of the implementation strategies in relation to the number of correctly referred 
patients.
Participants
Clinicians from eighteen hospitals will participate. All their patients diagnosed with CRC 
under the age of 70 years during the six-month inclusion period are eligible for inclusion. 
Patients must be able to provide informed consent and be able to read and understand 
Dutch. Patients previously referred for genetic counselling for CRC are excluded. Patients 
will be selected by PALGA (Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief), 
the nationwide network and registry of histo- and cytopathology in the Netherlands.20 
All patients will receive a patient information letter, signed by their treating clinician, along 
with an informed consent form. After signing the informed consent form, they will be 
included in the study. 
Interventions
Implementation strategies in both groups
In both the control group and the intervention group, clinicians will receive the FHCC 
guideline. 
Intensive implementation strategy in the intervention group
The intensive implementation strategy is summarized in figure 1 and consists of the following 
implementation tools: a website for patients and clinicians; education for clinicians; and a 
risk communication tool for clinicians.
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Figure 1. Intensive implementation strategy for the intervention group, aimed 
at both patients and clinicians
Figure 1. Intensive imple enta ion strategy for the intervention group, aimed at both patients and 
clin cians 
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The rhombuses in this figure represent the tasks clinicians have in calculation, interpretation and 
communication of the familial colorectal cancer (CRC) risk in CRC patients. It also shows the various 
elements of the intensive implementation strategy aimed at both patients and clinicians (in yellow and 
green, respectively) that will be compared to dissemination of the guideline on familial and hereditary 
colorectal cancer only. 
Familial CRC risk: cumulative lifetime risk of developing CRC for first-degree relatives of CRC patients. 
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Website
The website consists of the following items: 
1. A summary of evidence-based and relevant information about familial CRC risk (lifetime 
risk of developing CRC). Natural frequencies with the same denominator and visual 
displays will be used. Absolute risks will be presented, as well as in comparison to the 
population risk. The outcomes are offered in both positive and negative frames (e.g., 
the risk of developing CRC as well as the chance of not developing CRC). The focus is 
on familial CRC risk and the different follow-up policies. The information is presented in 
two different formats, one for patients and one for clinicians.
2. A risk assessment tool to calculate patients’ familial CRC risk. Patients fill in medical 
information about themselves and their relatives with regard to CRC and other cancers. 
Clinicians can use the tool as well. The calculated familial CRC risk is given in the same 
format as the rest of the website. Advice for follow-up is offered based on this risk, as 
well as a reminder to use the corresponding decision aid, if applicable.
3. Decision aids, aimed at facilitating decisions involving the uptake of the indicated 
follow-up policy (one for surveillance and one for genetic counselling). Tools supporting 
patients in making informed choices about their healthcare, such as decision aids, have 
been shown to improve knowledge, clarify preferences, and reduce uncertainty around 
decision making, with high levels of acceptability among consumers.21,22 The decision 
aids used in this trial provide balanced information on different options, i.e., to be 
referred for surveillance/genetic counselling or not. The following items are addressed: 
background information, benefits and harms, and the potential impact on the patient 
and their relatives. Worksheets are provided for patients to list and rate the importance 
of the benefits and harms for themselves. 
The website is available exclusively to patients and clinicians in the intervention group. A 
login name and password will be provided upon inclusion. Patients can use the website 
independently before or after regular follow-up visits, and are encouraged to discuss the 
results with their clinician. They are instructed to keep the decision aid within their family, 
and not share it for reasons of research integrity. To minimize contamination bias, after the 
trial all patients in the control group will be asked if they were exposed to the website. 
Education
In an educational meeting, clinicians in the intervention group will be trained to use the 
FHCC guideline. 
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Risk communication tool
Clinicians will receive a tool for communicating the familial CRC risk with their patients 
during a regular follow-up visit. The tool consists of written information and visual displays 
of the population risk of CRC, an explanation of the risk level of the patient and his/her 
relatives, as well as the indicated follow-up policy. It is designed in the same format as the 
website. 
Development of  the implementation tools
During development, the content and presentation of the website and the risk 
communication tool will be reviewed by physicians not specifically trained in genetics, and 
by non-medical personnel as well as representatives from the Dutch CRC patient associations 
(Vereniging HNPCC-Lynch and Stichting Doorgang). Improvements will be made based on 
their comments. Before use, the tools will be tested among approximately 20 patients and 
20 clinicians. The purpose of this pilot is determining whether the website and the tools are 
acceptable, the information is presented clearly, and the completion of the tools is feasible. 
Power calculation
To detect a difference of 20% between the intervention group and the control group in 
uptake of surveillance by colonoscopy in patients at moderate familial CRC risk, and 
referral for genetic counselling in patients at a high familial CRC risk, at least 186 patients 
are required (alpha=0.05, a two-sided testing and power=0.80). However, considering an 
intracluster-correlation coefficient of 0.15 and an average of five patients per clinician, at 
least sixty clinicians and 300 patients are needed. For eighteen hospitals this means three to 
four clinicians and 15 to 20 patients per hospital. 
Data collection
Baseline characteristics
Baseline characteristics from patients, clinicians, and hospitals will be collected in the 
following manner:
1. Patients: From PALGA, data including age, gender, and some medical information will 
be collected. Medical information includes diagnoses of cancer (diagnosed since 1971), 
cancer type, and age at diagnosis, as well as the result of MSI testing. The following data 
will be collected by a self-administered questionnaire: ethnicity, current marital status, 
educational level, previous medical or health training, and family history of cancer (type 
of cancer and age at diagnosis). Family history is collected for first-degree relatives (i.e., 
parents, siblings, and children).
2. Clinicians: All participating clinicians will be asked to provide baseline data (e.g., 
specialization, number of years of experience) in a questionnaire.
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3. Hospitals: From the hospitals’ websites, characteristics such as size, teaching status, 
and presence of an outpatient department for genetic counselling will be obtained.
Effect evaluation
Before introducing the implementation strategies, a baseline assessment of risk calculation, 
interpretation, and communication will be performed. Both the baseline assessment and 
the evaluation of the implementation strategies will be performed retrospectively in the 
same manner. Baseline characteristics will be collected in the manner described above. The 
measuring instruments will be developed by identifying all relevant variables and translating 
these into questionnaires. When possible, existing validated questionnaires will be used. 
The family history as reported by the patient in the questionnaire will be used to calculate a 
formal familial CRC risk and determine the indicated follow-up policy. This will be compared 
to the family history taken by the clinician, along with the risk calculation and interpretation 
performed by the clinician. These data will be extracted from the patients’ medical records. 
The medical records will also be used to determine the number of patients with whom the 
familial CRC risk and corresponding follow-up policy has been communicated. To determine 
the number of referred patients who actually visit a familial cancer clinic, these clinics 
will be asked to report whether these patients have visited. The uptake of surveillance by 
colonoscopy by first-degree relatives will be determined by asking the patients whether 
their relatives are actually screened. Medical records and results from the decision aids on 
the website will be used to determine whether patients at an increased risk who were not 
referred for surveillance or genetic counselling were not referred because they had chosen 
not to be referred or because it was not discussed. 
Process evaluation
In the process evaluation, data are collected on actual exposure of patients and clinicians 
to the different elements of the implementation strategies, as well as their experience with 
these elements:
1. Website: The website automatically records the following data when it is used: who 
used which elements; how often did users visit the different elements of the website; 
and how long did it take to use the different elements. By using questionnaires, users’ 
experiences with the website will be ascertained. 
2. Education: Attendance at the meetings will be determined by keeping an attendance 
list. The duration of the meetings will be recorded. In addition, clinicians’ experience 
with the meetings will be ascertained by using a questionnaire.
3. Risk communication tool: Patients and clinicians will be asked whether the tool was 
used. Their experience with the tool will be measured using questionnaires focussing 
on the perceived usefulness and usability of the tool. 
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Cost evaluation
Costs accompanied with the development and implementation of the website and risk 
communication tool will be accounted for, as well as the costs for dissemination of the 
guideline. Clinicians will provide time estimates to use the different elements. Costs will be 
correlated to the number of correctly referred patients.
Data analysis 
Effect evaluation
To analyze the effectiveness of both implementation strategies, descriptive statistics 
and multilevel analysis will be used. Patient, clinician, and hospital characteristics will be 
included in the multilevel analysis, allowing for correction of the effectiveness for probable 
differences in case mix between the different hospitals. The statistical analyses will be 
performed using SPSS version 16.0 for Windows. 
The percentage of correctly referred patients is defined as follows:
1. The percentage of patients at an average familial CRC risk who are not referred for 
surveillance or genetic counselling.
2. The percentage of patients at a moderate familial CRC risk who want to be referred and 
are referred for surveillance.
3. The percentage of patients at a moderate familial CRC risk who do not want to be 
referred and are not referred for surveillance.
4. The percentage of patients at a high familial CRC risk who want to be referred and are 
referred for genetic counselling.
5. The percentage of patients at a high familial CRC risk who do not want to be referred 
and are not referred for genetic counselling but are referred for surveillance if they opt 
for it.
6. The percentage of patients at a high familial CRC risk who do not want to be referred 
and are not referred for genetic counselling or surveillance.
Process evaluation
Frequencies and means are used to assess the actual exposure of the patients and clinicians 
to the elements of the implementation strategies and to assess their experience with 
these elements. A multilevel regression analysis will be applied to assess which elements 
of the intensive implementation strategy were particularly associated with effective 
implementation of the new FHCC guideline. 
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Cost evaluation
The costs of implementation related resource use will be calculated on a per patient basis. 
The costs of the use of each element per correctly referred patient will be calculated. The 
costs of the intensive implementation strategy will be compared to the costs of dissemination 
of the guideline only. 
DISCUSSION
Objectives
The aim of this trial is to compare two implementation strategies: a common implementation 
strategy (dissemination of the guideline only) versus an intensive implementation strategy, 
focussing on clinicians’ risk calculation, interpretation, and communication, as well as 
patients’ uptake of the indicated follow-up policy, such as referral for colonoscopy or genetic 
counselling.
Strengths and weaknesses 
To our knowledge, this is the first study of an implementation strategy designed to improve 
the recognition of patients’ familial CRC risk by addressing both patients and their clinicians 
(surgeons and gastroenterologists). If the intensive implementation strategy is successful, 
the elements (the website and the risk communication tool) can be released for general use 
by patients and clinicians. They may also serve as an example for other hereditary and non-
hereditary diseases. Our study will add knowledge to the effectiveness of patient decision 
aids and the best way of supplying patients and clinicians with information on disease risks. 
Some limitations need to be addressed. Family history as reported by the clinician will be 
compared to the family history reported by the patient in a self-administered questionnaire. 
Previous research has shown that the accuracy of family history of CRC in first-degree 
relatives reported by patients is approximately 90%.23 The optimal way of ensuring that 
the family history reported by the patient is accurate is by reviewing medical records of 
the affected relatives. Since written permission from relatives is needed to do so, this is not 
feasible and will therefore not be done in this study.
In our evaluation, only patients will be included; their relatives are not. Patients will be 
asked whether their relatives are screened, but the relatives will not be contacted to assess 
whether they actually received the results from the risk assessment and the matching 
advice. 
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Measurements may be contaminated in case others are provided with the login code for 
the website. 
Collecting data from medical records does not monitor everything that is discussed between 
the clinician and the patient. This may lead to underestimation of the risk interpretation and 
communication. Videotaping the consultations would shed light on the content and quality 
of the risk communication, but would also influence the intervention by reminding the 
clinician of the intervention. In this study, regular clinical practice will be left undisturbed as 
much as possible.
Implications 
The results of this study will help determine the most effective way of improving the 
recognition of individuals at an increased familial CRC risk. It will provide insight into the 
experiences of both patients and clinicians with these strategies.
This is important because many people are currently not treated according to evidence-based 
guidelines, and can benefit from proper cancer risk assessment and appropriate follow-
up, which has been proven to reduce morbidity and mortality. The knowledge gathered 
in this study may improve the recognition of familial and hereditary CRC at national and 
international level and serve as an example to improve care for patients and their relatives 
worldwide. In addition, our results may be useful in improving healthcare in other diseases.
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ABSTRACT
Objective: To describe the stepwise optimisation of a website aimed at improving familial 
colorectal cancer risk calculation, interpretation and communication. 
Design: Observational study.
Setting: University hospital in the Netherlands.
Participants: Colorectal cancer patients (n=20) and clinicians (n=12).
Intervention: A website with information on familial colorectal cancer, risk calculators for 
patients and clinicians and a decision support intervention for patients, based on scientific 
evidence and expert opinions.
Main outcome measures: Usability, understandability and perceived effectiveness of the 
website, and reasons for use.
Results: Pilot testing in two steps resulted in several improvements, particularly in 
the navigation and decision support intervention. After implementing these changes, 
users found the website easy to use and the information understandable. Patients and 
clinicians considered the website helpful in improving familial colorectal cancer risk 
calculation, interpretation and communication. Patients mainly wanted to use the website 
for information, while clinicians wanted to determine whether to refer their patients for 
preventive measures. 
Conclusions: Pilot tests among patients and clinicians show that the website is easy to use, 
understandable and seems effective in improving familial colorectal cancer risk calculation, 
interpretation and communication. Using a stepwise approach made it possible to 
thoroughly evaluate the website with a limited number of users. It is important to include 
representatives from possible users in the development process, since their reasons to use 
the website differ. Wide-spread implementation of the website could improve quality of 
care for colorectal cancer patients and their relatives by enabling them to undergo highly 
effective cancer prevention.
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INTRODUCTION
Surveillance colonoscopies in individuals with an increased familial colorectal cancer (CRC) 
risk reduce CRC-related morbidity and mortality with up to 80%.1,2 To enable CRC patients 
and their relatives to take these highly effective preventive measures, clinicians need to 
calculate the familial risk, determine whether preventive measures are indicated, and 
communicate this with their patients, who are asked to share this information with their 
relatives. However, currently only 12-30% of individuals with an increased familial CRC risk 
are referred for preventive measures in accordance with international guidelines.3-10
Familial CRC risk is divided into three categories: high (i.e., a cumulative lifetime CRC risk 
of more than 15%), moderate (10-15%), and low (below 10%).7,9,10 For high-risk families, 
genetic counselling is recommended. A clinical geneticist determines familial CRC risk 
and preventive measures for patients and their relatives, based on family history and 
DNA analysis. Less stringent surveillance is recommended for moderate-risk individuals: 
surveillance colonoscopies every six years, starting at age 45.7 Individuals with a low familial 
CRC risk are advised to participate in population screening programs.
To improve referral of patients and relatives with an increased familial CRC risk, both 
patient-directed and clinician-directed education can be effective.11 Supplying patients 
with information and decision support interventions can improve their knowledge and 
ability to discuss decisions regarding referral with their clinician.12 Patients’ knowledge and 
understanding are most effectively improved with tailored and interactive information, 
for which the Internet is an attractive option.13 Many patients are interested in obtaining 
cancer information and support online, and approve of computerized tools for familial risk 
assessment.14 A large number of clinicians use information and communication technologies 
in clinical practice, provided they are beneficial and easy to use.15
Thus, referral for surveillance colonoscopies and genetic counselling may be improved 
by providing CRC patients and clinicians with a website about familial CRC risk. Here we 
describe the pilot test of this website, which contains information, risk calculators, and a 
decision support intervention (DSI). Previous articles about development processes of 
similar tools emphasize the need for rigorous testing in several rounds.16-18 Since this is not 
always practical, we used a stepwise approach in the pilot test of our website, implementing 
changes from a limited number of participants (4-8) before going to the next round of 
testing. In addition to assessment of the website’s usability, understandability, perceived 
effectiveness, and reasons for use, we determined the effectiveness of this stepwise 
optimisation process.
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METHODS
General development
The website was developed together with stakeholders in accordance with published 
frameworks.16,17 During development, an expert panel provided their expertise on medical 
issues, patient communication and other issues. Subsequent versions were reviewed by 
representatives from patient associations and by clinical geneticists, genetic counsellors and 
other medical and non-medical personnel from the Radboud University Nijmegen Medical 
Centre (RUNMC). The website was available to users with a login code at http://www.risco-
darmkanker.nl. 
Description of  the website
Information on familial CRC risk
The information on familial CRC risk was presented in separate formats for patients and 
clinicians. It was based on the Dutch guideline for hereditary colorectal cancer and additional 
literature.7 Based on literature reviews and the views of our expert panel and the patient 
representatives, the information for patients contained information on general and familial 
CRC risk, surveillance colonoscopies and genetic counselling. The information for clinicians 
consisted of information on CRC risk, familial and hereditary CRC, including referral criteria 
for preventive measures. 
Much research has been done about how to optimise patients’ understanding and risk 
perception.13,19,20 Therefore, risks were presented in absolute frequencies and percentages, 
in both positive and negative frames. Risks were visualized using pie charts and pictographs 
(figure 1).
Risk calculators
Two separate familial CRC risk calculators were developed for patients and clinicians. Publicly 
available risk calculators were used as an inspiration to develop ours. Risk calculations were 
based on referral criteria for surveillance colonoscopies for moderate-risk families and 
genetic counselling for high-risk families.7 To check whether the results were consistent 
with the input, the risk calculators were tested using scenarios representing all possible 
combinations of answers. 
In the final versions, users entered information about cancer type and age at diagnosis for 
themselves and their first- and second-degree relatives. Cancer types included CRC and 
other tumours that influence familial CRC risk, such as endometrial and gastric cancer. Upon 
completion, familial CRC risk levels were given for the patient and their relatives, along 
with the corresponding advice (i.e., no measures, surveillance colonoscopies, or genetic 
counselling for a low, moderate and high familial CRC risk, respectively). Patients were 
encouraged to discuss these results with their clinician. 
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Figure 1. Example of  risk visualization: population risk of  colorectal cancer
Decision support intervention
Most high-risk CRC patients for whom genetic counselling is indicated, want to be referred.21,22 
Yet, since genetic counselling and testing can have negative psychosocial consequences, up 
to 20% of patients decline genetic counselling or have uncertainties regarding referral.21 
Therefore, a decision support intervention (DSI) was developed to help high-risk CRC 
patients elicit their values with regard to genetic counselling and make a personal decision 
whether or not to be referred. No DSI was developed for moderate-risk patients, as they will 
be in follow-up for at least five years after being diagnosed with CRC, and are not yet eligible 
for surveillance colonoscopies for their increased familial risk. 
The DSI was based on available examples, the Ottawa Decision Support Framework and 
International Patient Decision Aids collaboration’s checklist.23,24 It consisted of five steps. 
First, patients were encouraged to read information on genetic counselling, which explicitly 
stated that not everyone knows whether they want to be referred. On page two, patients 
answered general questions on their risk perception and decision making preferences. Next, 
eight commonly named pros and cons of genetic counselling were provided, which were 
collected from literature and reviewed by patient representatives, clinical geneticists and 
genetic counsellors. Patients could add one or two attributes that were important to them 
personally. In step three, they ranked these attributes on a Likert scale (1=very important; 
4=not important/not applicable). In step four, they were asked whether these items were 
reasons for them to be referred for genetic counselling or not. For example, for many people, 
receiving information on their risk of developing another cancer is a reason to attend genetic 
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counselling. However, this can be a reason to refrain from genetic counselling if one does 
not want to know this risk. Finally, patients identified the most important reason in step five.
The answers from step three and four were combined on a Likert scale (1=very important 
reason not to be referred for genetic counselling; 7=very important reason to be referred 
for genetic counselling). The score from step five was doubled and added to the total score. 
If the patient’s score was lower than the middle score, this means that they did not want to 
be referred (and vice versa). This was presented as follows: “Your answers indicate that you 
(want to / do not want to / do not yet know whether you want to) be referred for genetic 
counselling.” Patients were encouraged to discuss this with their clinician. 
Pilot test
In 2010-2011, a pilot test was performed to determine the website’s usability, 
understandability of the information, perceived effectiveness of the risk calculators and the 
DSI, as well as reasons to use the website. Patients diagnosed with CRC below age 75 who 
visited the surgery outpatient department or the familial cancer clinic of the RUNMC were 
asked to participate by their surgeon, surgical nurse or one of the researchers (ND). Patients 
were asked to read all information on familial CRC risk and to use their risk calculator and 
the DSI, regardless of their familial CRC risk. Additionally, surgeons, gastroenterologists, and 
medical oncologists of the RUNMC reviewed the website. These clinicians were asked to 
read all information and use their risk calculator. 
Users’ opinions and recommendations for improvement were collected with think-aloud 
techniques, semi-structured interviews and questionnaires. Questions were asked about 
their general opinion, usability and lay-out of the website. Understandability and added 
value of the information was assessed. For the risk calculators and DSI, users’ opinions 
were collected regarding ease of use and understandability of the results. Time needed to 
complete the risk calculators was measured, and perceived effectiveness was determined 
by asking users whether it provided more insight into the familial CRC risk. For the DSI, 
perceived effectiveness in supporting decision making regarding referral for genetic 
counselling was assessed. 
Users were invited for the pilot test until no more new suggestions for improvement were 
made. Technical problems were solved immediately; other changes were made after 
approximately one-third of potential users had reviewed the website, before going to the 
next revision round. The website was finalized using the recommendations of all users.
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RESULTS
Baseline characteristics 
Thirty-four colorectal cancer patients were invited to participate in the pilot test. Twenty of 
them (59%) participated: nine women and eleven men. Median age was 60 years (range: 
41-71 years); all patients were of Dutch ancestry. Patients had been diagnosed with CRC 
1-175 months previously (median: 22 months). Eight patients had finished higher education. 
Familial CRC risk was distributed as follows: six low, six moderate, and eight high risk. 
All twelve invited clinicians participated in the pilot test: seven surgeons, three medical 
oncologists and two gastroenterologists. Eight clinicians were men; median age was 45 
years (range: 36-57 years). Clinicians had been working as an attending clinician for 2-21 
years (median: 11 years) and treated between 1-100 new CRC patients each year (median: 
24). 
Pilot testing by patients
With a score of 7.5 on a scale of 1-10, CRC patients were generally positive about the 
website (table 1). This score was higher after implementing the adaptations from the first 
eight patients (7.3 vs. 7.7, respectively). Six of the first eight patients had problems with the 
navigation: it was not clear to them which information they had already read. Therefore, a 
contents page and an overview of the website were added. After these adjustments, users 
were much more positive about the navigation and could find their information more easily.
Sixteen patients (80%) felt the website was an addition to the information they had received 
from their clinician. Patients were particularly interested in the risk factors for CRC, and 
would have liked more information in this area, particularly on dietary issues. Changes 
included minor textual changes as well as the addition of short patient testimonials to help 
users imagine what surveillance colonoscopies or genetic counselling might mean for them. 
As for the risk calculator, four of the first eight patients found it difficult to use and 
offered suggestions for improvement. After implementing these, the next twelve patients 
considered the risk calculator easy to use, and found the results clear and helpful in providing 
more insight into their familial CRC risk and preventive measures for themselves and their 
relatives. Patients completed the tool in 3-11 minutes (mean: 6 minutes).
Although patients were generally positive about the decision support intervention, several 
adjustments had to be made during the pilot test. For example, the question “How important 
are these attributes to you?” led most patients to think that they were asked to which extent 
they agreed with the item. Therefore, the sentence “For me, this is ...” was added to each 
item. This had the wanted effect: in the new version, patients considered whether the 
items were important to them personally. Also, since patients found it difficult to name 
one main reason for (not) wanting to be referred for genetic counselling, this was changed 
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into providing two main reasons. After implementing the adjustments, eight out of twelve 
patients found the DSI easy to use, and helpful in deciding whether or not to be referred for 
genetic counselling. The final version of step three of the DSI is shown in figure 2. 
Patients mainly wanted to use the website to obtain more information and to review the 
information at their own convenience.
Table 1. Results from the pilot test of  the website
Items Questions Patients
n=20
Clinicians
n=12
n / score % / range n / score % / range
General opinion Total score (1-10)
Attractiveness
Improved risk communication
Use the website again
Recommend to others
                            To patients
                            To clinicians
7.5
17
ND
16
20
ND
6-9
85%
80%
100%
7.8
8
10
12
11
11
6-9
67%
83%
100%
92%
92%
Usability Ease of use
Ease of finding information
Navigation
16
16
12
80%
80%
60%
9
8
7
75%
67%
58%
Layout Clarity of information presentation
Use of visual displays
19
18
95%
90%
10
10
83%
83%
Information on CRC Added information / knowledge
Understandability of information
16
19
80%
95%
6
8
50%
67%
Risk calculator Ease of use
Understandability of results
More insight in familial CRC risk
16
14
15
80%
70%
75%
9
9
9
75%
75%
75%
Decision support 
intervention
Ease of use
Understandability of results
Helpfulness in decision making
11
16
12
55%
80%
60%
ND
ND
ND
CRC = colorectal cancer; ND = not determined
Pilot testing by clinicians
As shown in table 1, clinicians were positive about the website, with a mean score of 7.8 out 
of 10. This score was higher after implementing the adaptations from the first four clinicians 
(7.0 vs. 8.3, respectively). Clinicians found the website useful to review information, and 
mainly wanted to use it to determine whether to refer their patients for preventive measures. 
Their suggestions for improvement included leaving out ten-year risks of developing CRC 
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and only using lifetime risks, as well as improving the clarity of the text and moving around 
information to make it easier to find.
All clinicians felt that the risk calculator helped them calculate and interpret their patients’ 
familial CRC risk, completing the tool within 2-3 minutes, using an example of a patient with 
a positive family history of CRC.
Figure 2. Step three of  the decision support intervention for genetic counselling
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DISCUSSION
In this study, a website about familial colorectal cancer risk calculation, interpretation and 
communication was effectively optimised by following a two-step approach with a limited 
number of participants. Furthermore, we show the importance of involving users in the 
development of materials meant for them. While both patients and clinicians offered 
important suggestions for improvements, their reasons to use the website and therefore 
their suggestions for adjustments differed significantly. Patients mainly wanted to use 
the website to obtain information and to review it at their own convenience. In contrast, 
clinicians mainly wanted to use the website to determine whether or not to refer their 
patients for surveillance colonoscopies and/or genetic counselling. Adapting the website to 
users’ needs and preferences is important, to ensure benefit for future users. Doing this in 
a stepwise manner resulted in a thoroughly tested website with limited resources and time, 
making it a very practical development method.
The framework used to develop our website, the Knowledge To Action framework, resembles 
the development process as described by Elwyn et al.16,17 Among others, both recommend 
multiple review rounds by surrogate users. We show that a condensed form of this rigorous 
development process, with implementation of changes recommended by the first four to 
eight users, led to an effective optimisation of the website, with very positive judgments 
from the remaining participants. Users were invited until saturation was reached, in this case 
twenty patients and twelve clinicians in only two rounds, making this stepwise approach an 
attractive option for the development of future tools.  
Our website enables CRC patients to find out whether they have an increased familial risk, 
and which preventive measures are indicated for them and their relatives. The information 
and the decision support intervention help patients to make a personal choice regarding 
referral for genetic counselling and participate in a more equal discussion with their 
healthcare provider. This may be an important manner to improve quality of care, which 
is necessary as currently only 12-30% of high-risk individuals are referred for preventive 
measures.3-6 
One of the added values of our website over previous websites is that it combines information 
on familial CRC risk with risk calculators and a decision support intervention, suitable for 
both patients and clinicians. For example, Family Healthware™ is a self-administered, web-
based tool that assesses familial risk for CRC and other common diseases, and provides a 
personalized prevention plan.14,25 Some of their findings during usability testing were in line 
with our study, such as users skimming over texts instead of reading everything. However, 
Optimisation of  web-based interventions for familial colorectal cancer
87
5
Family Healthware™ does not provide specific information on familial CRC risk, and assesses 
risk for six diseases, whereas our website focuses specifically on CRC. In addition, their 
tool does not take into account other tumours that may influence familial CRC risk, such 
as endometrial cancer. Another strength of our website is that it is aimed at all risk groups. 
Many organizations provide information on hereditary CRC, but none of them provide 
specific information for individuals with a moderate familial CRC risk. 
Since our website contains is based on international evidence, it can easily be translated into 
English and other languages, reaching a large number of CRC patients and their relatives 
worldwide. However, it remains necessary to have the website evaluated by foreign patients, 
as all participants in our study were of Dutch descent. All foreign patients who were invited 
for the study declined, often because of an inability to understand Dutch.  
The use of patient testimonials remains controversial. Some authors have shown that 
patient testimonials influence users in making a choice, since it is difficult to balance the 
information and present it in such a manner that users view all options.26 Others find it 
helps patients in understanding their options, and how it may affect them if they choose one 
option or the other.27 Based on patients’ advice, we added short statements, derived from 
statements that patients gave during the pilot test. They were balanced to give both positive 
and negative views of surveillance colonoscopies and genetic counselling. 
The website is currently being evaluated in a randomised controlled trial to determine its 
effect on familial CRC risk calculation, interpretation and communication in clinical practice.28 
If the website and other materials are effective in improving the recognition of individuals 
with an increased familial CRC risk, they will become publicly available. Furthermore, the 
website will be adapted for use in healthy individuals interested in their familial CRC risk.
In conclusion, we show that using a stepwise approach to optimise a website aimed at 
improving familial colorectal cancer risk calculation, interpretation and communication is 
an effective manner to easily optimise it with a limited number of surrogate users. It is 
important to include representatives from all possible users in the development process of 
similar instruments, since their reasons to use the website, and thus their suggestions for 
improvement, may differ. Pilot tests among patients and clinicians show that the website 
is easy to use, understandable and is perceived as effective. Wide-spread implementation 
of the website could improve the quality of care for colorectal cancer patients and their 
relatives worldwide by enabling them to take highly effective cancer prevention measures.
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ABSTRACT
Aims: Only 12-49% of individuals with an increased familial colorectal cancer (CRC) risk are 
referred for effective preventive measures. This study determined use of and experiences 
with web-based and paper tools and their effect on uptake of genetic counselling (high risk) 
and surveillance colonoscopies (moderate risk).
Methods: Eighteen hospitals participated in a clustered randomised controlled trial. Nine 
intervention hospitals received access to a website for patients and clinicians, patient 
brochures, and education and pocket cards for clinicians. Patients in nine control hospitals 
received usual care. Data were collected from questionnaires and medical records. 
Results: Data were complete for 358/820 CRC patients (44%) and 50/137 clinicians (36%) at 
baseline, and for 392/862 patients (45%) and 47/137 clinicians (34%) at endpoint. 
Uptake of genetic counselling by high-risk patients was equal in the intervention group and 
the control group: 33% at baseline versus 15% at endpoint (p=0.003). Uptake of surveillance 
colonoscopies by moderate-risk relatives did not change significantly (intervention group: 
33% at baseline versus 19% at endpoint; control group: 36% at baseline versus 41% at 
endpoint). 
In the intervention group, 94/140 patients (67%) and 25/72 clinicians (35%) visited the 
website; 34/140 patients (24%) read the brochure. Patients valued clinicians’ information as 
most useful; clinicians preferred pocket cards and education. 
Conclusion: We found no effect of our tools on referral for preventive measures. Although 
the tools were appreciated, patients preferred clinicians’ advice regarding referral for 
preventive measures. It may therefore be useful to aim future interventions at healthcare 
professionals to improve familial cancer prevention.
* RISCO study group: E. Adang,  J. Kleibeuker, R. Tollenaar, E. Dekker, F. Menko, M. van Leerdam, P. van 
Duijvendijk, A. Tan, G. Nieuwenhuijzen, M. Liem, B. Lemaire, J. Tjhie-Wensing, K. Bosscha, D. Schipper, 
L. Engels, E. Keulen, M. Verhulst, G. Slooter, C. Hoff, H. Jebbink, F. Wolters, E. van Duijn, N. van Bentem, 
F. Berends, P. van de Meeberg, K. van Engelenburg, M. Grubben, J. Heisterkamp, I. Ahmad, A. Brink, A. 
Claassen, P. Swartbol, R. Van Roermund, J. Baumann, K. Bruin, M. Ibelings, R. Tobon Morales, J. Groen.
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INTRODUCTION
Surveillance colonoscopies for individuals with an increased familial colorectal cancer (CRC) 
risk decrease this risk with up to 80%.1-3 Recommendations on surveillance colonoscopies 
and genetic counselling are given in international guidelines.4-8 However, only 12-49% of 
increased-risk individuals are referred for these preventive measures.9-13 
In the Netherlands, a hereditary CRC guideline was developed in 2008.4 Three risk categories 
with corresponding preventive measures are distinguished. Individuals with a high familial 
CRC risk (above 15%) are advised to attend genetic counselling. A clinical geneticist then 
provides testing for hereditary cancer syndromes like Lynch syndrome and surveillance 
recommendations for patients and their relatives. For moderate-risk individuals (familial risk 
10-15%), surveillance colonoscopies are recommended every six years from age 45. For low-
risk individuals (familial risk below 10%), genetic counselling and surveillance colonoscopies 
are not recommended. 
The mere existence of guidelines does not mean that they are adhered to in practice. 
Generally, multiple barriers exist to guideline implementation.14 During development of the 
hereditary CRC guideline, clinicians and patients expected that important implementation 
barriers would be clinicians’ lack of knowledge of familial CRC risk interpretation (i.e. 
determination of preventive measures) and communication, and a lack of awareness among 
patients. As guideline implementation strategies are most effective when they tackle existing 
barriers, a tailored multi-faceted strategy was developed.14,15
We performed a clustered randomised controlled trial (c-RCT) evaluating the effect of the 
implementation strategy on referral for preventive measures. We aimed to increase referral 
adherence of increased-risk patients from 30% to 50%.9,15 To understand which elements of 
the implementation strategy were most effective, patients’ and clinicians’ exposure to and 
experiences with these elements were assessed in a process evaluation.
METHODS
Study design and setting
The c-RCT was performed among CRC patients and their clinicians (gastroenterologists and 
surgeons) in eighteen Dutch community hospitals.15,16 Hospitals were randomised using a 
computerized randomisation system after stratification according to size (<500, 500-700, 
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and >700 beds) and number of departments (gastroenterology, surgery, or both). The nature 
of the intervention prevented blinding. 
Participants
Newly diagnosed patients with colorectal adenocarcinoma under age 70 between January 
1st and July 31st, 2009 were selected by the hospitals and invited to participate in the baseline 
measurements. Between June 2010 and January 2011, all CRC patients diagnosed in the 
seven months following an introduction meeting for clinicians were invited for the endpoint 
measurements. Patients with known hereditary CRC were excluded. Patients received an 
information letter, signed by their clinician or local study coordinator, with an informed 
consent form. In the baseline measurements and the control group, a questionnaire was sent 
with the information letter 2-9 months after diagnosis. In the intervention group, patients 
were invited 2-3 months after diagnosis and asked to provide their e-mail address on the 
informed consent form to receive a login code for the website, followed by a questionnaire 
2-3 months later. Non-responders received one reminder.
Interventions
In nine control hospitals, the study was briefly introduced after the baseline measurements. 
Other than this presentation, usual care was followed. In the nine intervention hospitals, the 
implementation strategy was introduced, consisting of a website for patients and clinicians, 
patient brochures, and education and referral cards for clinicians. 
The website contained evidence-based information on familial CRC risk, risk calculators 
for CRC patients and clinicians, and a decision support intervention for high-risk patients, 
supporting them in deciding whether to be referred for genetic counselling. In pilot tests, 
CRC patients and clinicians found the website easy to use, understandable and helpful in 
determining which preventive measures were recommended, and in deciding whether 
to be referred for genetic counselling. Website access was restricted to users who were 
e-mailed login codes. 
Patient brochures, containing information on familial CRC risk and corresponding preventive 
measures, were given to clinicians for distribution among all new CRC patients. 
Clinician education consisted of a 30-minute presentation on familial CRC risk assessment 
and referral for preventive measures, given during routine clinical meetings. Pocket cards 
with referral criteria for genetic counselling and surveillance colonoscopies were handed 
out during this presentation.
Outcome measures
The main outcome measure was the percentage of CRC patients and/or first-degree 
relatives undergoing preventive measures in accordance with guidelines.4 Additional 
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outcome measures of the effect evaluation were the percentage of patients with whom 
their familial risk and preventive measures were communicated and the effect on the 
expected barriers: clinicians’ and patients’ knowledge and patients’ willingness to undergo 
preventive measures. For the process evaluation, exposure to and experiences with the 
implementation tools were studied.
Power calculation
As described elsewhere, sixty clinicians and 300 CRC patients were needed to detect a 
20% difference (30-50%) between the intervention group and control group in uptake of 
preventive measures by increased-risk patients, with alpha=5% and ICC=0.15.15
Data collection
Participants’ characteristics
Patients’ clinical characteristics such as age and educational level were collected with 
questionnaires and medical records. Clinicians completed anonymous questionnaires with 
items about their characteristics before and after the study.
Effect evaluation
Familial CRC risk
To determine whether family history was taken, questionnaires and medical records were 
used. If positive for cancer, the number of affected relatives, cancer type, age at diagnosis 
and level of kinship were collected from medical records. To determine familial CRC risk 
and corresponding indications for preventive measures, personal and family history of 
cancer were combined with the results from microsatellite instability (MSI) analysis, a test 
performed to determine the presence of an increased risk for Lynch syndrome.4,17 
Preventive measures
We recorded uptake of preventive measures and whether these were in accordance with 
guidelines.4 For high-risk patients and their relatives, attendance of genetic counselling 
or an appointment within the next six months was collected from questionnaires and 
familial cancer clinics. For moderate-risk families, patients were asked in questionnaires 
whether their relatives had planned or undergone one or more colonoscopies. For low-risk 
individuals, explicit absence of preventive measures was recorded as being in accordance 
with guidelines. Surveillance colonoscopies for CRC patients were not included, since they 
undergo colonoscopies for 5 years after diagnosis and not yet eligible for surveillance for 
their familial risk. 
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Secondary outcome measures
Clinicians’ objective knowledge was measured using seven clinical vignettes.16 Clinicians 
assessed familial CRC risk and preventive measures for each vignette. Patients’ and clinicians’ 
subjective knowledge of familial CRC risk and preventive measures was measured by asking 
them to score how much they felt they knew about these subjects on a Visual Analogue 
Scale of 0-100 mm. 
From medical records and patient questionnaires, communication of familial CRC risk and 
preventive measures by clinicians was assessed. Aspects of communication by patients with 
relatives about familial CRC risk were assessed with the Openness to Discuss Hereditary 
Cancer in the Family Scale.18 
Willingness to undergo preventive measures was determined by asking whether patients 
would want to attend genetic counselling, or whether their relatives would want to undergo 
surveillance colonoscopies, if recommended by their clinician. 
Process evaluation
Questionnaires, attendance lists and website records were used to assess patients’ and 
clinicians’ exposure to the implementation tools. Their experiences with these tools were 
collected from questionnaires, including reasons not to use the tools. Perceived effectiveness 
was determined with questions about the tools’ effect on knowledge, participation in 
decision making, and reassurance. Patients were asked whether they had discussed the 
website and brochure with their clinician and/or relatives. Patients and clinicians were 
asked to rate the three most useful tools. Clinicians were asked whether they would use the 
tools with future patients.
Data analysis
Clinical characteristics and outcome measures in high/moderate/low categories were 
reported using descriptive statistics, and compared between the intervention group and 
control group and between the baseline and endpoint measurements using univariate and 
multivariate logistic regression, independent samples T-tests and Pearson Chi-square tests. 
Multilevel analyses were not performed for lack of interhospital variation. All analyses were 
performed with SPSS v16.0, with significance at p<0.05. 
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RESULTS
Participants
Questionnaires were completed by 537/820 patients (65%) at baseline and 573/862 
patients (66%) at endpoint (figure 1). During medical record analysis, 100 and 97 patients 
met exclusion criteria, respectively. Formal familial CRC risks could not be determined in 
another 79 and 84 patients since their medical records lacked data on family history and MSI 
analysis. Clinical characteristics from the final cohort (358 at baseline and 392 at endpoint) 
are shown in table 1. Baseline and endpoint questionnaires were completed by 50 (36%) 
and 47 (34%) of 137 participating clinicians, respectively. 
Effect evaluation
Familial CRC risk
Family history was taken in 99% of patients at baseline (n=353) and at endpoint (n=388). 
Familial CRC risk was increased in 97 patients (27%) at baseline and in 118 patients (30%) at 
endpoint (figure 1).16 
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Table 1. Clinical characteristics of  colorectal cancer patients 
In table 1, clinical characteristics of the participating colorectal cancer patients are shown. Significant 
differences were seen for gender in the intervention group at baseline versus endpoint (1 p=0.012); 
for TNM stage in the control group at baseline versus endpoint (2 p=0.024); and for the distribution of 
familial risk of CRC at baseline in the intervention group versus the control group (3 p=0.001). Totals do 
not always add up to 100% due to missing data and/or rounding off. 
Baseline Endpoint
Intervention 
n=187
Control 
n=171
Intervention 
n=140
Control 
n=252
n % / SD n % / SD n % / SD n % / SD
Gender 1 Male 107 57% 109 64% 99 71% 167 66%
Age at diagnosis Mean (SD) 59 7.6 60 8.2 60 7.3 59 7.5
Nationality Dutch 185 99% 168 98% 136 97% 248 98%
Marital status Married/cohabitant 152 81% 149 87% 116 83% 211 84%
Educational level
 Low
 Medium
 High  
60
78
48
32%
42%
26%
58
72
38
34%
42%
22%
33
59
44
24%
42%
31%
87
98
62
35%
39%
25%
Previous medical training 10 5% 9 5% 7 5% 16 6%
Personal history of cancer
 Second CRC
 LSAT
8
1
4%
1%
12
3
7%
2%
7
2
5%
1%
11
2
4%
1%
TNM stage 2
 I
 II
 III
 IV
 Unknown
29
53
67
32
6
16%
28%
36%
17%
3%
29
60
62
17
3
17%
35%
36%
10%
2%
27
38
56
19
0
19%
27%
40%
14%
0%
62
56
100
32
2
25%
22%
40%
13%
1%
Tumour location (proximal) 42 23% 41 24% 39 28% 61 24%
Family history of cancer
 CRC
 LSAT 
54
9
29%
5%
49
10
29%
6%
44
8
31%
6%
81
12
32%
5%
Familial CRC risk 3
 High
 Moderate
 Low
9
39
139
5%
21%
74%
27
22
122
16%
13%
71%
13
26
101
9%
19%
72%
33
46
173
13%
18%
69%
CRC = colorectal cancer; LSAT = Lynch syndrome associated tumours (i.e. malignancies of the endometrium, 
ovaries, stomach, small bowel, bile ducts, upper urinary tract and sebaceous glands); SD = standard 
deviation; TNM = pathological staging of tumour size and invasion, lymph nodes and metastasis 
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Figure 1. Patient flow at endpoint


Total invited 
n=862 
Control group 
Invited 
n=470 
Completed 
questionnaire 
n=356 (76%) 
Medical record 
analysis 
n=314 (67%) 
Intervention group  
Invited 
n=392 
Website access and 
sent questionnaire 
n=247 (63%) 
Completed 
questionnaire 
n=217 (55%) 
Medical record 
analysis 
n=162 (41%) 
Deceased: n=5 
No CRC: n=3 
Double: n=1 
 
No participation: n=42 
No response: n=63 
Incorrect diagnosis date: n=28 
No CRC: n=3 
Age > 69: n=4 
Hereditary CRC: n=2 
Unknown: n=5 
No internet: n=17 
Deceased: n=5 
No CRC: n=1 
Double: n=1 
Mental retardation: n=1 
 
No participation: n=65 
No response: n=54 
Deceased: n=2 
No CRC: n=2 
Lynch syndrome: n=1 
 
No response: n=25 
Incorrect diagnosis date: n=39 
No CRC: n=7 
Age > 69: n=2 
Hereditary CRC: n=4 
Unknown: n=3 
Familial risk unclassifiable 
n=62 
Familial risk unclassifiable 
n=22 
Low risk 
n=173 
Moderate risk 
n=33 
High risk 
n=46 
Increased  risk 
n=79 
Low risk 
n=101 
Moderate risk 
n=26 
High risk 
n=13 
Increased  risk 
n=39 
In figure 1, the flow of colorectal cancer patients in the endpoint group is depicted. 
CRC = colorectal cancer 
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Preventive measures
Uptake of genetic counselling by high-risk CRC patients and their relatives was 33% at 
baseline versus 15% at endpoint (p=0.003), with equal percentages in the intervention 
group and the control group (table 2). Uptake of surveillance colonoscopies by moderate-
risk relatives was comparable at baseline (intervention group: 33%; control group: 36%), but 
lower in the endpoint intervention group (19%) than in the control group (41%, p=0.015).
Secondary outcome measures
Overall, clinicians’ knowledge was better in the intervention group than in the control group 
at baseline and endpoint (table 3). In the intervention group, knowledge of familial CRC 
risk was lower at endpoint compared to baseline (p<0.001), while knowledge of preventive 
measures had increased (p=0.010). In the control group, objective knowledge of familial 
risk (p=0.015) and preventive measures (p<0.001) was higher at endpoint, while subjective 
knowledge had decreased (p<0.001). 
Patients’ secondary outcomes are shown in table 4. Subjective knowledge of familial risk 
was higher in the endpoint intervention group than in the control group (p=0.024), while 
knowledge of surveillance colonoscopies was lower at endpoint compared to baseline in 
both the intervention (p<0.001) and the control group (p=0.035). 
Familial CRC risk was communicated by clinicians with 23% of patients at baseline (n=84) 
and 37% of patients at endpoint (n=146; p<0.001), with increases in all risk categories, but 
no differences between control and intervention hospitals. In the endpoint intervention 
group, patients considered communication about familial CRC risk with relatives easier than 
at baseline (p=0.003) and compared to the endpoint control group (p=0.033). 
Willingness to undergo preventive measures did not change after the intervention.
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Process evaluation
The website was used by 94/140 patients (67%), of whom 83 completed questionnaires. 
Sixty-one patients (73%) were positive about the website, mainly because it increased their 
knowledge (n=46), enabled them to better participate in decision making (n=29), and/
or increased reassurance (n=25). Patients’ main reasons not to use the website were not 
wanting to deal with potential hereditary CRC (n=40), and technical problems including 
forgotten login codes (n=34). Nine patients (11%) reported negative experiences, mainly 
increased worry (n=6) and/or confusion (n=6). Five patients (6%) discussed the website 
with their clinician or general practitioner, and 19 patients (23%) discussed it with relatives. 
Thirty-four patients (24%) read the brochure; 91% of patients who did not read it reported 
that they had not received it. Patients valued information from their doctor as the most 
useful, followed by the brochure and our website (figure 2). 
Two-thirds of clinicians (n=48/72) attended the education meeting, and 25 (35%) used the 
website. Twenty clinicians completed questionnaires. They rated the referral cards and the 
education meeting as the most useful implementation tools (figure 2). Fifteen clinicians 
(75%) indicated that they intended to continue to use the tools.
Figure 2. Perceived usefulness of  the implementation tools by patients and 
clinicians 
Information from clinician Clinicians
Information from other healthcare Patients
provider
Brochure
Information on other websites
Information on our website
Decision suppport intervention
Risk calculator
Pocket referral card
Education meeting
Other
0 0,5 1 1,5 2 2,5 3
In figure 2, the perceived usefulness of the implementation tools by colorectal cancer patients and clinicians 
is depicted. Higher scores reflect a higher perceived usefulness.
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DISCUSSION
After introducing a tailored guideline implementation strategy, less individuals with an 
increased familial colorectal cancer risk attended surveillance colonoscopies and genetic 
counselling. CRC patients preferred advice from their doctor regarding preventive measures 
for an increased familial risk, while web-based and paper tools were appreciated as additional 
resources. Nevertheless, positive effects were seen regarding patient outcomes: familial risk 
was discussed more often, patients felt better informed and more able to participate in 
decision making, and found it easier to discuss familial risk and preventive measures with 
their relatives. 
Unexpectedly, fewer patients underwent preventive measures at endpoint. Others have 
found that patients’ uptake of CRC screening was lower after using a decision aid.21 It is 
unlikely that this was the case in our study, since patients’ willingness to undergo preventive 
measures did not change. Probably, less increased-risk patients were referred for preventive 
measures by their clinician. Clinicians may assume that patients do not want to be confronted 
with an increased familial risk shortly after receiving a cancer diagnosis, or referral may not 
have taken place yet, since referral was assessed 2-12 months after diagnosis. 
Our findings are in line with an international survey among 15,165 people, where 88% 
of participants regarded clinicians as the most credible health information source.19 
Others found that the Internet was patients’ first information source for hereditary cancer, 
followed by their doctor.20 Since clinicians play such an important role, it is vital that they 
can identify and refer patients with an increased familial risk. Their knowledge needs to 
be improved, and clinicians realize this. It may be useful to focus on improving clinicians’ 
familial CRC risk interpretation and communication, ensuring better referral, in addition to 
patients’ understanding and acceptance of why they are (not) referred.
Our intervention was effective on improving patient-related outcomes. Patients who used 
the tools had better knowledge, felt they could participate better in decision making, and 
found it easier to communicate with their relatives. A strength of our study is the fact that 
the implementation tools were based on international evidence and developed together 
with potential users in a thorough manner, making the results applicable for non-Dutch 
patients and their clinicians. Furthermore, clinical practice was left undisturbed as much 
as possible, making it easier to estimate the effect of the implementation tools outside the 
research setting. However, only a limited number of participants used the implementation 
tools. Another limitation of this study is that using a combined intervention does not allow 
insight in what is more effective: clinician-directed or patient-directed components. Also, the 
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small number of patients with an increased familial CRC risk and the different recruitment of 
the endpoint intervention group need to be taken into account. A recruitment bias cannot 
be excluded, as shown by the differences in clinicians’ knowledge and in patients’ gender 
and TNM stage.
For better referral rates, familial CRC risk interpretation needs to be incorporated into routine 
clinical practice. Possible solutions include making one well-trained healthcare provider 
responsible for familial risk interpretation in all new CRC patients, and providing them with 
tools to do this, possibly further augmented with reminders.22 Recently, we developed a 
digital referral test for assessment of familial CRC risk and preventive measures, which has a 
high sensitivity and was found easy to use.23 
In this era of e-health and patient-based interventions, CRC patients value their doctors’ 
advice as most important when considering preventive measures for an increased familial 
risk. Web-based and paper tools may be used additionally, to improve patients’ knowledge, 
communication and participation in decision making. Since only a minority of CRC patients 
and their relatives undergo effective cancer preventive measures, improvement is needed. 
While empowering patients remains important, focussing on improving healthcare 
providers’ knowledge may be needed for better cancer prevention. 
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ABSTRACT
Aims: Currently, only 12-30% of individuals with a high risk for Lynch syndrome, the most 
common hereditary colorectal cancer (CRC) syndrome, are referred for genetic counselling. 
We assessed sensitivity, usability and user experiences of a new online referral test aimed at 
improving referral of high-risk individuals for genetic counselling.
Methods: Sensitivity was assessed by entering pedigree data from high-risk individuals 
(i.e., Lynch syndrome mutation carriers) into the referral test to determine whether genetic 
counselling was recommended. For usability, we assessed non-medical staff members’ ability 
to determine referral according to guidelines in seven fictive clinical cases using the referral 
test after minimal training. Real-life users answered questions about their experience with 
the referral test.
Results: Sensitivity of the referral test was 91% for mutation carriers with CRC (n=164) and 
73% for all affected and non-affected mutation carriers (n=420). Non-medical staff members 
(n=20) determined referral according to guidelines in 84% of cases using the referral test. 
Ten percent of real-life users (n=256/2470) provided feedback about experiences; 71% of 
them reported that the referral test increased reassurance, certainty about their familial risk 
and/or certainty about referral. 
Conclusion: The referral test has a high sensitivity in detecting individuals with a high risk 
of Lynch syndrome and is suitable for use in clinical practice. Widespread use of the referral 
test should improve cancer prevention in high-risk patients and their relatives. 
Referral test detects most patients with a high familial colorectal cancer risk
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INTRODUCTION
Individuals with an increased familial risk of colorectal cancer (CRC) can decrease their risk 
of developing CRC with up to 80% by undergoing surveillance colonoscopies.1,2 Surveillance 
recommendations depend on the familial CRC risk level, which can be high, moderate or 
low.3-5 For individuals with a high familial CRC risk of more than 15%, genetic counselling is 
recommended. Based on family history and DNA analysis, a clinical geneticist can diagnose 
the presence of hereditary CRC such as Lynch syndrome (Hereditary Nonpolyposis Colorectal 
Cancer or HNPCC). Lynch syndrome is caused by mutations in the mismatch repair (MMR) 
genes MLH1, MSH2, MSH6, PMS2 and the EPCAM gene.6 Mutation carriers have a very high 
lifetime risk of developing CRC and endometrial cancer of up to 80% and 71%, respectively, 
and increased risks of other Lynch syndrome associated tumours such as ovarian, urothelial, 
gastric, and other cancers.6-11 The risk of these cancers varies for different gene mutations; 
for example, extracolonic cancers are more prevalent in MSH2 mutation carriers, compared 
to MLH1 and MSH6.8-10
For individuals with a high familial CRC risk, surveillance recommendations in international 
guidelines include biennial colonoscopies starting at age 25, gynaecological surveillance 
from age 30-35, and in selected families, surveillance for urothelial and gastric cancer.3-5 
For individuals with a moderate familial CRC risk of 10-15%, less stringent surveillance is 
advised with colonoscopies once every 6 years from age 45 without genetic counselling.3 
For individuals with a low familial risk (below 10%), participation in population screening 
programs is recommended.
Both patients affected with cancer and their healthy relatives with a high familial CRC 
risk can be referred for genetic counselling, although further genetic testing is preferably 
performed in affected relatives first. In the Netherlands, costs of genetic counselling and 
testing are fully covered by health insurance, which is compulsory for all citizens. However, 
many CRC patients and their relatives encounter difficulties when determining whether 
they are eligible for genetic counselling, since little information is available to them.12 Many 
clinicians lack knowledge on calculation and interpretation of the familial CRC risk, as these 
tasks are new for most clinicians outside the field of genetics.13 Consequently, at present 
only 12-30% of CRC patients and their relatives at high risk for Lynch syndrome are referred 
for genetic counselling and highly effective surveillance colonoscopies.14-16 
To improve referral rates for genetic counselling, providing clinicians, patients and their 
relatives with information on their familial CRC risk can be effective.17 Prior research has 
shown that web-based interventions offer several advantages over traditional media such 
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as printed materials, including easy wide-spread distribution and tailoring of surveillance 
recommendations to individual users at low cost. 18-20 Such applications are highly acceptable 
to both patients and clinicians, provided they come from a reliable source, and are effective 
and easy to use.21,22 Providing users with personal advices on how to decrease health risks is 
one important reason why users keep using health-related websites.19 
Therefore, a new online referral test was developed, which provides users with 
recommendations for genetic counselling (for a high familial CRC risk), surveillance 
colonoscopies (for a moderate familial CRC risk) or neither, based on their personal and 
family history of CRC and related tumours. Before this referral test is implemented in daily 
practice, it is important to assess sensitivity, specificity, usability and real users’ experiences. 
In the first part of this paper, we focus on the sensitivity of the referral test for identifying 
individuals with a high familial CRC risk for whom genetic counselling is indicated. 
Unfortunately, the specificity of the referral test could not be determined, because a 
control group from the general population could not be assessed for ethical reasons. In 
addition, we determine test usability by assessing whether non-medical staff members 
can determine appropriate referral using the test after minimal training. This would enable 
them to complete the referral test together with patients, thus enhancing the effectiveness 
and quality of the consultation with the clinician or general practitioner. Finally, we assess 
real users’ experiences to improve the referral test. Therefore, the aim of this study was to 
(1) assess sensitivity of the referral test for identifying individuals with a high familial CRC 
risk eligible for genetic counselling; and (2) determine its usability and user experiences.
METHODS
Development of  the referral test
The aim of the online referral test “Risk of hereditary colon cancer” is to determine whether 
patients and their relatives are eligible for genetic counselling for a high familial CRC risk 
or surveillance colonoscopies for a moderate familial CRC risk. The version described in 
this article is aimed at healthcare providers as well as non-medical users from the general 
population, whether they are affected with CRC or not. The content was based on the 
Dutch guidelines on hereditary colorectal cancer.3 A literature and an internet search were 
performed to identify existing risk calculation tools publicly available online, in English and/
or Dutch. These tools were used as an inspiration for the format of our referral test. To 
check the quality of the results, the referral test was tested using scenarios representing all 
possible combinations of answers.
Referral test detects most patients with a high familial colorectal cancer risk
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To assess acceptability, understandability and feasibility of completion, subsequent versions 
were reviewed by oncogeneticists and genetic counsellors, representatives from CRC patient 
organizations and non-medical personnel from the Radboud University Nijmegen Medical 
Centre (RUNMC). Changes were mainly textual. Opinions differed about the format of the 
answer options (filling in yes/no for each item versus only checking the applicable items); in 
the version of the referral test described in this paper, the yes/no option was used.
Format of  the referral test
Users enter the history of CRC and other Lynch syndrome associated tumours such as 
endometrial, ovarian and urothelial cancer for patients and their first- and second-degree 
relatives (figure 1). These entries are weighed against the referral criteria for genetic 
counselling (for a high familial CRC risk) and surveillance colonoscopies (for a moderate 
familial risk) from the evidence-based guideline, as shown in table 1.3 One of three 
possible results is provided: 1) high familial CRC risk with advice for genetic counselling; 2) 
moderate familial CRC risk with advice for surveillance colonoscopies every 6 years from 
age 45; or 3) low familial CRC risk with advice for no additional measures, as the Dutch 
population screening program had not yet started at the time of this study. Also, a link to 
more information is given. Non-medical users are recommended to discuss the results with 
their healthcare provider, who can then refer them for genetic counselling or surveillance 
colonoscopies in case of an increased familial CRC risk.
Figure 1. Screen shots and QR code of  referral test 
    
In figure 1, screen shots of the referral test are shown, which is freely available at 
http://www.umcn.nl/verwijzers (see QR code).
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Sensitivity 
First, the sensitivity of the referral test for genetic counselling was assessed. The referral test 
was completed by medical students for patients and their relatives with a high familial CRC 
risk (i.e., known Lynch syndrome mutation carriers), who had attended genetic counselling 
at the RUNMC familial cancer clinic between 1996 and 2011. All participants provided 
informed consent for pedigree use. Cancer diagnoses were confirmed through pathology 
reports. All pedigrees were entered into the referral test from the point of view of the index 
case, defined as the first patient or relative to have undergone DNA testing, and from the 
point of view of all relatives with an MMR gene mutation. Data for relatives were entered as 
if they were ignorant of the previous diagnosis of Lynch syndrome in their family. Whether 
or not the referral test recommended referral for genetic counselling was recorded. Fisher’s 
Exact tests were used in SPSS v16.0 to compare sensitivity for different MMR gene mutations 
(MLH1, MSH2, MSH6 and PMS2), level of kinship and cancer type (CRC, EC or other Lynch 
syndrome associated tumours). Significance levels were set at p<0.05.  
Table 1. Set-up of  the referral test 
In table 1, the set-up of the referral test is shown. If individuals meet guideline criteria for a high 
familial risk of CRC, genetic counselling is recommended.3 For those meeting criteria for a moderate 
familial risk of CRC but not a high familial risk, surveillance colonoscopies are recommended. No extra 
measures are recommended for individuals who do not meet criteria for an increased familial risk of 
CRC.
Question Answer options Referral advice
Colon cancer gene mutation in family Yes Genetic counselling 
Colon cancer before age 50 in patient or first-degree 
relatives
Yes (one or more) Genetic counselling 
Recurrent colon cancer in one person before age 70 in 
patient or first-degree relatives
Yes (one or more) Genetic counselling 
Urinary tract, uterine or ovarian cancer before age 50 in 
patient or first-degree relatives
Yes (one or more) Genetic counselling 
Colon cancer between age 50-70 in patient, first-degree 
relatives or second-degree relatives
Three or more 
affected
Two affected
One or none 
affected
Genetic counselling 
Surveillance 
colonoscopies 
No extra measures 
None of the above No extra measures
Referral test detects most patients with a high familial colorectal cancer risk
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Usability 
If non-medical staff members such as a secretary complete the referral test together 
with the patient before the consultation, clinicians can use the saved time to discuss the 
actual referral. To determine whether non-medical staff members could assess referral in 
accordance with the guideline using the referral test, secretaries and other non-medical 
staff members from different RUNMC departments were invited to participate in a training 
to familiarise them with the referral test.3 One of the study coordinators (ND) briefly 
introduced the referral test and asked participants to complete a random two out of seven 
fictive clinical cases (four high-risk, one moderate-risk and two low-risk cases). The referral 
test provided the referral advice (genetic counselling; surveillance colonoscopies; or neither), 
which the staff members reported back to the study coordinator. Three months later, the 
same staff members were asked to complete all seven cases by themselves (anonymously), 
and provided the referral advice that the test gave them. 
We determined whether the referral advice was correct (i.e., in accordance with guidelines), 
underestimated (i.e., no referral advice for a moderate familial CRC risk, or no referral 
advice or surveillance colonoscopies for a high risk) or overestimated (referral advice for 
surveillance colonoscopies and/or genetic counselling for a low familial CRC risk, or genetic 
counselling for a moderate risk).3 Baseline data (gender and age) and referral advices were 
reported using descriptive statistics from SPSS v16.0. 
User experiences
For this study, the referral test was freely accessible for healthcare providers and non-medical 
users between January and May 2011. It was advertised to the general and medical press 
by the public relations department of the RUNMC and by employees of the department of 
Human Genetics during conferences, meetings etcetera. 
Upon completion, all users were asked to provide anonymous feedback by answering four 
short questions about their experiences with the referral test. The first question concerned 
users’ background: healthy relative with/without a family history of CRC, CRC patient, or 
healthcare provider. Next, we determined through what channel they had found the referral 
test (e.g., through the internet, recommendation from healthcare provider). Also, we asked 
how the referral test had helped them or not: by providing more or less certainty about 
users’ familial CRC risk and surveillance options, and more or less reassurance. Finally, 
suggestions for improvement were collected. 
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RESULTS
Sensitivity 
To determine whether the referral test would provide the correct result (i.e., high familial 
CRC risk with advice for genetic counselling), pedigree data from Lynch syndrome mutation 
carriers (n=420) were entered in the referral test. Eighty-three percent of the 81 index 
patients and 29% of the 339 relatives had CRC (table 2). Mismatch repair gene mutations 
were distributed as follows: 88 MLH1, 190 MSH2, 134 MSH6 and 8 PMS2 mutations. 
Sensitivity varied between the different subgroups. The correct result “genetic counselling” 
was given for 90% of index patients and 73% of the total group. Sensitivity decreased from 
83% in first-degree relatives to 60% in second-degree relatives (p<0.001). Healthy mutation 
carriers received advice for genetic counselling in 57% of cases, whereas affected mutation 
carriers received this advice in 91% if they had CRC (p<0.001) or endometrial cancer 
(p=0.002). No significant differences in sensitivity were found for the other Lynch syndrome 
associated tumours. The correct result “genetic counselling” was given more often in MLH1 
mutation carriers (85%) compared to those with MSH2 (73%; p=0.03) or MSH6 mutations 
(64%; p=0.001). All PMS2 mutation carriers received advice for genetic counselling; this was 
not significant compared to the other MMR gene mutations. 
Table 2. Lynch syndrome mutation carriers’ baseline data and outcome of  the 
referral test
In table 2, baseline data are shown from 420 Lynch syndrome mutation carriers whose pedigree 
data were entered into the referral test for the sensitivity analysis. In the bottom row, the number of 
individuals is shown for whom the referral test result was correct, i.e. “referral for genetic counselling 
for a high familial risk of CRC.”
Lynch – index 
n=81
Lynch – relative 
n=339
Total
n=420
n % n % n %
Gender         Male 39 48 169 50 208 50
Age a             Mean (standard deviation) 57 (12) 59 (22) 59 (20)
Cancer           
- None
- Colorectal cancer
- Endometrial cancer
- Lynch syndrome associated tumours c
- Other cancer
1 b
67
11
1
1
1
83
14
1
1
202
97
10
14
16
60
29
3
4
5
203
164
21
15
17
48
39
5
4
4
Outcome referral test:
“High familial risk of colorectal cancer” 73 90 235 69 308 73
a Calculated by extracting the date of birth from the date of the study (March 31st, 2011)
b Patients with multiple colorectal polyps but no cancer
c Malignancies of the ovaries, stomach, upper urinary tract, small bowel and sebaceous glands 
Referral test detects most patients with a high familial colorectal cancer risk
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Usability 
Twenty-six secretaries and other non-medical RUNMC staff members were invited 
to participate in a training session for the use of the online referral test. Six declined to 
participate for lack of time. Twenty of them (77%) completed one (n=2) or two cases (n=18). 
All were women; their median age was 43 years (range, 28-59 years). After completing 
the 38 cases, referral advice was in accordance with guidelines for 29 cases (76%) and 
overestimated in all remaining cases (24%).3 
After three months, the same 26 non-medical staff members were asked to complete all 
seven cases. Again, 20 of them participated and completed all cases. Referral advice was 
in accordance with guidelines in 84% of cases, underestimated in 5% and overestimated in 
11% (table 3).3 
Table 3. Referral advice given by non-medical staff  members using the referral 
test
In table 3, the referral advice given by 20 non-medical staff members using the referral test is shown 
for seven clinical cases. The answers in accordance with the guideline are shown in bold.3
Answer options %
High familial risk of colorectal cancer 
(4 cases)
No results
No extra measures (low risk)
Surveillance colonoscopies (moderate risk)
Genetic counselling (high risk)
5
8
0
88
Moderate familial risk of colorectal cancer 
(1 case)
No results
No extra measures (low risk)
Surveillance colonoscopies (moderate risk)
Genetic counselling (high risk)
5
5
60
30
Low familial risk of colorectal cancer
(2 cases)
No results
No extra measures (low risk)
Surveillance colonoscopies (moderate risk)
Genetic counselling (high risk)
5
75
20
0
User experiences
In the four months that the referral test was freely accessible, it was completed 2470 times. 
The feedback questions were completed by 256 users (10%). Seventy percent were healthy 
individuals with a family history of CRC; 13% were healthy individuals without a family 
history of CRC; 13% were healthcare providers and 3% were CRC patients; 2% of the users 
did not answer this question. Sixty percent found the referral test through the internet, 
either through search engines or through direct referrals from other websites. Other sources 
(reported by 5-10% of users each) included medical societies, healthcare providers, medical 
journals, relatives and friends, and newspapers. In total, 181 users (71%) were positive 
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about the referral test. Details about their feedback are shown in figure 2. Eight users (3%) 
reported one or more negative effects: less certainty about their familial CRC risk (n=4) or 
surveillance options (n=2), or less reassurance (n=5). Suggestions for improvement were 
provided by 59 users. Most of them wanted to include more relatives and receive more 
information about the familial CRC risk.
Figure 2. Opinions of  real-life users about the referral test 
In figure 2, the opinions of real-life users about the referral test are depicted. Users could provide more than 
one answer.
DISCUSSION 
This study supports the use of our online familial colorectal cancer referral test in clinical 
practice, as it reliably identifies those at high risk for Lynch syndrome, is easy to use, and 
has positive user experiences. Non-medical staff members in our study used the referral test 
correctly in 84% of cases after only minimal training. 
As expected, sensitivity of the referral test was higher for mutation carriers affected with 
cancer than for healthy relatives. Also, referral for genetic counselling was recommended 
significantly more often by the test for MLH1 mutation carriers compared to carriers of MSH2 
Referral test detects most patients with a high familial colorectal cancer risk
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and MSH6 mutations. This is surprising, since MLH1 and MSH2 confer a similar CRC risk.8 
However, extracolonic cancers are more prevalent in MSH2 mutation carriers, compared 
to MLH1 and MSH6.8-10 Since the referral test focuses on CRC, it will recognize those at 
high risk for Lynch syndrome less often in families with more extracolonic Lynch syndrome 
associated tumours. Since MMR gene mutations are found in only a small proportion of 
patients undergoing genetic testing, the actual sensitivity for untested individuals may be 
even higher.
Our referral test has several advantages over other available tools. Previously, two tools 
for patients were developed, aimed at collecting family history to determine their risk of 
hereditary CRC.22 These tools facilitated professional nurses in selecting CRC patients eligible 
for genetic counselling, as did our referral test, which could easily be used by non-medical 
personnel. Unfortunately, the authors do not provide the sensitivity of their tools. Their tools 
were paper-based, limiting widespread use, and differed from ours in the type of tumours 
(our tool includes urothelial cancer, but not gastric cancer and colon polyps). We did not 
include colon polyps, as the vast majority of affected individuals will not know whether 
they had adenomas (which influence their CRC risk) or other types of polyps that do not 
increase their CRC risk. Furthermore, one of their tools also included third-degree relatives. 
We did not include these in our referral test, as in the Dutch guidelines only first-degree and 
second-degree relatives are taken into account for familial CRC risk assessment.3 Also, our 
tool is aimed at identifying moderate-risk individuals eligible for surveillance colonoscopies, 
not only high-risk individuals eligible for genetic counselling. 
Several tools are available to help clinicians determine whether genetic testing for Lynch 
syndrome is indicated for their patients. These include the Leiden or Wijnen model, 
Barnetson or MMRpredict, MMRpro, AIFEG and PREMM
1,2,6
 models.23-27 These models 
provide quantitative estimates of MMR gene mutation risks, which may be difficult to 
interpret by clinicians outside the field of genetics, as no clear cut-off levels for referral for 
genetic counselling and testing are defined, and thus sensitivity of these models varies. The 
advantage of our referral test is the clear surveillance advice. Moreover, previous models 
have only included MLH1, MSH2, and MSH6, whereas our study has also included PMS2 
gene mutation carriers. The referral test recommended genetic counselling for all PMS2 
gene mutation carriers, suggesting a high sensitivity for PMS2. While PMS2 may have the 
lowest penetrance for CRC, this high sensitivity may be explained by the fact that all but one 
PMS2 gene mutation carrier had CRC.11 Evaluation in a larger sample of PMS2 gene mutation 
carriers is needed for more reliable conclusions. 
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Using the referral test, non-medical staff members determined the correct referral advice 
in 84% of clinical cases. The incorrect results were spread among staff members and 
cases, making it unlikely that these were due to users’ misunderstanding or systematic 
misclassification of cases. Having non-medical staff help patients use the referral test may 
increase the effectiveness of the clinician or general practitioner and might actually improve 
referral rates.
A limitation of this study is that we concentrated on non-polyposis CRC patients in the 
sensitivity analysis. For the evaluation of MMR gene mutation-positive relatives, their 
knowledge of a familial mutation was ignored. Normally, they would have been referred 
for genetic counselling based on this information. Instead of directly using input from 
the patients or their relatives, the sensitivity analysis was based on data collected by 
experienced genetic counsellors and confirmed from pathology reports. This is not expected 
to significantly affect the data, as the accuracy of a family history of CRC, the main tumour 
type for the referral test, is approximately 90% for first-degree relatives.28 Polyposis patients 
have not been evaluated. Most of these patients develop CRC before age 50; thus, the 
referral test will give advice for referral for genetic counselling.29
As said, the specificity of the referral test could not be determined, because a control group 
from the general population could not be assessed for ethical reasons. Also, sensitivity was 
only determined for the result “genetic counselling”, not for surveillance colonoscopies 
for a moderate familial CRC risk due to the difficulty of collecting such individuals. Other 
limitations include the fact that the anonymity of the usability test prevented the assessment 
of intra-user reproducibility and that reasons for not completing the training or final usability 
questionnaire were not collected. 
The referral test’s popularity (almost 2,500 users in the first four months) shows that many 
people are interested in finding out whether they are eligible for preventive measures for 
an increased familial CRC risk. Currently, the referral test is only available for healthcare 
providers due to ethico-legal reasons. A patient version is under development, which will be 
more rigorously tested for its effect on psychosocial outcomes and effectiveness on referral 
for preventive measures before it is introduced in clinical practice. In addition, several users 
indicated that they wanted more detailed information on their familial CRC risk level and 
surveillance measures itself, even though many users like to use a simple online test that 
tells them whether genetic counselling is appropriate for them. Therefore, more detailed 
web- and paper-based materials, aimed at both patients and clinicians, are being evaluated 
in a randomised controlled trial.30
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In conclusion, the online referral test presented here has a high sensitivity in detecting 
individuals with a high familial colorectal cancer risk and is suitable for use in clinical practice. 
Sensitivity is highest for patients affected with cancer, and higher for families with CRC than 
families with predominantly extracolonic Lynch syndrome associated tumours. The referral 
test is a promising new initiative for clinicians and non-medical staff members, who can 
easily use it to identify individuals with an increased familial CRC risk. These increased-risk 
individuals can then choose to take appropriate surveillance measures. As such, widespread 
use of the referral test could lead to better cancer prevention. 
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ABSTRACT
During cancer genetic counseling, different items which counselors consider important 
are discussed. However, relatively little empirical evidence exists regarding the needs 
and preferences of counselees. In this study needs and preferences were assessed from 
counselees with a personal and/or family history of colorectal cancer (CRC), who were 
referred for genetic counseling regarding CRC. They received a slightly modified version of 
the QUOTE-GENE
ca questionnaire prior to their first visit to the Hereditary Cancer Clinic. 
Response rate was 60% (48/80 participants). Counselees rated the importance of 45 
items assessing their needs and preferences regarding the content and process of genetic 
counseling. Participants rated the items regarding discussion of information about their 
familial CRC risk (100%) and preventive options (98%) as important or very important. Fewer 
participants rated items concerning general information on genetics as important. Sensitive 
communication during counseling was considered very important by a large percentage of 
counselees. Generally, no major differences were seen between participants in relation to 
individual characteristics. Our data suggest that focusing on familial CRC risk and surveillance 
options, in combination with sensitive communication may lead to better satisfaction with 
genetic counseling.
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INTRODUCTION
The lifetime risk of developing colorectal cancer (CRC) in Western society is approximately 
5-6%.1,2 The majority of these patients have sporadic CRC, while familial and hereditary 
cancers account for approximately 15 to 20% of all CRCs.3-5 In these families, healthy 
relatives of CRC patients have an increased risk of developing CRC themselves, which may 
be prevented by surveillance colonoscopies.6-7
Familial CRC risk is generally divided into three groups, based on cumulative lifetime risks of 
developing CRC:8 
•	 Average – familial CRC risk below 10%
•	 Moderate – familial CRC risk of 10-15%
•	 High – familial CRC risk above 15%
For patients with a high familial CRC risk, referral for genetic counseling is recommended. 
During genetic counseling, patients and their relatives receive information on the 
consequences and nature of hereditary CRC, the most common being Lynch syndrome. 
In a subset of families, genetic analysis for Lynch syndrome is performed by microsatellite 
instability (MSI) and/or DNA-testing. Based on these test results and the interpreted family 
history, a tailored surveillance plan is proposed by the clinical geneticist or genetic counselor. 
Regular surveillance by colonoscopy is crucial for individuals with an increased familial CRC 
risk, as it can reduce CRC-related morbidity and mortality up to 80%.6-7 
Currently, most at-risk individuals for CRC have not had a surveillance colonoscopy.9 
Amongst other reasons, one underlying cause seems to be the inadequate recognition of 
individuals at risk for CRC. To improve this aspect of healthcare, a new Dutch guideline on 
familial and hereditary CRC was introduced in 2008, in which clinicians have new tasks in 
calculating, interpreting, and communicating familial CRC risk.8 These tasks should lead to 
better recognition of individuals at an increased familial CRC risk, enabling them to undergo 
surveillance colonoscopies. 
Family history, the basis of clinical indication, does not predict by itself whether an individual 
undergoes CRC surveillance or not.10 Therefore, there must be other barriers for at-risk 
individuals to undergo surveillance. Some of these barriers might even be related to socio-
demographic factors, such as age or education level.11-12 However, several studies showed 
that recommendation for CRC screening by a healthcare provider is a significant predictor of 
timely screening for individuals at increased risk for CRC.10,13 Interventions also seem to be 
most successful when recommendations are tailored to individuals or communities.14 From 
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this perspective, tailoring genetic counseling to the needs and preferences of the counselee 
may lead to better understanding of the importance of CRC screening and thus increase 
surveillance uptake.
The traditional model for cancer genetic counseling focuses on the systematic discussion of 
cancer genetics, medical facts, risks of developing cancer, psychosocial consequences, and 
surveillance policy. This model is based on general key goals of genetic counseling regarding 
hereditary cancer as previously established by the counselors: (a) identifying individual 
needs and concerns of the counselee, (b) providing information on genes and chromosomes, 
(c) giving an individual risk assessment in the context of supportive interaction, and (d) 
discussing the pros and cons of genetic testing and drawing up a surveillance plan.15 During 
counseling, careful attention must also be given to the patient’s autonomy and ability to 
make well-informed decisions regarding testing and adoption of preventive strategies.16-17 
Counselors’ main goals of genetic counseling for hereditary CRC are well known; however, 
to our knowledge, the needs and preferences of counselees have scarcely been assessed. 
Previous studies investigated women’s preferences for the genetic counseling aspects of 
providing cancer, gene, and risk information (information); giving advice about cancer 
surveillance (surveillance); preparing for genetic testing (preparation); and assistance 
with decision-making (direction). The researchers found that women who were offered 
BRCA1/2 testing had the highest preference for getting information and lowest preference 
for direction.18-19 Counselees may also need information about the genetic counseling 
procedure prior to a first counseling visit.20
Yet, in order to provide optimal tailoring of genetic counseling for hereditary CRC, further 
investigation of specific needs and preferences of the counselee and their relation to 
socio-demographic factors is required. Knowing what patients need and prefer enables 
the counselor to tailor information on a surveillance plan as much as possible. Such a 
personalized recommendation for CRC screening by a healthcare provider may increase the 
probability that those individuals at risk for CRC will undergo timely surveillance.
This exploratory pilot study was performed to answer the following research questions: 
1) During genetic counseling, which counseling items and communication strategies are 
important to counselees suspected of hereditary CRC?; and 2) Are counselees’ preferences 
related to their individual characteristics such as medical history, genetic counseling history, 
gender, and age?
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METHODS
Participants
Counselees referred to the Hereditary Cancer Clinic of the Radboud University Nijmegen 
Medical Centre, the Netherlands, between May 2010 and July 2010 for genetic counseling 
on hereditary colorectal cancer (CRC) were eligible for this study. Inclusion criteria were (a) 
referral for genetic counseling for familial CRC or Lynch syndrome, and (b) age 18 years and 
above. Counselors included both clinical geneticists and genetic counselors. Due to ethical 
reasons, no data were collected from non-participants.
Procedures
To evaluate counselees’ requirements concerning genetic counseling in case of hereditary 
cancer, an instrument called QUOTE-geneca was developed by Pieterse et al.21 In the current 
study, counselees received a standard invitation to the Hereditary Cancer Clinic, as well as 
a pre-visit anonymous questionnaire based on QUOTE-geneca. Counselees were asked to 
return the questionnaire within one week. Clinical records were consulted to determine 
the medical status of the participant (affected or unaffected with CRC) and whether the 
counselee was the first in the family seeking genetic advice (index patient) or sought 
presymptomatic testing (in case of a known mutation in the family). Mutation carriers were 
offered surveillance by regular colonoscopies. Non-carriers (true negatives, being patients 
in whom a known family mutation is not found) were told that undergoing surveillance 
was unnecessary. If there was no known family mutation and no mutation was found in 
the patient, either no surveillance plan or a less intensive surveillance plan was drawn up 
according to national guidelines for familial CRC, based on family history.8
Questionnaire
The first part of the pre-visit questionnaire assessed gender, age, education level 
and nationality. The main part of the questionnaire was based on the QUOTE-geneca 
questionnaire, which in turn is derived from the QUOTE scale (‘Quality of Care Through 
the Patients’ Eyes’).21-22 The QUOTE-geneca questionnaire intends to measure needs and 
preferences in genetic counseling for hereditary cancer. This questionnaire has been shown 
to capture relevant issues of concern with a high internal consistency, and is associated with 
previously validated measures of coping style and distress.21 Some items were rephrased, 
without changing the content of each item. For example, the item “my risk or the risk for 
my family” was split into two separate items: “my own risk” and “the risk for my family.” 
Also, an item about “the option of additional support by a social worker” was added. As 
these are minor changes, we expect the psychometric properties of our questionnaire to be 
comparable to the original QUOTE-geneca questionnaire.
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The questionnaire contained a list of cancer-specific items and a list of generic items. Cancer-
specific items included “own risk of developing cancer,” “determination and meaning of 
being a carrier of a cancer gene,” “emotional aspects for counselee and family,” and 
“heredity of cancer in general.” Generic items included “procedural aspects of counseling,” 
“sensitive communication,” “emotional support,” and “assessment of susceptibility to the 
disease.” Counselees rated the importance of each item using a four-point, Likert-type scale 
(1 = not important, 2 = fairly important, 3 = important, 4 = extremely important). For data 
analysis, ratings 1 and 2 were merged to “(not or fairly) important” and ratings 3 and 4 to 
“(very) important.”
Data analysis
The interrelations between patients’ needs and preferences and their individual 
characteristics were compared using cross tabs and the Pearson Chi-square test. Individual 
characteristics used in the statistical analyses were: gender (men versus women), age 
(< 35 years versus 35-50 years versus > 50 years), medical status (affected with CRC versus 
unaffected with CRC), education (low versus middle versus high) and medical background 
(medical background versus no medical background). Education levels were subdivided 
into “low” (primary school), “middle” (junior and senior secondary vocational education), 
and “high” (higher vocational education and university education). All computations were 
done with the SPSS statistical package (release 16.0). Two-sided p-values below 0.05 were 
considered to be statistically significant.
RESULTS
Participants
Forty-eight of 80 counselees (60%) participated in this study. Table 1 shows the baseline 
characteristics of these 48 participants. There were 22 men (46%) and 26 women (54%). Their 
mean age upon completion of the questionnaire was 51.6 years (SD=11.3; range=19-72).
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Table 1. Participant baseline characteristics (n=48)a
n %
Age (years)
                       Mean (SD)
                       Range
51.6 (11.3)
19-72
Gender
                       Men
                       Women
22
26
46
54
Kind of referral
                       First in family seeking advice (index)
                       Presymptomatic
40
7
83
15
Personal medical history
                       Participant affected with CRC
                       Participant unaffected with CRC
15
33
31
69
Education b
                       Low
                       Middle 
                       High
25
20
12
31
42
25
Social status
                       Living together (cohabitant, married)
                       Living alone (single, widowed, divorced)
39
9
81
19
Medical background
                       No
                       Yes
40
7
83
15
Nationality
                       Dutch
                       Other
46
2
96
4
a Sample sizes vary due to missing data; b Low = primary school; Middle = junior and senior secondary 
vocational education; High = higher vocational education and university education. CRC = colorectal cancer; 
SD = standard deviation.
Needs and preferences prior to the first visit
As shown in table 2, counselor provision of information about the counselee’s own risk of 
developing (a second) CRC, as well as this risk for relatives, was rated as important by every 
participant (100%). Almost every participant wanted to know what to do if they had an 
increased risk of developing CRC (98%). Counselor explanation of emotional consequences 
for themselves and for their family were rated as (very) important by 70% and 81% of 
participants, respectively. Fewer participants considered the items about heredity of cancer 
in general as (very) important, e.g. the prevalence of cancer in the Netherlands (35%). 
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Table 2. Frequencies of  counselees’ ratings of  cancer-specific needs and 
preferences as important or very important (n=48)a 
During counseling, the counselor should explain… (Very) important
 n %
How risks for myself and my family are computed 46 96
Own risk of developing cancer
                   My risk of developing cancer (again)
                   What to do if I have an increased risk of cancer
                   What to do if I do not have an increased risk of cancer
48
46
36
100
98
77
Determination and meaning of being a carrier of a cancer gene
                   Whether the cancer in my family is hereditary
                   Why I am / am not considered for further examination
                   What it means to be a carrier of a certain gene
                   Possibilities of DNA-testing
                   What it means to be a carrier of a cancer gene
                   Limitations of DNA-testing
                   The procedure of DNA-testing
45
44
43
43
43
41
39
94
94
90
90
90
85
81
Emotional aspects for counselee and family
                   My family members’ risk of developing cancer (again)
                   What it means not to be a carrier of a cancer gene
                   Emotional consequences for my family as a result of genetic counseling
                   The procedure of studying the family history
                   Emotional consequences for myself as a result of genetic counseling
47
40
38
35
33
100
83
81
74
70
Heredity of cancer in general
                   How cancer is inherited in a family
                   How often cancer is hereditary
                   Background information (chromosomes, DNA, genes)
                   The prevalence of cancer in the Netherlands
41
34
34
17
85
71
71
35
a Sample sizes vary due to missing data
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With regard to generic items of genetic counseling, all participants considered it (very) 
important that the counselor takes them seriously, listens carefully, gives enough time and 
attention, involves them in decisions that are made, and provides clear and understandable 
explanations (100%). These items represent sensitive communication during genetic 
counseling; every item in this category was rated as (very) important by all or almost every 
participant. Fewer participants considered discussion by the counselor of the option of 
additional support by a social worker (44%), communication with family members (60%), and 
talking about the emotional aspects of the diagnostic procedure (65%) as (very) important. 
These items represent emotional support during genetic counseling (see table 3).
Items involving cancer-specific topics
Unaffected participants were more likely to consider receiving information about the 
procedure of studying the family history (very) important compared to participants 
affected with cancer. In other words, a greater percentage of healthy participants wanted 
to know how a genetic risk assessment is made compared to affected patients (85% vs. 
50%, respectively; p=0.025). As reported previously, receiving an explanation about their 
own risk of developing cancer or developing cancer again was rated as (very) important 
by all participants. Thus, no major differences due to participants’ background variables 
were seen for this item. No other significant relationships were obtained for participant 
characteristics and their ratings of the cancer-specific questionnaire items.
Differences on generic items due to participants’ individual characteristics
Sensitive communication was (very) important for almost all participants and was not 
significantly related to their individual characteristics. However, women more often than 
men rated the item ‘the counselor is open to their wishes, values and opinions’ as (very) 
important (100% vs. 77%, respectively; p=0.015). No other significant differences on general 
items were seen as a function of participants’ individual characteristics.
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Table 3. Frequencies of  counselees’ ratings of  generic needs and preferences 
as important or very important (n=48)a
During counseling, the counselor should… (Very) important
 n %
Provide me with clear and understandable explanations 48 100
Sensitive communication
                       Take me seriously
                       Listen carefully
                       Give me enough time and attention
                       Involve me in the decisions that are made
                       Be skilled
                       Give advice
                       Give me the opportunity to ask questions
                       Be open to my wishes, values and my opinions
48
48
48
48
47
47
47
43
100
100
100
100
98
98
98
90
Procedural aspects of counseling
                       Give medical information
                       Explain the procedure of genetic counseling
                       Be punctual with appointments
                       Inform me sufficiently about what to expect
                       Cooperate well with my other doctors, e.g. GP or specialist
                       Give the opportunity to ask questions at any time
                       Explain the roles of the providers
                       Tell me how much time the diagnostic procedure takes
46
46
45
44
44
44
42
32
96
96
94
92
92
92
88
67
Assessment of susceptibility to disease
                       Tell me what the risk for my family is
                       Tell me what my risk is
                       Carry out a DNA-test on me or a family member
                       Analyze the family history
46
44
39
38
96
94
81
81
Emotional support
                       Provide me (also) with written information
                       Reassure me
                       Show understanding and sympathy
                       Talk about the emotional aspects of the diagnostic procedure
                       Discuss communication with family members
                       Discuss the option of additional support by a social worker
43
36
36
31
28
21
90
77
75
65
60
44
a Sample sizes vary due to missing data. GP = general practitioner
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DISCUSSION
Major findings
The results of this study show that the most prevalent information topics perceived as 
important by counselees prior to their first genetic counseling session are their familial 
colorectal cancer risk and surveillance options. Additionally, sensitive communication during 
genetic counseling is considered of extreme importance by counselees. Fewer counselees 
considered emotional aspects and general information on genetics as important. Ratings of 
the importance of needs and preferences generally did not differ significantly between the 
different socio-demographic groups.
The meaning and importance of  these findings
Sensitive communication during counseling was considered very important as well by a 
large percentage of counselees. Especially, counselees consider it very important that the 
counselor takes him or her seriously, listens carefully, gives enough time and attention, 
and involves him or her in the decisions that are made. Evidently, the interaction between 
counselor and counselee is viewed as fundamental for successful counseling. This was also 
seen in a study by Veach et al, who published the results of a consensus meeting among 
genetic counselors and other healthcare professionals, in which they describe a reciprocal-
engagement model of genetic counseling practice including goals and strategies that can be 
used during the genetic counseling process.23
 
Our results can be used to adapt future genetic counseling on hereditary CRC to the needs 
and preferences of the counselee. By better adapting the genetic counseling to the needs 
and preferences of the counselee, consultation time can be saved and used to explain 
important and complex issues instead, such as familial CRC risk and surveillance options for 
those who are at risk for CRC. The focus of genetic counseling must be on topics considered 
important and less on topics not considered essential by both counselor and counselee. 
By adapting genetic counseling to counselees’ preferences, counseling may become more 
effective and more attention can be given to surveillance options for those who warrant 
surveillance.
Although generally no significant differences in needs and preferences were found in relation 
to counselees’ socio-demographic characteristics, it is important to keep in mind that every 
counselee has specific needs and preferences based on other factors. Besides, this study 
showed that sensitive communication was considered very important by every counselee. 
Counselors should take into account what might explain observed trends in different needs 
and preferences. For example, presymptomatic counselees may consider emotional aspects 
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during genetic counseling more important than patients who are the first members of a 
family seeking advice on hereditary CRC. These so-called index patients may not always 
foresee possible outcomes. In addition, in this study, healthy participants were more likely 
to consider it important to understand the process of genetic risk assessment compared 
to affected participants. It is possible that participants with CRC consider risk assessment 
less important because they were affected already with CRC. Also, the present findings 
suggest women consider it more important than men that the counselor is open to their 
wishes, values, and opinions. One explanation could be that men have more interest in facts 
and medical information, while women consider communication itself more important. 
In consideration of these interpersonal differences, counselors always need to verify a 
counselee’s personal background and adapt their counseling to their individual situation.
Relation of  the findings to those of  similar studies
The results of our study are partly in line with findings from other research. Peacock et al 
showed that women’s preferences include information and surveillance advice.18 Our study 
distinguishes between medical information (see table 3) and background information (see 
table 2) and shows that especially medical information is considered (very) important by 
96% of the counselees. The need for background information on chromosomes, DNA, and 
genes is considered (very) important by 71% of the counselees. 
Our results also concur with previous findings by Pieterse et al.21 In their study, 200 new 
counselees, primarily counseled for breast and colon cancer, completed a QUOTE-geneca 
questionnaire prior to their first consultation. They found that the patients’ preferences when 
interacting with the counselor were receiving information, risk and preventive strategies for 
oneself and/or family members and information about the procedure of genetic counseling. 
Less patients considered emotional support and discussing emotional aspects as very 
important beforehand. However, 91% of the counselees in that study were women. This 
leads to difficulties with extrapolation of these findings to genetic counseling for late-onset 
diseases that men and women seek more equally, such as CRC. Although the power of our 
study was limited, no major significant differences in needs and preferences between men 
and women were found. This indicates that this instrument can be meaningfully adapted to 
counselees for other types of late-onset hereditary cancers.
In another study by Pieterse et al, 130 counselees, referred mainly for breast or colon cancer, 
completed a questionnaire containing the QUOTE-geneca before their first appointment 
at a genetic clinic.20 They showed that counselees had a stronger psychosocial focus than 
counselors, as counselees initiated the discussion of emotional consequences of DNA 
testing more often than their counselor, compared to other topics assessed. However, our 
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study shows that counselees seeking presymptomatic testing consider emotional aspects of 
genetic counseling more important than those who are the first in the family seeking genetic 
advice. Providing more information on the counseling content and procedure prior to their 
visit may prepare counselees for possible unforeseen consequences of genetic counseling. 
Furthermore, new counselees may be advised to prepare for the visit more thoroughly, 
allowing them to verbalize questions more frequently during consultation.20,24 
Study limitations
The results of our study are based on a limited number of counselees from one country. 
In addition, 40% of the eligible participants did not enroll in this study, possibly limiting 
generalizability of the results. Since no data were collected for the non-participants, the 
possibility of an enrollment bias cannot be excluded. However, a strength of our study 
is that the group of participating counselees was very diverse, for instance in age, being 
affected with cancer or not, education, and gender. Another limitation to consider is that, 
by asking preselected questions, participants get an idea of possible items being addressed 
during genetic counseling. The fact that these items are proposed in the questionnaire, 
implies that they are at least important to someone else. This may be the reason that 
some participants were inclined to score all topics as (very) important, which may cause a 
social desirability bias. Also, a four point scale without a mid-point appears to push more 
respondents towards the positive end of the scale.25 In addition, educational level may have 
influenced counselees’ understanding of the questionnaire items. However, the percentage 
of low educated participants is normal compared to the general population and almost 
all questions were answered in which no differences were seen among counselees with 
different education levels, suggesting that this was not the case. 
Practice implications and research recommendations
The results of our study may contribute to optimal adaptation of genetic counseling for 
hereditary colorectal cancer to counselees’ needs. Focusing on familial CRC risk and 
surveillance options may lead to better satisfaction with genetic counseling and improved 
adherence to surveillance policies. However, it remains important for all counselors to keep 
in mind that every counselee has their own specific needs and preferences. Since there is 
great variability among counselees, using a questionnaire such as the QUOTE-geneca prior to 
the first genetic counseling session may help genetic counselors to determine which items 
to discuss with the counselee. However, it is necessary to explore the best content and 
format as well as assess the added value of this strategy. Additionally, larger studies are 
needed to determine whether indeed, very few differences in needs and preferences are 
present between counselees with different socio-demographics. It will also be necessary 
to explore whether patient satisfaction and surveillance uptake for colorectal cancer can 
indeed be improved in this manner.
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General discussion
With every end there comes a new beginning 
(Tarzan)
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GENERAL DISCUSSION
For effective cancer prevention, it is important that individuals with an increased familial 
colorectal cancer (CRC) risk are identified and referred for adequate preventive measures 
such as surveillance colonoscopies, and those without such familial risk are not. The 
increasing amount of evidence regarding the effectiveness of preventive measures has led 
to the development of a Dutch multidisciplinary guideline on hereditary CRC in 2008.1 In line 
with international guidelines, the Dutch guideline clearly distinguishes three familial CRC 
risk categories (high, moderate and low), each with corresponding recommendations for 
preventive measures.1-4 These recommendations are: genetic counselling for a high familial 
CRC risk; surveillance colonoscopies for a moderate risk; and population screening with 
faecal occult blood tests in case of a low familial CRC risk, which in the Netherlands will start 
in 2013.5 Difficulties with guideline implementation in clinical practice were expected by 
the developers, because familial CRC risk assessment, interpretation and communication, 
which are essential for adequate risk identification and referral for preventive measures, are 
relatively new to many clinicians outside the field of genetics. 
The RISCO study (risk of colorectal cancer) was undertaken to study whether identification and 
referral of these at-risk individuals could be improved by introducing a multifaceted guideline 
implementation strategy aimed at CRC patients and their clinicians (gastroenterologists 
and surgeons). The purpose of the RISCO study was two-fold: 1) to explore the current 
situation regarding familial CRC risk assessment, interpretation and communication; and 2) 
to determine the effectiveness and feasibility of two guideline implementation strategies 
regarding familial CRC risk assessment, interpretation and communication in a clustered 
randomised controlled trial (c-RCT). 
To determine whether the introduction of the new guideline had improved referral rates 
for preventive measures from the previously reported 12-30%, a cross-sectional study was 
performed in eighteen Dutch community hospitals (figure 1).6-13 Results are described in 
chapter 2. These data also served as the baseline measurements for the c-RCT described in 
the second part of this thesis (chapters 4 through 6). In chapters 3 and 7, alternatives for 
guideline implementation were explored, such as the population CRC screening program 
and a novel online referral test. Familial CRC risk communication in the clinical genetics 
setting was studied in chapter 8.
In this final chapter, the principal findings from the RISCO study are summarised, compared 
to existing literature, and discussed. We reflect on the methods used in this thesis and 
provide implications for clinical practice and future research. 
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Figure 1. Overview of  the hospitals participating in the randomised controlled 
trial
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SUMMARY OF PRINCIPAL FINDINGS
The following principal findings can be formulated from the studies described in this thesis 
(figure 2): 
•	 With traditional implementation methods, only one-third of colorectal cancer patients 
with an increased familial risk are referred for surveillance colonoscopies or genetic 
counselling in accordance with guidelines, while 23% of patients with a low familial risk 
is also referred for these preventive measures. (Chapter 2)
•	 Pilot tests of the RISCO website among patients and clinicians show that the website 
is easy to use, understandable, and is perceived as effective in improving knowledge. 
(Chapter 5)
•	 After the introduction of an intensive guideline implementation strategy, including 
the RISCO website, fewer patients and relatives with an increased familial colorectal 
cancer risk underwent preventive measures (surveillance colonoscopies and genetic 
counselling), while referral rates for these preventive measures did not change among 
low-risk individuals. (Chapter 6)
•	 Many clinicians lack knowledge of familial colorectal cancer risk and preventive 
measures (surveillance colonoscopies and genetic counselling). (Chapters 2 and 6) 
•	 Although colorectal cancer patients and clinicians appreciated web-based and paper 
tools aimed at improving familial colorectal cancer risk assessment, interpretation and 
communication, patients preferred clinicians’ advice regarding referral for preventive 
measures. (Chapter 6)
•	 Family history is taken in virtually all colorectal cancer patients, but reported in 82% of 
their medical records. (Chapters 2 and 6) 
•	 Microsatellite instability analysis was performed in 63% of colorectal cancer patients 
meeting criteria for this analysis; and while most patients with a microsatellite 
instable tumour are referred for genetic counselling, most relatives of patients with 
microsatellite stable tumours are not referred for surveillance colonoscopies although 
these are indicated. (Chapters 2 and 6)
•	 After the introduction of an intensive guideline implementation strategy, clinicians 
discussed familial risk significantly more often with their patients (37% versus 23%). 
(Chapters 2 and 6)
•	 Six percent of participants with a positive faecal occult blood test in a pilot population 
screening program have an increased familial colorectal cancer risk. (Chapter 3)
•	 Performing familial colorectal cancer risk assessment in all participants of the population 
screening program could prevent an additional 172-184 colorectal cancers annually. 
(Chapter 3)
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•	 Evaluation of a new online referral test for hereditary colorectal cancer showed that it 
has a high sensitivity in detecting individuals with a high risk of Lynch syndrome and is 
suitable for use in clinical practice. (Chapter 7)
•	 Genetic counselling for colorectal cancer may be improved by focussing on familial risk 
and preventive measures, combined with sensitive communication, as these items are 
considered the most important by counselees. (Chapter 8) 
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Figure 2. Pathway for familial colorectal cancer identification and referral
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In figure 1, the pathway for familial colorectal cancer identification and referral is shown for colorectal cancer 
patients and individuals unaffected with cancer. Results are shown as ‘baseline’ → ‘endpoint’ measurements of 
the RISCO study. Recommendations for preventive measures are in accordance with national guidelines.3 
Chapters of this thesis in which the items are addressed are shown.  
* <0.05; CRC: colorectal cancer; FOBT: faecal occult blood test; MSI: microsatellite instability analysis
Surveillance 
colonoscopies 
once every 6 years 
from age 45 
Genetic counselling 
with tailored 
surveillance 
recommendations  
Moderate  
familial CRC risk  
(10-15%) 
Assessment of familial CRC risk 
 Personal history (100% → 100%) 
 Family history (taken 99% → 99% , recorded 80% → 82%) 
 MSI test results in tumour tissue (67% → 61%) 
High 
familial CRC risk  
(> 15%) 
Communication of familial CRC risk  
 Clinician with patient (23% → 37%)* 
 Patient with relatives (37% → 35%) 
Population 
screening program 
with FOBT 
Healthy individual presenting to: 
 Population screening program 
 Healthcare provider    
Low  
familial CRC risk  
(< 10%) 
Actual referral  
 Low risk – no referral (77% → 79%) 
 Moderate risk – surveillance colonoscopies (34% → 33%) 
 High risk – genetic counselling (33% → 15%)* 
Interpretation of familial CRC risk 
 Low risk – no referral (77% → 75%) 
 Moderate risk – surveillance colonoscopies (51% → 28%)* 
 High risk – genetic counselling (33% → 44%) 
Patient with CRC  
presenting to healthcare provider 
Chapters 3, 7, 8 Chapters 2,4-7 
Chapters 2-7 
Chapters 2-7 
Chapter 8 Chapter 3 
Chapters 2,4-6,8 
Chapters 2,6 
In figure 1, the pathway for familial colorectal cancer identification and referral is shown for colorectal cancer 
pati s and individuals unaffected with ancer. Results are shown as ‘baselin ’ → ‘endpoint’ asurements 
of the RISCO study. Recommendations for preventive measures are in accordance with national guidelines.3 
Chapters of this thesis in which the items are addressed are shown. 
* p<0.05; CRC: colorectal cancer; FOBT: faecal occult blood test; MSI: microsatellite instability analysis 
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DISCUSSION OF PRINCIPAL FINDINGS
Referral for preventive measures
Principal findings regarding referral for preventive measures
With traditional implementation methods, only one-third of colorectal cancer patients with 
an increased familial risk are referred for surveillance colonoscopies or genetic counselling in 
accordance with guidelines, while 23% of patients with a low familial risk is also referred for these 
preventive measures. (Chapter 2)
After the introduction of an intensive guideline implementation strategy, fewer patients and 
relatives with an increased familial colorectal cancer risk underwent preventive measures 
(surveillance colonoscopies and genetic counselling), while referral rates for these preventive 
measures did not change among low-risk individuals. (Chapter 6)
After the introduction of an intensive guideline implementation strategy, clinicians discussed 
familial risk significantly more often with colorectal cancer patients (37% versus 23%). (Chapters 
2 and 6)
In this thesis, we confirm existing data that less than half of CRC patients with an increased 
familial risk are referred for preventive measures in accordance with international guidelines, 
such as genetic counselling for a high familial CRC risk, and surveillance colonoscopies for a 
moderate familial risk, even after the introduction of an intensive guideline implementation 
strategy (chapters 2 and 6).6-13 These low referral rates may be due to several reasons. In 
general, change is difficult, and the effect of implementation strategies is usually limited.14 
The hereditary CRC guidelines are complicated, and contain tasks in familial CRC risk 
assessment, interpretation and communication that are new to many clinicians outside the 
field of genetics.1 Moreover, clinicians often lack time to take a complete family history, 
determine whether preventive measures are indicated, and communicate these with their 
patients.15,16 This was also seen in our study, where even after the intervention, clinicians 
discussed familial risk with only 37% of colorectal cancer patients, versus 23% before this 
intervention (chapters 2 and 6). Similar percentages were seen in previous studies.6
Even though communication of familial CRC risk improved in all risk categories, referral rates 
for preventive measures did not. In fact, fewer patients underwent preventive measures after 
the introduction of the intensive implementation strategy. Patients’ willingness to undergo 
preventive measures did not change before and after the intervention, suggesting that 
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fewer increased risk patients were referred for preventive measures by their clinician. Our 
finding supports this: more high risk patients reported receiving advice genetic counselling 
(44% versus 33% before) at the endpoint measurements (figure 1), although this difference 
was not statistically significant. However, referral advice for surveillance colonoscopies 
for relatives with a moderate familial CRC risk decreased significantly, from 51% to 28%. 
Referral may simply not have taken place yet, since referral data were collected 2-12 months 
after the intervention. A longer follow-up period may have shown higher referral rates but 
was not feasible in this study. Also, clinicians may assume that patients do not want to be 
confronted with an increased risk of CRC for their relatives shortly after receiving a cancer 
diagnosis. While family history is taken in most patients, subsequent assessment of whether 
preventive measures are indicated seems to be delayed often. Family history is usually taken 
during the first consultation, when the patient has just been diagnosed with cancer. Both 
patients and clinicians may consider it inappropriate to discuss a familial predisposition at 
this time, or during the subsequent treatment. However, many patients want to know as 
soon as possible whether their relatives (in particular their children) have an increased risk 
of developing cancer.17 Landsbergen et al have shown that patients who were diagnosed 
with CRC less than one year before undergoing genetic analysis for Lynch syndrome, the 
most common hereditary CRC syndrome, reported less psychological distress than patients 
with a longer interval since diagnosis.18 This supports guideline recommendations that 
familial CRC risk assessment needs to take place upon diagnosing CRC, because the risk of 
delaying referral is that it is often forgotten, thereby limiting the options of relatives with an 
increased cancer risk to take highly effective preventive measures.1 
In addition to the under-referral of individuals with an increased familial CRC risk, almost one 
quarter of all CRC patients and their relatives with a low familial risk in our c-RCT were referred 
for surveillance colonoscopies and genetic counselling, which fall outside the indications of 
the current guideline.1 We found that low risk individuals with a high educational level were 
referred for preventive measures more often than lower educated low risk patients (chapter 
6). In addition, clinicians with less knowledge refer more CRC patients for unnecessary 
preventive measures. This over-referral has a significant impact. Besides increasing cancer-
related worry in patients and their relatives, serious medical complications such as sustained 
bleeding or perforations occur in 0.1-0.3% of colonoscopies.19-21 Furthermore, the costs of 
these referrals outside the current guideline are high, which is undesirable especially in the 
current climate of medical budget cuts.
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Clinicians’ knowledge of  familial colorectal cancer risk and preventive 
measures
Principal findings regarding clinicians’ knowledge of familial colorectal cancer risk and preventive 
measures
Many clinicians lack knowledge of familial colorectal cancer risk and preventive measures 
(surveillance colonoscopies and genetic counselling). (Chapters 2 and 6) 
An important finding from our study is that unfortunately, many clinicians lack knowledge 
and skills in familial CRC risk assessment and referral for preventive measures (chapters 2 
and 6). Clinicians’ objective and subjective knowledge of preventive measures had improved 
after the intervention, even though no positive effect on referral rates was observed. It is 
likely that there is a delayed program effect, as the intervention should lead to short term 
and long term changes in referral behaviour, and behavioural changes generally take a long 
time.22 
One option to improve correct referral rates would be to support healthcare providers with 
the risk calculators (chapter 5) or the online referral test (chapter 7) developed in this study. 
Both patients and clinicians were positive about the familial CRC risk calculator in the pilot 
tests and the c-RCT, and would recommend it to other patients and clinicians. Users of the 
referral test, including medical and non-medical personnel, found this referral test easy to 
use. However, implementation issues remain, as only 7 out of 72 clinicians in our study used 
the risk calculator (chapter 6). This may be due to lack of time or lack of internet access 
during the consultation. Also, clinicians may incorrectly assume that they already know 
whether or not to refer their patients. In our study, clinicians’ subjective knowledge scores 
were higher than scores on clinical cases designed to assess their objective knowledge 
(chapters 2 and 6). Another explanation for the limited use of the risk calculator may be that 
clinicians are often sceptical of using web-based tools because they find that these tools do 
not work for them or the benefit of their patients.23
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Patient awareness
Principal findings regarding patient awareness
Although colorectal cancer patients and clinicians appreciated web-based and paper tools aimed at 
improving familial colorectal cancer risk assessment, interpretation and communication, patients 
preferred clinicians’ advice regarding referral for preventive measures. (Chapter 6)
Even in this era of e-health and patient-based interventions, CRC patients mainly rely on 
their doctors’ advice when considering referral for preventive measures for an increased 
familial CRC risk (chapter 6). However, none of the implementation tools from the RISCO 
study influenced referrals by clinicians. This was also seen in a previous study to improve 
referral of colorectal cancer patients with a high familial CRC risk for genetic counselling, 
which was aimed at surgeons.24
Therefore, besides improving clinicians’ knowledge and skills, it remains necessary to 
empower patients and their relatives, by making them more aware that they may have an 
increased familial CRC risk, and increasing their knowledge on the indications for preventive 
measures for them personally. A previous study has shown that patient-directed education 
is as effective in referral for genetic counselling as physician-directed education (42% vs. 
51% referral, respectively).25 Other options to improve patient awareness are discussed in 
the “Implications for clinical practice” section.
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Identification of  familial colorectal cancer risk
Principal findings regarding the identification of familial colorectal cancer risk 
Family history is taken in virtually all colorectal cancer patients, but reported in 82% of their 
medical records. (Chapters 2 and 6) 
Microsatellite instability analysis was performed in 63% of colorectal cancer patients meeting 
criteria for this analysis and while most patients with a microsatellite instable tumour are referred 
for genetic counselling as indicated, most relatives of patients with microsatellite stable tumours 
are not referred for surveillance colonoscopies although these are indicated. (Chapters 2 and 6)
Current guidelines recommend that family history be taken when a patient is diagnosed with 
CRC, and include cancer diagnoses of at least first- and second-degree relatives.1,26-28 For all 
affected relatives, type of cancer, age at diagnosis, level of kinship and side of the family 
(maternal or paternal) need to be recorded. In our c-RCT, family history was reported in 
medical records in 82% of patients at both baseline (chapter 2) and endpoint measurements 
(chapter 6). Prior studies have shown a wide variation in this area, with entries of family 
history in medical records in 16-88% of cancer patients.6-8,29-31
The high family history assessment rates in our c-RCT do not automatically mean that the 
familial CRC risk based on the medical record data was always correct. Prior research has 
demonstrated that family history in medical records is not always complete and may lack 
information that is needed for familial risk assessment.29-31 Missing data often include 
related tumours (such as endometrial cancer), age at diagnosis, and adequate information 
from relatives beyond the immediate family. This was also suspected in our study, but could 
not be confirmed as only family history for first-degree relatives was collected in the patient 
questionnaires. 
Although family history is a useful tool for familial CRC risk assessment, it has its limitations. 
Families are getting smaller, restricting the informative value of a negative family history.32 
Additionally, patients are not always aware of their family history. Previous studies have 
shown that the accuracy of a family history for colorectal cancer in first-degree relatives 
is high, being approximately 90%.15,33 Accuracy is lower for more distant relatives, and 
for extracolonic malignancies that influence familial CRC risk, especially gynaecological 
cancers which have a positive predictive value of 37-76% for first- and second-degree 
relatives. So while family history remains an important tool for the identification of familial 
risk, additional methods are needed to detect patients with an increased familial CRC risk 
without an obvious family history.
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Besides family history, MSI analysis can be used for familial CRC risk assessment. This patient-
directed approach has been shown to be complementary to family history by Manders et 
al.34 In the Netherlands, MSI analysis can be initiated in recently diagnosed patients by 
the pathologist, when patients meet the so-called MIPA (MSI-analysis-by-a-pathologist) 
criteria.35 These criteria include CRC before age 50, or a second CRC, or CRC and another 
Lynch syndrome associated tumour such as endometrial cancer before age 70. Other 
studies have shown a large variation in MSI analysis rates in patients meeting similar criteria, 
ranging from 14-59%.24,36 In our c-RCT, MSI analysis was performed in 63% of CRC patients 
meeting MIPA criteria. This higher rate may be due to the reminder system for pathologists 
to perform MSI analysis in patients meeting MIPA criteria which was introduced in 2005-
2006.24 In an RCT, this reminder system was significantly associated with the identification 
of patients with a high familial CRC risk: 78% versus 59% of patients with or without the 
reminder system, respectively (OR 4.2 [95% CI 1.7–10.1]).
 
Another major finding of the RISCO study is that many clinicians need support in the 
interpretation of microsatellite instability (MSI) results. More than 90% of all CRCs associated 
with Lynch syndrome are MSI-positive, compared to 15% of sporadic CRCs.37 Virtually all 
patients with an MSI-positive tumour in our study were referred for genetic counselling, 
in line with international recommendations.1,37,38 In contrast, the majority of relatives of 
patients with an early onset MSI-negative CRC did not receive surveillance colonoscopies. 
If no other high risk criteria are met, these individuals are considered a moderate risk 
group, warranting surveillance colonoscopies once every 6 years from age 45.1 Clinicians 
may assume that no further action is needed in case of an MSI-negative result. Also, in 
our experience, MSI results are usually reported later than the initial pathology report, in 
which case the clinician may miss them. More rapid ways to perform MSI analysis are worth 
looking into, especially since MSI status increasingly influences treatment decisions. Many 
studies have shown that patients with CRCs associated with Lynch syndrome do not benefit 
from 5-FU-based chemotherapy, while these patients may benefit from subtotal colectomy 
instead of limited resection to decrease their risk of metachronous CRCs, which may be as 
high as 29% within ten years.39-42 A way to speed up the diagnosis of Lynch syndrome for 
surgical decision making could be to perform MSI analysis on the initial biopsy material, 
followed by a “fast-track” genetic counselling (i.e. genetic counselling after diagnosis but 
before the start of treatment) and testing for mismatch repair mutations. A pilot study in 
breast cancer patients has shown that such “fast-track” genetic counselling and testing 
may influence surgical treatment, without causing long-term psychosocial distress in the 
majority of patients.43
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Implementation strategies 
Principal findings regarding the implementation strategies
Pilot tests of the RISCO website among patients and clinicians show that the website is easy to use, 
understandable, and is perceived as effective in improving knowledge. (Chapter 5) 
Although colorectal cancer patients and clinicians appreciated web-based and paper tools aimed at 
improving familial colorectal cancer risk assessment, interpretation and communication, patients 
preferred clinicians’ advice regarding referral for preventive measures. (Chapter 6)
Evaluation of a new online referral test for hereditary colorectal cancer showed that it has a high 
sensitivity in detecting individuals with a high risk of Lynch syndrome and is suitable for use in 
clinical practice. (Chapter 7)
In chapter 5, the development and step-wise pilot testing of the RISCO website are described. 
One of the added values of our website over existing websites such as Family Healthware™ 
is that it combines information on familial CRC risk with risk calculators suitable for both 
patients and clinicians, and a decision support intervention for patients with a high familial 
CRC risk.44,45 These pilot tests among CRC patients and clinicians showed that the website 
is easy to use, understandable and is perceived as effective in improving awareness and 
knowledge of familial CRC risk and preventive measures. Surrogate users also found that the 
decision support intervention helps patients in deciding whether to be referred for genetic 
counselling.
According to diffusion theory and social marketing principles, one of the main processes 
to increase the use of new web-based interventions is program development.46,47 By 
considering and incorporating the opinions of potential future users, involvement is 
expected to increase, resulting in positive user experiences and higher levels of use.48,49 New 
interventions should thus be developed in close collaboration with potential users from the 
target population. In our study, we confirmed how important it is to include representatives 
from all possible users in the development process of such tools. While both patients and 
clinicians offered important suggestions for improvements, their reasons to use the website 
and therefore their suggestions for adjustments differed significantly (chapter 5). Patients 
mainly wanted to use the website to obtain information and to review it at their own 
convenience. In contrast, clinicians mainly wanted to use the website to determine whether 
to refer their patients for surveillance colonoscopies and/or genetic counselling. 
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Since the tools on the RISCO website are quite extensive, and several users indicated that 
they would prefer a simpler tool to determine whether preventive measures are indicated for 
an increased familial CRC risk, an additional online referral test was developed (chapter 7). 
By completing the referral test for patients and their relatives with a high familial CRC risk 
(i.e. known Lynch syndrome mutation carriers), we showed that the referral test has a high 
sensitivity (91% for mutation carriers with CRC and 73% for all mutation carriers). Non-
medical staff members in the study correctly identified preventive measures in 84% of seven 
clinical vignettes after only minimal training. If non-medical staff members complete the 
referral test together with patients before the consultation, clinicians or general clinicians 
can use the saved time to discuss the actual referral. This may actually improve referral rates 
in a cost-effective manner.
Even though colorectal cancer patients as well as clinicians were positive about the 
implementation tools, these tools proved not to be effective in improving referral rates 
for preventive measures (chapters 5 and 6). It is possible that the sample of patients and 
clinicians was not representative for the final users. Participating patients may have been 
more interested in using additional web-based and paper information. And although we did 
ask whether clinicians would use the tools, we did not go into depths about practical issues 
that may arise in real-life use. We cannot exclude the presence of a social desirability bias 
in the answers, as the pilot users reviewed the website and brochure in the presence of 
one of the researchers. Also, these tools were developed based on the barriers that were 
expected by guideline developers, namely clinicians’ lack of knowledge and skills in familial 
CRC risk assessment, risk interpretation (i.e. determination of appropriate preventive 
measures) and risk communication, as well as a lack of awareness of the subject among CRC 
patients (chapter 1). Performing a more thorough analysis of possible barriers, as advocated 
by Grol, may have identified additional barriers which could have been tackled with other 
implementation strategies.14 These may have included barriers on other levels, such as 
hospital or societal level, whereas we focussed on the patient and clinician level.
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Population screening for colorectal cancer
Principal findings regarding population screening for colorectal cancer
Six percent of participants with a positive faecal occult blood test in a pilot population screening 
program have an increased familial colorectal cancer risk. (Chapter 3)
Performing familial colorectal cancer risk assessment in all participants of the population screening 
program could prevent an additional 172-184 colorectal cancers annually. (Chapter 3)
In the Netherlands, population screening will start in 2013 for individuals aged 55-75.5 This 
screening program includes biennial immunochemical faecal occult blood testing (FOBT), 
followed by colonoscopy in case of a positive FOBT result. Screening is recommended for 
individuals with a low familial CRC risk only, since those with an increased familial CRC 
risk should be identified at a younger age, so they and their relatives can receive earlier, 
more intensive surveillance instead of FOBT.5 With the current screening program, only 
participants with a positive FOBT are invited for colonoscopy and familial risk assessment. 
Thus, individuals with an increased familial CRC risk who decline to participate or have 
a negative FOBT will remain unidentified as being at-risk. In chapter 3, we show that 6% 
of participants with a positive FOBT have an increased familial CRC risk. Our findings are 
in line with international studies, which have shown that 4.2-4.9% of participants in a 
population screening have an increased familial CRC risk.50,51 These prevalences are higher 
than previously reported in the general Dutch population, where 2.3% of unaffected 
participants reported a family history consistent with an increased familial CRC risk.52 One 
possible explanation for this difference is that a positive family history of CRC is a reason to 
participate in a screening program.53 Also, CRCs might occur more often in participants with 
an increased familial CRC risk compared to those with a negative family history.54,55 
Adding familial CRC risk assessment to the new population screening program could prevent 
a significant number of CRCs compared to FOBT alone (chapter 3). We estimated that an 
additional 172-184 cases of CRC may be prevented annually among participants with a 
positive FOBT and their relatives in the eligible Dutch screening population of 3.5 million 
individuals (with an expected uptake of 60%).5 This is just the tip of the iceberg, since many 
participants with a negative FOBT, as well as non-participants, also have an increased familial 
CRC risk.
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Genetic counselling procedures
Principal findings regarding genetic counselling procedures
Genetic counselling for colorectal cancer may be improved by focussing on familial risk and 
preventive measures, combined with sensitive communication, as these items are considered the 
most important by counselees. (Chapter 8)
After high-risk CRC patients and their relatives have been identified and referred for 
genetic counselling, they are entitled to the best possible care at the familial cancer clinic. 
Familial CRC risk communication is a prominent part of the genetic counselling process. It 
is therefore important to identify the most effective risk communication strategies. Since 
involving patients in improving their own care is increasingly becoming standard practice, 
we assessed counselees’ needs and preferences regarding the content and process of the 
genetic counselling session (chapter 8). Counselees (n=48) rated the importance of 45 
items regarding their needs and preferences regarding the content and process of genetic 
counselling. This questionnaire was based on the QUOTE-Geneca questionnaire, which has 
been shown to capture relevant issues with a high internal consistency, and is associated 
with previously validated measures of coping style and distress.56 Participants regarded 
information about their familial CRC risk (100%) and preventive measures (98%) as very 
important, as well as sensitive communication (100%). General information about heredity 
was rated as less important. This was also seen in another study, where information needs 
were also shown to be irrespective of risk level.57 A systematic review has shown comparable 
results, namely that the supportive or emotional elements of genetic counselling provided 
more benefits to users than the informational or educational elements.58 
These results suggest that focusing on familial CRC risk and preventive measures, combined 
with sensitive communication, may increase satisfaction with genetic counselling and result 
in more efficient counselling, as only topics that are important to the counselee and the 
counsellor are discussed. However, other authors have warned that a greater emphasis on the 
counselling and supportive elements of communication should be seen as complementary 
to the risk communication itself, as resolving or addressing emotional issues may help 
improve counselees’ risk perception, responses to risk, and decision making.58 Furthermore, 
using this approach may enhance adherence to preventive colonoscopies, since adherence 
increases when surveillance recommendations are tailored, and when their importance is 
clear to the counselee.59
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METHODOLOGICAL REFLECTION
Strengths
A strong point of this thesis is the multidisciplinary approach. The starting point for the 
RISCO study was a multidisciplinary evidence-based guideline, which was developed 
by clinicians, researchers, patients and other experts to ensure that all aspects that are 
important for patient care were included in the guideline. This multidisciplinary approach 
was also followed in the knowledge measurements described in chapter 2, which were 
performed among all medical specialties involved in the care for CRC patients regarding 
hereditary CRC. This national study was undertaken to assess knowledge of familial CRC 
risk and preventive measures, which guideline developers considered to be one of the main 
barriers for guideline implementation. 
Barriers for guideline implementation usually exist on different levels (e.g. organisational, 
clinician, and patient level).14,60 Therefore, we evaluated a wide range of options to improve 
identification and referral of individuals with an increased familial CRC risk. This was done in 
different settings, as interventions are more likely to lead to changes in practice if they are 
aimed at multiple levels and focus on existing barriers in each target group.14 In our study, 
we included not only hospital care (chapters 2 and 6), but also the population screening 
programme which will soon start in the Netherlands (chapter 3). In addition to the evaluation 
of referral for preventive measures, we studied how genetic counselling could be improved, 
by assessing counselees’ needs and preferences regarding the content and process of the 
genetic counselling session (chapter 8). 
Another strength of the research described in this thesis is the thorough development 
process of the implementation tools. Different innovative tools, such as the website used 
in the RISCO study (chapters 4-6) and the online referral test (chapter 7), were developed 
based on the Dutch guideline and a thorough search of other available literature, especially 
for risk communication (for the risk calculators) and shared decision making, including the 
criteria from the International Patient Decision Aids collaboration (for the decision support 
intervention).1,61 The tools were then evaluated by patients and clinicians to create a solid 
basis for implementation (chapters 5 and 7). After pilot testing the RISCO implementation 
tools, their effectiveness and feasibility for improving familial CRC risk assessment, 
interpretation and communication were evaluated in a clustered randomised controlled 
trial (c-RCT). RCTs are generally considered to provide the highest level of evidence. Large 
numbers of patients from eighteen hospitals throughout the Netherlands completed 
questionnaires for the baseline measurements (n=537, 65% of invited patients, chapter 2) 
and the endpoint measurements (n=603, 70% of invited patients, chapter 6). 
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In any study, it is important to obtain the best possible view of actual practice to ensure 
reliability of the results. A good way to achieve this is by using mixed methods, which we 
did throughout our study. In the development process of the implementation tools and 
their evaluation in the c-RCT, a combination of qualitative and quantitative research was 
used (chapters 5 and 6). The risks of recall bias and social desirability bias were limited 
by adding the relatively objective data from medical records to patients’ questionnaires. 
We found that clinicians discuss more with their patients than is reported in their medical 
records, something that was also seen in other studies.62,63 Patient questionnaires were used 
to reveal these data, thereby further completing the picture of what really happened during 
the consultations.
In addition to evaluating the effectiveness of the implementation strategy as a whole, we 
gained insight in why the strategy did not improve referral rates for preventive measures as 
we had expected by looking at its feasibility. This was done by assessing actual use of the 
different elements of the implementation strategy by patients and clinicians, as well as their 
experiences with these elements in a process evaluation. Use of the implementation tools 
was limited, especially among clinicians. Patients appreciated the implementation tools, but 
only as an addition to the referral advice from their doctor, which was their main source 
of information and advice when deciding whether to be referred for preventive measures.
Limitations
An important limitation of the c-RCT is the high dropout rate after revision of the medical 
records, even though initial patient response rates were high (chapters 2 and 6). Hospitals 
provided lists of patients who were invited to participate. These lists were based on available 
hospital registries, which differed between hospitals, and included pathology reports but 
also clinical and financial registrations. In many cases, patients’ date of diagnosis, determined 
from the initial pathology report, did not fall within the study period, leading to exclusion of 
the patient. Dropout rates were especially high in the endpoint intervention group. This may 
reflect a selection bias, even though we did not mention in the invitations that the study 
was about familial CRC risk to prevent the selection of patients with an increased familial 
risk, who may have been more interested to participate in such a study. Since it is known 
that many e-health technologies face adoption problems, it is also possible that patients 
did not want to participate because of the website, which was specifically mentioned in the 
invitation letter as participants were asked to provide an e-mail address for access to the 
website.23 
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While the total number of included patients was higher than needed according to the 
power calculations (300 patients), only 30% had an increased familial CRC risk (chapters 2 
and 6). In addition to increasing the risk of a biased sample, which limits generalisability of 
the results, the small number of patients with an increased familial CRC risk prevented a 
detailed analysis of these subgroups. Future trials need to take this into account and base 
their power calculations on the expected number of patients with an increased familial 
CRC risk, even though this may affect feasibility due to the higher number of patients and 
hospitals necessary to perform a c-RCT. 
The results of the studies among clinicians must be generalised with caution, since their 
response rates were low (chapters 2 and 6). Clinicians may be reluctant to complete 
questionnaires for research purposes while already experiencing a large workload.64 This 
increases the risk of a selection bias, since the questionnaires may have been completed 
by motivated clinicians with a special interest in hereditary cancer. Also, the so-called 
Hawthorne effect may have influenced the results, as results from research tend to be 
better than results in actual clinical practice.65
Another limitation of the RISCO study concerns the limited use of the implementation tools, 
both among clinicians and patients, making the evaluation of their effectiveness difficult 
(chapter 6). The decision support intervention (DSI) was only used by 6/140 patients, all of 
whom had a moderate or low familial CRC risk and did not belong to the high-risk group for 
whom the DSI was intended. Systematic reviews have shown that DSIs can be cost-effective 
in improving patients’ knowledge and improve agreement between patients’ preferences 
and decisions regarding treatment, screening or surveillance.66 In our study, patients may 
not have needed a DSI as they already knew whether they wanted to be referred for genetic 
counselling. Also, the sample may have been too small, as in this part of the study only 13 
patients had a high familial CRC risk. 
Finally, willingness and actual uptake of surveillance colonoscopies by relatives (chapters 
2 and 6) were reported by the patient. Since these rates could not be confirmed for legal 
reasons, our results may not correctly reflect actual uptake.67,68 It is known that relatives 
do not always inform each other that they had a colonoscopy.69 The fact that surveillance 
recommendations for relatives were only recorded in medical records of a minority of 
patients suggest that most relatives were referred for surveillance colonoscopies by their 
own doctor. 
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IMPLICATIONS FOR CLINICAL PRACTICE
To improve the identification and referral of individuals with an increased familial colorectal 
cancer risk in clinical practice, two strategies are worthwhile focussing on: 1) increasing 
awareness of CRC patients and their relatives; and 2) supporting clinicians by increasing 
their knowledge in this area and improving the organisation of hospital care. In this section, 
we provide recommendations on how to achieve this. These recommendations are based 
on our own experiences, complemented with evidence from existing literature, and concern 
the entire referral process (figure 1). 
Patient awareness
To improve the acceptance of familial CRC risk level and uptake of indicated preventive 
measures, it remains necessary to empower patients and their relatives by making them 
more aware that they may have an increased familial CRC risk and increasing their knowledge 
on the indications for preventive measures for them personally. They can then discuss this 
with their healthcare provider. In this process, effective information provision is essential, 
which could consist of a number of different strategies. For all these strategies, however, it is 
important to remember that health information materials for achieving patient involvement 
are most effective when they supplement or augment, rather than replace, interactions 
between patients and professionals.66
In a systematic review, it was shown that information provision using most available 
communication tools (websites, brochures etc.) is better than no communication tool for 
increasing knowledge about health issues.70 Therefore, it may be useful to provide quality 
evidence-based information with tools that patients and their relatives can use to determine 
whether they are at risk and may benefit from preventive measures. In general, the effect 
of tools for communicating evidence on patient knowledge is larger if such tools are more 
structured, interactive and tailored.58,70,71 The web-based and paper tools developed 
in the studies described in this thesis were highly appreciated by surrogate and real-life 
users (chapters 5-7). Making such tools publicly available through reliable sources could 
also improve knowledge and referral rates by enhancing patient awareness. Many patients 
are interested in obtaining cancer information and support online, and approve the use of 
computerized tools for familial risk assessment, particularly when provided to them by their 
clinician or healthcare organisation.44
It is then necessary to inform patients and their relatives of the existence of such tools, and 
to convince them of the importance of the information and the tools. This may be achieved 
with national media campaigns, either by starting new ones or by focussing existing cancer 
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campaigns on familial risk.72 Such media campaigns can reach and possibly influence the 
general public as well as healthcare providers. In 2001, a mass media intervention consisting 
of newsletters and a week-long television series about hereditary cancer was launched in 
the New York region.73 When performing telephone interviews with 254 random citizens, 80 
reported having a conversation with their healthcare provider about hereditary cancer risks, 
of whom 9 received recommendations for genetic testing. A Cochrane review shows that 
mass media interventions may encourage the use of effective healthcare services, although 
another review found that their effect on guideline implementation is often limited.66,72 Such 
campaigns should clearly describe both the characteristics of an increased familial CRC risk 
as well as a low familial risk to increase use of preventive measures among those with an 
increased familial CRC risk and limit such referrals in low risk groups. It has been shown that 
combined oral and written information can indeed reduce use of health service resources.66 
In the Netherlands, population screening will start in 2013 for individuals with a low familial 
CRC risk aged 55-75.5 The screening program includes biennial immunochemical faecal 
occult blood testing (FOBT), followed by colonoscopy in case of a positive FOBT result. This 
program may also have a beneficial effect on awareness of the general public, which has 
been shown to be low in a survey among the general public in 21 European countries in 
2004.74 A clear lack of awareness of family history as a risk factor for developing CRC was 
seen, with only 54% of 20,710 respondents being aware. Since this study was performed 
before the screening program and its pilots were introduced in the Netherlands, it is likely 
that awareness has increased since then. 
Adding familial CRC risk assessment to the new population screening program could prevent 
a significant number of CRCs compared to faecal occult blood tests (FOBT) alone. In chapter 
3, we show that an additional 172-184 cases of CRC could be prevented annually in the 
Netherlands with the current screening program. Following this strategy will miss participants 
with a negative FOBT, who form approximately 95% of the screening population.75 We 
recommend that potential participants in this population screening program receive an 
invitation for familial CRC risk assessment along with the FOBT, to further enhance cancer 
prevention.
Clinician support 
As patients become more informed about their familial CRC risk and preventive options, and 
more empowered to choose whether they want to make use of these measures, clinicians 
will need to respond effectively to this demand.76 Overcoming the current knowledge 
gaps that are present among clinicians may be achieved by supporting them with easy 
and practical tools for familial CRC risk assessment and interpretation, such as the RISCO 
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website (chapters 4-6) and our novel online referral tool (chapter 7). The next challenge 
is to persuade clinicians to actually use these tools in clinical practice. Many clinicians use 
information and communication technologies in daily clinical practice, provided they are 
perceived as beneficial for the patient, and easy to use.77 This is something that developers 
and implementers of such tools need to take into account, as well as existing barriers which 
often include lack of time and unfamiliarity with similar online tools. This latter barrier may 
improve with time, as web-based tools are increasingly being incorporated into clinical 
practice. 
Clinicians realise that they lack knowledge, as shown by subjective knowledge scores of 
60-73% even after the intervention (chapter 6). This state of “conscious incompetence” 
is an ideal basis for educational programs. Two-thirds of the clinicians attended the 
educational meeting. After the intervention, clinicians’ objective and subjective knowledge 
scores increased slightly, but no effect on referral for preventive measures was seen. While 
knowledge has been shown to increase after single education sessions, a more structural 
training program, for instance a continuous e-based learning program, may have better 
results.25,78 Such a program could become a standard item in the training of clinicians involved 
in the care for CRC patients, such as gastroenterologists, surgeons, oncologists and general 
practitioners, both in the education for medical specialists and general practitioners in 
training and as a part of the continuous training program for these healthcare professionals. 
To support clinicians in identifying and referring more individuals with an increased familial 
CRC risk, the organisation of hospital care needs to be optimal. Much has already been 
achieved in our study and in previous projects, but further integration of familial CRC risk 
identification and referral for preventive measures in daily clinical practice is needed. One 
way to achieve this could be by making one healthcare professional responsible for familial 
risk assessment, interpretation and communication in all new CRC patients. A well-trained 
clinician or nurse practitioner could be appointed to do this. An Australian study has shown 
that dissemination of guidelines on surveillance colonoscopies among clinicians with 
supervision of all decisions by a nurse coordinator improved the proportion of surveillance 
decisions in accordance with guidelines for individuals with a moderate familial CRC risk 
from 62% to 96%.79 Furthermore, discussing which preventive measures are indicated during 
multidisciplinary oncology meetings may serve as a constant reminder for all healthcare 
providers to collect their patients’ family histories and MSI test results. 
As said, most CRC patients with an MSI-negative tumour and their relatives are not recognised 
as having a moderate familial CRC risk and are not referred for surveillance colonoscopies. 
Perhaps this could be improved by changing the current pathology reports and state more 
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clearly that surveillance colonoscopies may be indicated for patients and relatives in case of 
MSI-negative results.1
Others have suggested that better referral rates of patients with an increased familial CRC 
risk may be achieved by performing MSI and/or immunohistochemical analysis (IHC) in 
all CRC patients, regardless of age at diagnosis and family history, followed by referral for 
genetic counselling if MSI/IHC results are suggestive of Lynch syndrome.80-83 They showed 
that performing molecular analysis in all CRC patients detects 22-28% more patients with 
Lynch syndrome compared to using criteria which are based on age at diagnosis (such as 
the MIPA criteria) and family history (such as the Bethesda criteria).38 Their results were 
further substantiated by cost-effectiveness studies, which have shown that universal testing 
has incremental cost-effectiveness ratios of $22,552- $88,700 per life year saved compared 
to age-dependent testing.84,85 However, approximately 60% of MSI-high tumours in these 
studies were found to be sporadic. In contrast, the percentage of sporadic MSI-positive 
tumours was lower (47%) in patients meeting MIPA criteria.34 In the Netherlands, testing for 
sporadic causes of MSI-positive tumours such as hypermethylation of the MLH1 promotor is 
only performed after genetic counselling.1 In the case of universal MSI analysis, this means 
that most patients who are referred for genetic counselling because of an MSI-positive CRC 
will not have a hereditary cancer syndrome. This will not only unnecessarily alarm patients 
and their relatives, but also increase the burden on the familial cancer clinic as well as costs. 
Applying the MIPA criteria for MSI analysis among newly diagnosed CRC patients has a cost 
effectiveness ratio of €2,184 per life year saved, which is substantially lower than in other 
studies.35,84,85 We did not investigate whether simplifying the current criteria for MSI analysis 
improves the identification and referral of individuals with an increased familial CRC risk. 
However, based on the arguments presented here, we agree with current recommendations 
that only patients meeting MIPA and/or Bethesda criteria should undergo MSI analysis.1,35,38 
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IMPLICATIONS FOR FUTURE RESEARCH
Besides the recommendations in the preceding paragraphs, some additional ideas for future 
research are presented here. 
First, to find out which elements may be particularly effective for future implementation 
strategies, more insight is needed on why the hereditary CRC guideline is implemented 
by some, and not by others. As research continues to find out why uptake of e-health 
technologies and implementation of guidelines in general are low, specific strategies can be 
developed that focus on relieving the relevant barriers.14,23 Performing interviews or focus 
groups with clinicians could shed more light on how the hospitals with high correct referral 
rates achieve this, and what clinicians in hospitals with low correct referral rates need to 
improve these rates. And although our intervention did have positive effects on patient 
outcomes such as knowledge and communication, such effects on referral for preventive 
measures were not seen. Studying whether other strategies aimed at increasing patient 
and public awareness (see section “Implications for clinical practice”) will be effective in 
improving referral rates could be a focus for future research. 
A thorough cost evaluation could improve knowledge of the financial consequences of 
the current over- and under-referral of CRC patients and their relatives. In case of perfect 
referral, incremental costs per life year gained are estimated to be €980 when families 
with an increased CRC risk undergo surveillance, taking into account costs for all relatives 
referred to genetic counselling, including genetic risk assessment, mutation analysis, and 
surveillance colonoscopies (from age 25 and age 45 in case of a high and moderate familial 
CRC risk, respectively).86 Another study has shown that applying the MIPA criteria for MSI 
analysis among newly diagnosed CRC patients is a feasible method to identify patients at 
risk for Lynch syndrome, with a cost effectiveness ratio of €2,184 per life year gained.35
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FINAL CONSIDERATIONS
This thesis describes the current situation with regard to familial colorectal cancer risk 
identification and referral for preventive measures, as well as innovative interventions to 
improve referral rates. Even after the introduction of a multifaceted implementation strategy, 
less than half of CRC patients with an increased familial risk were referred for preventive 
measures in accordance with international guidelines, such as genetic counselling for a high 
familial CRC risk, and surveillance colonoscopies for a moderate familial risk. It is important 
to remember that guidelines are just that: tools guiding clinicians in their clinical decision 
making. Guidelines provide recommendations that may not be suitable for all patients, and 
therefore, 100% adherence to the guideline is not the ultimate goal of implementation 
trials such as ours. However, more attempts at improving guideline implementation remain 
necessary to further improve referral rates for preventive measures. We have shown that it 
may be useful to focus on clinicians to achieve this. In addition, we recommend that patients 
participate more actively in their own healthcare. Joint efforts of all stakeholders involved 
are needed to truly optimise the use of highly effective cancer prevention among colorectal 
cancer patients and their at-risk relatives.
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SUMMARY
Approximately one quarter of all colorectal cancer (CRC) patients has an increased familial 
risk, meaning that their relatives have an increased risk of developing CRC themselves, which 
is at least twice as high as the population risk of 5-6%. It is important that these families 
are identified, so they can take highly effective preventive measures, including surveillance 
colonoscopies. However, prior research has shown that only 12-30% of individuals with an 
increased familial CRC risk is referred for genetic counselling or surveillance. This thesis 
contains the results of the RISCO study (risk of colorectal cancer) and additional studies, 
which were performed to improve the identification and referral of CRC patients and their 
relatives with an increased familial risk. 
Chapter 1 is a general introduction, with information about the familial CRC risk and 
corresponding preventive measures. According to current guidelines on hereditary 
CRC, these are: genetic counselling for a high familial CRC risk (above 15%); surveillance 
colonoscopies once every 6 years starting at age 45 for a moderate familial CRC risk (10-15%); 
and no preventive measures for a low familial CRC risk (below 10%) other than participation 
in population screening with faecal occult blood tests (FOBT), which in the Netherlands will 
start in 2013. Furthermore, the rationale and goal of the studies in this thesis are described.
First, the current identification and referral of individuals with an increased familial CRC 
risk was studied in different settings. The first part of chapter 2 contains a cross-sectional 
study which was performed in eighteen community hospitals to measure assessment and 
communication of familial CRC risk and referral for preventive measures in clinical practice, 
one year after the introduction of the new guidelines. CRC patients and their clinicians 
(gastroenterologists and surgeons) completed questionnaires, and medical records were 
analysed. This study also serves as the baseline measurements for the clustered randomised 
controlled trial described in chapters 4 and 6. 
Familial CRC risk could be determined in 358/437 patients (82%). Of the 36 patients with 
a high familial CRC risk, 12 (33%) were referred for genetic counselling. Relatives of 21/61 
patients with a moderate familial CRC risk (34%) underwent surveillance colonoscopies. 
Overall, 67% of patients with an increased familial CRC risk (n=65/97) and 23% of patients 
with a low familial CRC risk (n=61/261) were referred for preventive measures. Better 
referral of CRC patients and their relatives with an increased familial risk and less referrals 
for low-risk individuals are needed for better and more efficacious cancer prevention.
Doctors’ knowledge plays an important role in the identification and referral of individuals 
with an increased familial CRC risk, and has been studied in the second part of chapter 2. 
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Gastroenterologists, surgeons and clinical geneticists from the Netherlands, including those 
in training, and general practitioners from the Nijmegen region (n=2,169) were sent a web-
based questionnaire with ten clinical vignettes. For each vignette, a CRC patient with his/her 
family history was described. Participants provided familial CRC risk (high, moderate, or low) 
and preventive measures (genetic counselling, surveillance colonoscopies, or neither) for 
each vignette. Fourteen percent of doctors participated (n=312). They provided the correct 
familial CRC risk in 55% of the vignettes, and the correct preventive measures in 65% of 
vignettes. In conclusion, education of doctors is necessary and may lead to better cancer 
prevention. 
In chapter 3, the prevalence of an increased familial CRC risk was assessed in participants in 
a pilot population screening program. In 324 participants with a positive FOBT, family history 
was taken by an experienced doctor or nurse. Six percent of these participants (n=17) had 
an increased familial CRC risk. If familial CRC risk is determined in all participants with a 
positive FOBT, and participants and their relatives with an increased familial risk are referred 
for surveillance colonoscopies and/or genetic counselling, an additional 172-184 CRCs could 
be prevented annually in the Netherlands.
Findings from the RISCO study and prior research demonstrate that many individuals 
with an increased familial CRC risk are not referred for preventive measures, leading to 
unnecessary morbidity and mortality. As such, there is still much room for improvement. In 
the second part of this thesis, the development and evaluation of improvement strategies 
are described, aimed at increasing the identification and referral of these at-risk individuals.
Chapter 4 contains a study protocol for a clustered randomised controlled trial (c-RCT). In 
nine of the eighteen hospitals described in chapter 2 (intervention group), a multifaceted 
implementation strategy was introduced, consisting of a website for CRC patients and 
clinicians, patient brochures, and education and pocket referral cards for clinicians. This was 
compared to usual care in nine control hospitals. In an effect evaluation, familial CRC risk 
assessment and communication and referral for preventive measures were determined. 
Actual exposure to and experience with the implementation strategy were assessed in a 
process evaluation.
The development and pilot test of the RISCO website is described in chapter 5. The website 
was developed together with clinicians, patients and researchers. It contains evidence-
based information about familial CRC risk, risk calculators for CRC patients and clinicians to 
determine familial CRC risk and preventive measures, and a decision support intervention 
or decision aid, which supports CRC patients with a high familial risk in deciding whether 
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or not to be referred for genetic counselling. Twenty CRC patients and twelve clinicians 
participated in a pilot test of the website. Their suggestions for improvement mainly 
focussed on the navigation and the decision support intervention. After implementing these 
changes, patients and clinicians found the information understandable, and the website 
easy to use and helpful in deciding which preventive measures were indicated. Patients 
mostly considered the website useful for information, while clinicians mainly wanted to use 
it to determine whether or not to refer their patients for preventive measures.
Chapter 6 contains the results of the c-RCT. Data from the 358 CRC patients from the baseline 
group (see chapter 2) are compared to those from the endpoint group, where familial CRC 
risk could be determined in 82% (n=392/476). At baseline, one-third of patients with a high 
familial CRC risk (n=12/36) was referred for genetic counselling; surprisingly, this decreased 
to 15% at endpoint (n=7/46, p=0.003). No differences were seen between the intervention 
group and the control group. Uptake of surveillance colonoscopies by moderate-risk 
relatives was lower in the endpoint intervention group (19%, n=5/26) than in the control 
group (41%, n=19/46, p=0.015) and at baseline (intervention 33%, n=13/39; control 36%, 
n=8/22; p>0.05 for both groups).
Of the 140 patients in the intervention group, 94 (67%) used the website, and 34 (24%) read 
the brochure. Patients preferred advice from their doctor regarding preventive measures 
for an increased familial risk of CRC, while the website and brochure were appreciated as 
additional materials. Of the 72 clinicians, 25 (35%) used the website, and two-thirds (n=48) 
attended the education session. Clinicians rated the education and pocket referral cards as 
most useful. The low referral rates and limited use of the intervention materials suggest that 
further implementation strategies are needed. 
Besides the tools that were studied in the c-RCT, a short online referral test was developed. 
In chapter 7, the sensitivity of the referral test for identifying individuals with a high 
familial CRC risk was determined. Data from 420 Lynch syndrome mutation carriers from 
81 families were retrospectively entered into the referral test to determine whether genetic 
counselling was recommended. The sensitivity of the referral test was 91% for mutation 
carriers affected with CRC (n=164), and 73% overall. For usability, we assessed non-medical 
staff members’ ability to correctly determine referral in seven clinical vignettes, using the 
referral test. Twenty participants provided the correct referral advice in 84% of cases after 
minimal training. Finally, 256/2470 real-life users (10%) answered questions about their 
experiences with the referral test. Seventy-one percent was positive about the referral test, 
since it provided them with more certainty about their familial CRC risk and/or preventive 
measures, and more reassurance. 
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Adherence to preventive measures increases when recommendations are tailored, and 
when their importance is understood. In the study described in chapter 8, questionnaires 
were sent to counselees referred for genetic counselling for an increased familial CRC risk, 
to determine how genetic counselling can be improved. Counselees rated the importance of 
45 items assessing their needs and preferences regarding the content and process of genetic 
counselling. Participants (n=48) regarded information about their familial CRC risk (100%) 
and preventive measures (98%) as very important, as well as sensitive communication 
(100%). Focusing on these items may increase satisfaction with genetic counselling and 
improve adherence to surveillance colonoscopies.
In a general discussion in chapter 9, these findings are discussed, together with the limitations 
of the study, and the implications for patient care and research. Our overall conclusion is 
that even after the introduction of a multifaceted implementation strategy, less than half 
of CRC patients with an increased familial risk were referred for preventive measures in 
accordance with international guidelines, such as genetic counselling for a high familial CRC 
risk, and surveillance colonoscopies for a moderate familial risk. Therefore, more attempts 
at improving guideline implementation remain necessary to further improve referral rates 
for preventive measures. We have shown that it may be useful to focus on clinicians to 
achieve this. In addition, we recommend that patients participate more actively in their 
own healthcare. Joint efforts of all stakeholders involved are needed to truly optimise the 
use of highly effective cancer prevention among colorectal cancer patients and their at-risk 
relatives.
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SAMENVATTING 
Familieleden van ongeveer een kwart van alle patiënten met colorectaal carcinoom (CRC) 
hebben zelf een verhoogd risico op CRC. Dat wil zeggen dat hun risico tenminste twee maal 
zo hoog is als het bevolkingsrisico van 5-6%. Het is belangrijk dat deze mensen tijdig herkend 
worden, zodat ze zeer effectieve preventieve maatregelen kunnen nemen, waaronder 
regelmatige colonoscopieën (darmonderzoeken). Uit eerder onderzoek is echter gebleken 
dat slechts 12-30% van de mensen met een verhoogd familiair risico op CRC verwezen 
wordt voor erfelijkheidsonderzoek of preventieve colonoscopieën. Dit proefschrift bevat 
de resultaten van de RISCO-studie (risico op colorectaal carcinoom) en aanvullende 
onderzoeken die gedaan zijn om de identificatie en verwijzing van CRC-patiënten en hun 
familieleden met een verhoogd familiair risico te verbeteren. 
Hoofdstuk 1 is een algemene introductie, met informatie over het familiair risico op 
CRC en de bijbehorende preventieve maatregelen. Volgens de huidige richtlijnen zijn 
dit: erfelijkheidsonderzoek bij een hoog familiair risico (meer dan 15%); preventieve 
colonoscopieën één keer in de 6 jaar vanaf 45-jarige leeftijd bij een matig verhoogd 
familiair risico (10-15%); en geen preventieve maatregelen anders dan deelname aan het 
bevolkingsonderzoek met fecaal occult bloedtesten (FOBT) bij een laag familiair risico op 
CRC (minder dan 10%), zodra dit bevolkingsonderzoek in Nederland start in 2013. Ook 
wordt beschreven waarom en hoe de studies in dit proefschrift tot stand zijn gekomen.
De eerste studies in het proefschrift betreffen onderzoeken naar de huidige identificatie en 
verwijzing van mensen met een verhoogd familiair risico op CRC in verschillende settings. 
Het eerste deel van hoofdstuk 2 bevat een cross-sectionele studie waarin de huidige zorg 
voor CRC-patiënten is onderzocht in 18 Nederlandse ziekenhuizen. Er werd gekeken naar 
verwijzingen voor preventieve maatregelen vanwege een verhoogd familiair risico op CRC 
en de communicatie hierover, één jaar na de introductie van de nieuwe richtlijn. Hiervoor is 
gebruikt gemaakt van medisch dossieronderzoek en vragenlijsten onder CRC-patiënten en 
hun behandelend artsen (chirurgen en maag-darm-leverartsen). Dit onderzoek diende ook 
als de basismetingen voor de geclusterde gecontroleerde gerandomiseerde studie (c-RCT) 
beschreven in hoofdstuk 4 en 6. 
Van de 437 patiënten die meededen, kon bij 358 (82%) het familiair risico op CRC worden 
bepaald. Van de 36 patiënten met een hoog familiair risico werd een derde (n=12) verwezen 
voor erfelijkheidsonderzoek. Familieleden van 21 van de 61 patiënten met een matig 
verhoogd familiair risico (34%) ondergingen preventieve colonoscopieën. In totaal werden 
67% van de patiënten met een verhoogd familiair risico (n=65/97) en 23% van de patiënten 
met een laag familiair risico op CRC (n=61/261) verwezen voor preventieve maatregelen. 
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Betere verwijzing van CRC-patiënten en hun familieleden met een verhoogd familiair risico 
en het beperken van dergelijke verwijzingen voor mensen met een laag familiair risico op 
CRC zijn nodig voor betere en meer efficiënte preventie van kanker.
Kennis van artsen speelt een belangrijke rol bij het herkennen van mensen met een verhoogd 
familiair risico op CRC. Dit is onderzocht in het tweede deel van hoofdstuk 2. Maag-darm-
leverartsen, chirurgen en klinisch genetici (in opleiding) in heel Nederland en huisartsen in 
de regio Nijmegen (n=2169) kregen een digitale vragenlijst toegestuurd. Deze bestond uit 
tien casus, waarin CRC-patiënten en hun familiegeschiedenis werden beschreven, met de 
vraag om voor iedere casus het familiair risico op CRC (hoog, matig of laag) en de passende 
preventieve maatregel (respectievelijk erfelijkheidsonderzoek, surveillance colonoscopieën, 
of geen van beide) te geven. Er deden 312 artsen mee (14%). Het familiair risico op CRC 
werd bij 55% van de casus goed ingeschat; bij 65% werd de juiste preventieve maatregel 
geadviseerd. Hieruit concluderen wij dat het verhogen van de kennis bij artsen nodig is en 
mogelijk leidt tot betere preventie van kanker.
In hoofdstuk 3 is de prevalentie van een positieve familieanamnese en van een verhoogd 
familiair risico op CRC onderzocht in deelnemers aan een proefbevolkingsonderzoek naar 
CRC-screening. Bij 324 deelnemers met een positieve fecaal occult bloedtest (FOBT) werd de 
familieanamnese afgenomen door een ervaren arts of verpleegkundige. Zes procent van de 
deelnemers (n=17) had een verhoogd familiair risico op CRC. Als het familiair risico bepaald 
wordt in alle deelnemers met een positieve FOBT en deelnemers en hun familieleden 
met een verhoogd risico op CRC verwezen worden voor preventieve colonoscopieën en/
of erfelijkheidsonderzoek, kunnen in Nederland jaarlijks 172-184 extra gevallen van CRC 
voorkómen worden. 
De bevindingen uit de RISCO-studie en eerdere onderzoeken tonen aan dat veel mensen 
met een verhoogd familiair risico op CRC niet verwezen worden voor preventieve 
maatregelen. Dit leidt tot onnodige morbiditeit en mortaliteit. Er is dus nog veel ruimte voor 
verbetering. In het tweede deel van dit proefschrift worden de ontwikkeling en evaluatie 
van verbeterstrategieën beschreven. Het doel van deze strategieën is het verbeteren van de 
identificatie en verwijzing van deze mensen met een verhoogd familiair risico op CRC.
Hoofdstuk 4 bestaat uit een studieprotocol voor een geclusterde gerandomiseerde 
gecontroleerde studie (c-RCT). In negen van de in hoofdstuk 2 genoemde ziekenhuizen 
werd alleen de richtlijn erfelijke darmkanker verspreid (controlegroep). De andere negen 
ziekenhuizen (interventiegroep) kregen een veelzijdige implementatiestrategie aangeboden, 
bestaande uit een website voor CRC-patiënten en artsen, patiëntenfolders, en scholing en 
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verwijskaartjes voor artsen. In een effectevaluatie werd bepaald voor hoeveel patiënten 
het familiair risico op CRC goed werd berekend, geïnterpreteerd en gecommuniceerd, voor 
en na het invoeren van de implementatiestrategie. Het gebruik van de hulpmiddelen en 
de ervaring van CRC-patiënten en artsen met de hulpmiddelen werden gemeten in een 
procesevaluatie. 
De ontwikkeling en het pilot-testen van de RISCO-website is beschreven in hoofdstuk 5. 
Deze website werd ontwikkeld door artsen, patiënten en wetenschappers. De website 
bevat evidence-based informatie over het familiair risico op CRC, rekenprogramma’s 
waarmee artsen en patiënten dit risico kunnen berekenen, en een keuzehulp waarmee 
patiënten met een hoog familiair risico kunnen bepalen of zij verwezen willen worden voor 
erfelijkheidsonderzoek. Twintig CRC-patiënten en 12 artsen deden mee aan de pilotstudie 
van de website. Na het doorvoeren van verbetersuggesties van de eerste gebruikers, vooral 
in de navigatie en de keuzehulp, vonden patiënten en artsen de informatie goed te begrijpen 
en de website makkelijk te gebruiken en nuttig om te bepalen welke preventieve maatregelen 
geïndiceerd waren. Patiënten zagen de website vooral als bron van informatie, terwijl artsen 
de website vooral wilden gebruiken om te bepalen of hun patiënten in aanmerking kwamen 
voor preventieve maatregelen. 
In hoofdstuk 6 worden de resultaten van de geclusterde gerandomiseerde gecontroleerde 
studie (c-RCT) gepresenteerd. Bij 392 van de 476 patiënten (82%) in de nameting kon het 
familiair risico op CRC bepaald worden. Hun gegevens werden vergeleken met de 358 
CRC-patiënten uit de voormeting (hoofdstuk 2). Van de patiënten met een hoog familiair 
risico werd 33% in de voormeting verwezen voor erfelijkheidsonderzoek (n=12/36); in de 
nameting was dit 15% (n=7/46, p=0.003) in zowel de interventiegroep als de controlegroep. 
Familieleden met een matig verhoogd familiair risico in de interventiegroep ondergingen 
minder vaak preventieve colonoscopieën (n=5/26, 19%) dan in de controlegroep (n=19/46, 
41%; p=0.015) en de voormeting (interventiegroep 33%, n=13/39; controlegroep 36%, 
n=8/22; p>0.05 voor beide groepen).
Van de 140 patiënten in de interventiegroep gebruikte 67% de website (n=94) en lazen 34 
patiënten (24%) de folder. Patiënten gaven de voorkeur aan advies van hun arts wanneer 
het ging om de keuze om verwezen te worden voor preventieve maatregelen terwijl de 
folders en website gewaardeerd werden als aanvullende hulpmiddelen. Van de 72 artsen 
gebruikte 35% de website (n=25) en nam tweederde deel aan de scholing (n=48). Artsen 
beoordeelden de scholing en de verwijskaartjes als meest nuttige hulpmiddelen. De lage 
verwijzingspercentages en beperkt gebruik van de hulpmiddelen suggereren dat aanvullende 
implementatiestrategieën nodig zijn. 
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Naast de hulpmiddelen die in de c-RCT zijn onderzocht, is ook een kortere digitale verwijstest 
ontwikkeld. In het in hoofdstuk 7 beschreven onderzoek werd de sensitiviteit van de 
verwijstest gemeten voor het identificeren van patiënten met een hoog familiair risico op 
CRC. Hiervoor werden retrospectief stamboomgegevens van 420 mutatiedragers uit 81 
families met het Lynchsyndroom in de verwijstest ingevoerd om te bepalen of verwijzing 
voor erfelijkheidsonderzoek werd geadviseerd. De sensitiviteit van de verwijstest was 91% 
voor mutatiedragers die zelf CRC hadden (n=164), en 73% voor alle mutatiedragers. De 
bruikbaarheid werd getest door te meten hoe goed niet-medisch personeel verwijsadvies 
kon geven met behulp van de verwijstest. Na een korte uitleg gaven de 20 deelnemers in 
84% van zeven klinische casus het juiste verwijsadvies. Tenslotte beantwoordden 256/2470 
gebruikers (10%) vier vragen over het nut van de verwijstest. Hiervan was 71% positief 
over de verwijstest, omdat deze meer duidelijkheid gaf over hun familiair risico op CRC en 
preventieve maatregelen en omdat de test ze geruststelde. 
Adviezen voor preventieve maatregelen worden beter opgevolgd wanneer deze adviezen op 
maat gemaakt zijn en men overtuigd is van het nut ervan. In een in hoofdstuk 8 beschreven 
studie werd onderzocht hoe erfelijkheidsadvies kan worden verbeterd. Mensen die werden 
verwezen voor erfelijkheidsonderzoek konden van een lijst met 45 items over de inhoud 
en vorm van erfelijkheidsadvisering aangeven hoe belangrijk zij deze items vonden. 
Deelnemers (n=48) vonden vooral informatie over het familiair risico op CRC (100%) en 
preventieve maatregelen (98%) zeer belangrijk, evenals sensitieve communicatie (100%). 
Meer aandacht voor deze onderwerpen kan mogelijk leiden tot meer tevredenheid over 
erfelijkheidsadvisering en het beter opvolgen van adviezen voor preventieve colonoscopieën. 
In een algemene discussie in hoofdstuk 9 gaan we in op bovenstaande bevindingen, de 
beperkingen van het onderzoek en de implicaties voor patiëntenzorg en toekomstige 
onderzoeken. Onze algemene conclusie is dat zelfs na de introductie van een veelzijdige 
implementatiestrategie minder dan de helft van de CRC-patiënten met een verhoogd 
familiair risico werd verwezen voor preventieve maatregelen volgens internationale 
richtlijnen, zoals erfelijkheidsonderzoek voor een hoog familiair risico en preventieve 
colonoscopieën voor een matig familiair risico. Daarom is het noodzakelijk dat er nieuwe 
strategieën worden ontwikkeld om het aantal verwijzingen voor preventieve maatregelen 
verder te verbeteren. We hebben aangetoond dat het zinvol kan zijn om hiervoor op artsen 
en andere zorgverleners in te zetten. Daarnaast adviseren wij dat patiënten meer actief 
deel gaan nemen aan hun eigen zorg. Gezamenlijke inzet van alle betrokkenen is nodig om 
een echte verbetering te bewerkstelligen van het gebruik van zeer effectieve maatregelen 
om kanker te voorkómen bij darmkankerpatiënten en hun familieleden met een verhoogd 
familiair risico.
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Allereerst wil ik iedereen bedanken die op de een of andere manier heeft bijgedragen aan de 
RISCO-studie: alle patiënten, artsen, verpleegkundigen, secretaresses en andere vrijwilligers 
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Geachte prof. dr. Hoogerbrugge, beste Nicoline: wat heb ik veel van je geleerd. Ik ben 
regelmatig gevallen, maar iedere keer hielp je me weer opstaan en stuurde je me terug in 
de juiste richting. Ik heb genoten van je intensieve begeleiding, je wijze inzichten en vooral 
je schaterlach, die hopelijk nog heel vaak over de afdeling schalt.
Geachte dr. Hermens, beste Rosella: wat ben ik gezegend met jou als copromotor. Ondanks 
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Geachte leden van de RISCO-projectgroep en RISCO-stuurgroep, heel erg bedankt voor 
het bedenken van deze studie en jullie inspirerende commentaar. Geachte leden van de 
manuscriptcommissie en oppositiecommissie, bedankt voor het lezen en goedkeuren van 
mijn manuscript en jullie bijdrage aan deze bijzondere plechtigheid. Ook onze coauteurs wil 
ik hartelijk bedanken voor hun medewerking en commentaar. Ik heb er veel van geleerd.
Dear prof. Elwyn, dear Glyn: thank you for your part in the RISCO study. I wish you all the best 
in the USA and UK and please remember: there is no need to apologize for not providing 
comments on a paper within 48 hours. 
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Mijn kamergenoten, keldergenoten, kantoortuinmaatjes en alle andere collega’s bij Genetica 
en IQ healthcare wil ik bedanken voor de gezelligheid, inspiratie, wijze lessen en steun in 
de afgelopen jaren. En niet te vergeten de borrels, film- en spelletjesavonden, zanglessen, 
tafeltennismatches, lunches, barbecues en andere etentjes, etcetera. 
Inge: heerlijk dat wij de afgelopen 3½ jaar samen konden werken, al was het in de kelder. 
Heel veel succes met je onderzoek, je komt er wel. 
Kirsten: dank je wel voor de mooie tijden in de kantoortuin. Ik wens je alle goeds in Utrecht. 
Marc en Dennis: heel erg bedankt voor jullie tomeloze inzet voor de RISCO-website, widgets 
en alles waar we tussendoor ook nog even mee aan kwamen zetten. Zelfs avond-, weekend- 
en nachtwerk was jullie niet te gortig. Bedankt voor het bovenhalen van de computernerd 
in mij. 
Nelleke en Simone: ik vond het fijn om jullie zo intensief te begeleiden en heb er ontzettend 
veel van geleerd. Dank jullie wel dat we samen zo hebben mogen groeien. 
Annemarie, Karen, Jeannette, Belinda en Cateleyne: jullie kregen het altijd weer voor 
elkaar om afspraken te regelen in alle drukke agenda’s. Dank daarvoor, en voor alle fijne 
kletsmomenten. 
Lucy: je integere en humorvolle begeleiding was een groot cadeau, bedankt daarvoor.
En dan mijn paranimfen. Geertje, wat heb ik genoten van onze bijna-dagelijkse fietstochtjes, 
roadtrips met Pink Panda naar Frankrijk en Denemarken en de avonturen met Sebastiaan 
en zijn familieleden. Aisha, het was geweldig om een kamer te delen met iemand die net zo 
spontaan en vals meefluit met Disneyliedjes, dezelfde voorkeur heeft voor schattige posters, 
Loesje-teksten en musicals, en altijd een luisterend oor bood. Ik vind het fantastisch dat 
jullie mij bij mijn promotie bijstaan en hoop dat we elkaar nog veel blijven zien.
Anne Catrien, Marije, Corine, Anita, Marloes: dank voor jullie vriendschap. Onze wegen 
lopen soms wat uit elkaar, maar gelukkig hebben we altijd nog onze gedeelde liefde voor 
boeken, theater, zeilen, wandelen, weekendjes weg met sauna, schapen en flauwe humor. 
Ik kijk uit naar alle thee en wijntjes die we samen nog gaan drinken, met natuurlijk wat 
lekkers erbij.
Eén van de kostbaarste zaken in het leven is familie. Wat ben ik dankbaar dat ik altijd bij jullie 
terecht kan, voor praktische en emotionele steun, gezelligheid en rust. Liefde voor natuur, 
cultuur en zaterdagmiddagslaapjes: nature of nurture? Ik beloof plechtig dat we elkaar de 
komende jaren vaker gaan zien, nu dit proefschrift eindelijk echt af is.
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Big brother en kleine zus: ik ben ontzettend trots op jullie. Tycho, geweldig dat je een 
succesvol eigen bedrijf op hebt gezet, al tijdens je studie. En binnenkort echt af gaat 
studeren. Sary, toen ik nog studeerde moesten we het helaas bij lieve brieven en korte 
telefoontjes houden. Nu jij studeert zijn dat gelukkig lange telefoongesprekken, gezellige 
uitstapjes en logeerpartijen geworden. Dank voor jullie steun en interesse, en ik weet zeker: 
jullie komen er wel. 
Lieve mam en pap: jullie hebben me al van jongs af aan gestimuleerd om steeds meer te leren 
en alles uit het leven te halen wat er in zit. Ik kan altijd rekenen op jullie onvoorwaardelijke 
vertrouwen en praktische adviezen. Dank daarvoor. En hier sta ik dan, vol trots: jullie dochter 
doctor dokter Dekker!
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